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ABSTRACT 
The physiological role of calcitonin in mammals has been in question since it 
discovery. Many have speculated that the calcitonin/calcitonin gene-related p eptide 
(ctcgrp) gene has endured simply because of its alternate mRNA pathway to produce 
calcitonin gene-related peptide-a (CGRP-a) in neural tissue. Nevertheless, a few studies 
have persisted in suggesting that mammalian calcitonin is vital in times of increased 
calcium demand, such as during lactation. Unfortunately, these surgical based studies 
were fraught with experimental problems stemming from lack of true absence of 
calcitonin and confounding effects of thyroid ablation. This doctoral work, therefore, was 
carried out to test the theses that: calcitonin is required physiologically during lactation 
to protect the maternal skeleton against excessive resorption of mineral and that 
lactational bone losses in the absence of calcitonin involve a complex physiological 
circuitry between the breast, bone and brain. Studies were carried out using the murine 
ctcgrp null mouse model, which is completely void of calcitonin from conception 
onwards. Ctcgrp nulls were compared to the normal, wild-type (WT) siblings as controls. 
We have demonstrated that although calcitonin is unnecessary during pregnancy 
and the post-weaning period, it is indeed required physiologically during lactation since 
in its absence over half (51. 6% ± 4.6%) of the vertebral bone mineral content (BMC) is 
lost versus that seen in the WT (24.4% ± 5.4%). BMC losses were also significant within 
the hindlimb region and at the total body level. Loss of calcitonin during lactation is 
associated with increased trabecular thinning and separation. Despite these significant 
architectural changes, however, bone strength is no different in the ctcgrp null versus 
WT, likely due to a higher baseline bone volume in the ctcgrp null. 
11 
Mechanisms underlying significant BMC losses in the ctcgrp null versus the WT 
include increased mammary production of PTHrP, increased circulating PTH and 
increased bone resorption. Pituitary contributions to bone loss appear to be less 
significant. Excess calcium lost during lactation does not occur as a result of 
compromised intestinal absorption or increased urinary excretion but is most likely lost in 
the milk supply. 
Our studies therefore confinn an important physiological role of calcitonin in 
protecting the maternal skeleton against excessive resorption during lactation. hnportant 
physiological pathways regulating bone resorption at this time include the breast and 
bone, with potential contributions coming from the brain. Furthermore, the post-weaning 
ctcgrp null skeleton may offer an ideal context in which skeletal recovery could be 
examined because anabolic mechanisms are likely upregulated. 
11l 
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I. Introduction 
A. Preamble 
The following work provides important new evidence of a critical role for 
calcitonin during the reproductive period, as determined by the examination of mice 
lacking the ctcgrp gene. Whether calcitonin has a physiological role in mammalian 
mineral metabolism has been in question for the past 40 years, since its discovery (1, 2). 
To better appreciate the metabolic alterations during reproduction in the absence of 
calcitonin, this review will begin by describing how calcium metabolism is normally 
regulated in the non-pregnant human and rodent. Next, calcium and bone homeostasis 
during normal pregnancy, lactation and the post-weaning period, will be reviewed, 
including the prior studies that first examined whether calcitonin plays a role during 
reproduction, and thereby formed the basis of this doctoral research project. 
B. Functions of the Adult Skeleton 
The skeletal system has evolved to include an intricate framework ofbones, 
cartilage, ligaments and tendons. Bones partner with muscles to form the musculoskeletal 
system which allows movement. Other evident purposes of the adult skeleton include: 
protecting the internal organs from damage and aiding in hematopoiesis, the formation of 
blood cells in the marrow (3). Much less obvious, however, is the role that the skeleton 
plays in mineral homeostasis (4). Bone contains 99% of the calcium that is present in the 
mammalian organism (3, 4). If circulating calcium levels decrease below normal, calcium 
is released from the skeleton, in part through the action of parathyroid hormone (PTH) 
stimulated bone resorption, to meet the immediate metabolic needs (4). In contrast, when 
blood calcium levels increase above normal, excess calcium can be partly stored in the 
bone matrix (4). This dynamic function ofbone is particularly challenged in the maternal 
skeleton during pregnancy, lactation and the post-weaning period (5- 8). 
C. Bone Mass and Density 
Bone mass is the amount of bone present in the skeleton. Bone mineral content 
(BMC), however, is the amount of mineral in grams contained in the skeleton at a certain 
site. Ash weight can be used as a surrogate for true BMC in lab animals or excised bones. 
In contrast, bone mineral density (BMD) properly refers to bone mass per unit volume 
(glcm3). In clinical practice volumetric BMD (vBMD) is rarely measured because it 
requires computed tomographic scanning and high dose radiation exposure (9, 1 0). More 
commonly, a 2-dimensional measurement, areal bone density (g/cm2), is used to 
approximate volumetric BMD (9, 1 0). Clinically, less invasive techniques such as dual-
energy x-ray absorptiometry (DXA) are used to estimate in vivo BMC and areal BMD (9, 
1 0). These parameters are used to assess an individuals risk for fracture, or conditions 
characterized by low bone mass and increased skeletal fragility, such as osteoporosis (11 , 
12). In humans, and in many other species, a consistent pattern is seen in bone mass with 
age (I 1 -14) (Figure 1). 
1. Skeletal Growth and Achievement of Peak Bone Mass 
During infancy, childhood and adolescence bones grow significantly, not only in 
length but also in width (13, 14). These changes are facilitated by the sex steroids as well 
as other hormones and factors such as growth hormone (GH) and insulin-like growth 
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Figure 1: Pattern in Bone Mass with Age. During childhood and puberty bone mass 
increases significantly (13, 14). Peak bone mass (PBM) is achieved during young 
adulthood. Inevitably, endocrine changes cause a subsequent decrease in bone mass at 
menopause, as well as with old age (11-14). Typically bone loss in men occurs more 
gradually and at a later age (11- 14). 
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factor I (IGF-1) (13, 14). At the cellular level, skeletal growth is accompanied by the 
processes of bone modeling and remodeling (13, 14). Modeling is the process by which 
new bone is developed and remodeling is the dynamic process in which mature bone 
mass is maintained through the coordinated activities of the bone cells (i.e. the 
osteoblasts, osteoclasts and osteocytes) (3). Thus, contrary to its static-like appearance, 
bone actually exists in a dynamic state (3). Bone accumulates microfractures from day-to-
day damage and these areas of micro fracture are broken down via osteoclasts and 
replaced with healthy new bone via the actions of osteoblasts (3). Bone modeling and 
remodeling are intricate processes controlled by many hormones, growth factors, 
transcription factors, and intracellular signaling events (3). 
Peak bone mass (PBM) is achieved when the skeleton has reached its genetic and 
environmental capacity for a maximum bone mineral content/bone mineral density 
(BMC/BMD) (13- 16). The mineral that exists at PBM is used as a storehouse for life (3, 
13). The precise age at which PBM occurs can vary depending on gender and the site of 
the skeleton (i.e. axial versus appendicular) and the technique used to estimate it (12, 13) . 
. In general, PBM had been shown to occur anywhere from 17-35 years of age, with the 
mid-20' s being a commonly accepted time point (Figure 1) (13, 14). Peak height velocity 
(PHV), or the point in which we attain our adult height, typically occurs within two years 
of puberty (13, 14). 
Some of the factors that have been shown to influence the achievement of PBM 
and PHV include dietary intake (e.g. calcium, vitamin D, protein) (15), biomechanical 
loading (e.g. body weight, weight bearing physical activity) (15), timing of puberty (i.e. 
flux of gonadal steroids) (13, 14) and various genes (e.g. vitamin D receptor (VDR), 
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collagen receptor, estrogen receptor-a, transforming growth factor-~ (TGF~), a2HS-
glycoprotein, collagen 1a1 and the calcium receptor (CaR)) (16). It has been estimated 
that 60-80% of the variance in BMD is determined by genetic factors (12-16). 
Prior to the achievement ofPBM, bones exist in a relatively impressionable state 
(17, 18). Studies in young athletes who play racquet sports (e.g. tennis and squash) have 
shown that the 'dominant arm' has significantly greater BMD than the 'non-dominant' 
arm (17, 18). This effect, however, is not nearly as striking in individuals who start 
playing sports as adults, after the achievement of PBM (17, 18). 
After PBM has been achieved, bone mass plateaus (Figure 1) (14). This relatively 
steady state typically persists throughout adulthood and is maintained through the 
balanced activities of the osteoblasts and osteoclasts (i.e. equal formation and resorption 
rates) {14). In the nonnal adult skeleton this cellular balance typically cannot be altered to 
gain bone mass, once PBM has been achieved. Unfortunately, however, many factors can 
cause the adult skeleton to readily lose bone (11, 12, 15, 16). 
2. Loss of Bone Mass 
Some of the factors that could contribute to loss ofbone mass include: nutritional 
deficiencies (e.g. calcium, vitamin D, protein, etc) {19), prolonged periods of skeletal 
unloading (e.g. extended bed-rest or lack of gravitational force on bone seen during space 
missions) (20), endocrine disorders (e.g. hyperthyroidism, hyperparathyroidism), bone 
marrow disorders (e.g. leukemia), gastrointestinal conditions (e.g. celiac disease or 
inflammatory bowel disease) (21 ), long-term use of glucocorticoids (GC) (21) and age-
related endocrine changes (11 ). 
5 
Inevitable age-related endocrine changes are accompanied with a multitude of 
alterations in the bone microenvironment, many of which are not completely understood 
(11, 12). In women, a rapid loss ofbone occurs in the first 5 years of menopause and then 
a more gradual loss follows thereafter (Figure 1) (11, 12). In men, declines in bone mass 
are also seen (11, 12, 15). Typically, however, bone losses in men occur more gradually 
and at a later age (Figure 1) (15). Unfortunately, bone mass that is lost as a result of age 
or any of the other aforementioned reasons, is largely irreversible {11, 12, 15, 20, 21). 
3. Quantitative Assessment of Bone 
Quantitative assessment ofbone tissue may include an array of techniques, 
including: evaluation of bone mass, bone strength, markers ofbone turnover, and 
histomorphometric analysis (static and dynamic) (22- 27). The techniques that are most 
relevant to this research will be mentioned in more detail below. 
Bone Mineral Content and Bone Mineral Density 
DXA is frequently used in the clinical setting to assess areal BMD and BMC (22, 
23). DXA uses two low energy x-ray wavelengths that are relatively specific to being 
blocked by calcium (22, 23). The amount of x-ray reaching the detector is inversely 
proportional to the grams of calcium that lies between the x-ray source and the detector. 
The areal BMD is subsequently determined by dividing by the cross-sectional area of 
bone (22, 23). A low score may indicate that the bone is less dense than average and thus 
may be more prone to fracture. A limitation using areal BMD, is that the value is not 
corrected for height and weight, and thereby the size of the bone being measured. Thus, a 
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bone of normal density, but smaller width than average will give a low areal BMD 
reading (22, 23). 
Computed tomography, in contrast, provides three-dimensional imaging and 
reports BMD as a volumetric density measurement (22, 23). This method can be 
quantitative (i.e. qCT) and is capable of isolating the region of interest (ROI) from 
surrounding tissues and providing information pertaining to the trabecular 
microarchitecture (i.e. trabecular separation distribution, trabecular thickness distribution, 
etc.). The qCT radiation dose is much higher than that ofDXA, and that is why it is not 
routinely used for this purpose (22, 23). For smaller analyses, such as the assessment of 
rodent bone, micro CT (~CT) is also used. 
Bone Strength 
Biomechanical tests are often performed on bone biopsies, in animals, to 
quantitatively evaluate strength and elasticity (24). Bone strength is considered the 
capacity to resist the application of force and bone elasticity is the ability to deform under 
stress (24). Compromised strength and elasticity, resulting from excess demineralization, 
can result in increased bone fragility (24). Bone biomechanics is a complex field with 
established nomenclature (25). Commonly used biomechanical tests include the 3-point 
bend test (3PBT) and the vertebral crush test. 
The 3PBT is a flexural test that provides information regarding the amount of 
load (i.e. force in Newton's) that can be supplied to the bone until it breaks (i.e. failure 
point) and the displacement of the bone from its starting position after failure (Figure 2) 
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1000 Failure Point 
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Figure 2: Standard Load/ Displacement Biomechanical Curve. During a 3-point bend 
flexural test (3PBT) an increasing load (kilonewtons (kN)) is applied until the bone cannot 
with stand the additional weight. This is noted on the curve as the fai lure point. The distance 
the bone travels from its initial position is noted as its displacement millimeters (mm). 
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(24). This test can also provide values for the modulus of elasticity (i.e. the degree to 
which the sample deforms as determined by the degree of stiffness) (24). The main 
advantage of a 3PBT is the simplicity of the specimen preparation and analysis (24). 
However, this method also has some disadvantages: the results of the testing method are 
sensitive to specimen and loading geometry (24). 
The vertebral crush test, in contrast, is a compressive test, that supplies an evenly 
distributed load on the bone sample. Similar to the 3PBT, the main limitation of the 
vertebral crush test is the geometry of the bone. If a specimen has an irregular surface, the 
progressive test load may initially come into contact with a 'high-point' (i.e. a large 
irregularity) on the bone surface and cause erratic spikes on the load/displacement curve 
(Figure 3). These spikes may make it challenging to determine the mean failure point of 
each specimen. 
Bone Histomorphometry 
Bone biopsy samples can be assessed by looking at the microscopic organization 
via histomorphometry (25, 26). Samples can be examined both statically and 
dynamically. Static assessment includes quantification of such parameters as: number of 
osteoblasts, osteoclasts, osteocytes, osteoid surface, resorption surface, total surface and 
void surface. These measurements are typically expressed as length (mm), area (mm2) or 
absolute number and are obtained using computer-assisted software programs. Dynamic 
histomorphometry, in contrast, uses fluorochromes, such as tetracycline, that binds to 
newly formed bone at the unmineralized bone interface (bone/osteoid) where it presents 
9 
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Figure 3: Vertebral Crush Test Load/ Displacement Biomechanical Curve. Erratic 
spikes may be seen on the load/displacement curve if a specimen has an irregular surface. 
These spikes make it problematic to deterrnine the mean failure point of each specimen. The 
distance the bone travels from its initial position is noted as its displacement (mm). 
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as a linear fluorescent band under UV light microscopy. The double-labeling process 
involves two separate dosing periods, typically 11-14 days apart, and thus bone formation 
during this time interval can be quantified by measuring the distance between the two 
fluorescent labels. A relatively larger distance between fluorescent labels means that the 
rate ofbone formation is higher than if the bands were closer together, or if they 
happened to be superimposed or absent. 
Bone Turnover 
Biochemical markers of bone turnover are products present in the blood or urine 
as a result of bone formation or resorption, which are also used to assess bone turnover 
(27). This non-invasive technique is often used to complement static and dynamic 
histomorphometric analysis or used in place of it where bone biopsy is not commonly 
done (e.g. in humans). Bone turnover markers provide a reliable measure of bone 
formation and resorption in grouped data (e.g. population trials). Values are compared to 
normal controls to indicate if there is a relative change (27). Bone turnover markers, 
however, are not as reliable when looking at an individual subject. 
Osteoblasts secrete a number of proteins in the serum that are used to approximate 
bone formation. Commonly used bone fonnation markers include bone-specific alkaline 
phosphatase (BSALP), procollagen type 1 C propeptide (PICP), procollagen type I N 
propeptide (PINP), and osteocalcin (OC) (27). 
In contrast, bone resorption markers can be measured in both the serum and urine. 
Resorption markers typically assess the presence of bone collagen degradation (e.g. 
carboxyterminal cross-linking telopeptide (CTX) ofbone collagen deoxypyridinoline 
1] 
(DPD), pyridinoline (PYD), and crosslinked peptide of the carboxy-terminal telopeptide 
of type I collagen (ICTP), or are products secreted directly by osteoclast cells (e.g. 
tartrate-resistant acid phosphatase (TRAP)) (27). Bone resorption can also occur as a 
result of osteocyte activity, or a process called osteocytic osteolysis (3). 
D. Calcium Homeostasis in the Adult 
Calcium is necessary in humans as well as in other species for: nerve transduction, 
muscle contraction, growth, as well as cellular metabolism ( 4, 5, 28, 29). Although 
unique mechanisms for calcium regulation have evolved distinctly in different species 
(e.g. fish mainly use their gills to exchange calcium with the environment, whereas 
humans use calcium from food in the gut) deviations from a normal calcium ' set-point' 
may result in adverse effects in all species ( 4, 8, 28, 29). 
In general, calcium homeostasis refers to the series of physiological events that 
maintain the concentration of serum calcium such that normal body function is sustained 
and health is not compromised ( 4, 28, 29). Physiological compartments involved in the 
exchange of calcium include: dietary intake, intestinal absorption, fecal excretion, renal 
excretion and reabsorption, and bone formation and resorption (Figure 4). In 'positive 
calcium balance' dietary intake (i.e. mainly through dairy products and/or 
supplementation) and retention are greater than the corresponding losses in the urine, 
feces and intestines (28). In negative calcium balance, however, intestinal, urine and fecal 
losses exceed calcium intake and retention (28). A growing adolescent could be 
considered in a state of positive calcium balance (28). In contrast, an individual sustaining 
prolonged bed rest, in a postmenopausal state, or receiving glucocorticoid treatment could 
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Figure 4: Calcium Balance. Physiological compartments involved in calcium exchange 
include: dietary intake, intestinal absorption, fecal excretion, renal excretion and 
reabsorption, and bone formation and resorption. 
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likely be considered in negative mineral balance. In zero balance, there is no net loss or 
gain of calcium (28). 
1. Forms of Calcium 
Calcium is found in the body in three main forms: bone calcium, extra- cellular or 
blood calcium and intracellular calcium (4, 29). About 99% of the total calcium in the 
body is made up ofbone calcium in the form ofhydroxyapatite, a crystalline structure 
caught in the mineral phase ( 4, 29). The remaining 1% exists in a pool that can rapidly be 
exchanged with the extracellular calcium (4, 29). The serum contains calcium in three 
different forms: ionized or free, protein bound (i.e. bound to albumin or globulins), or 
complexed to different anions (i.e. phosphate, citrate or bicarbonate) (4). Intracellular 
calcium is mainly found within the mitochondria and microsomes, bound to phosphates in 
blood and muscle ( 4). 
All forms of calcium are tightly regulated (28, 29). Total blood calcium is often 
used for the clinical evaluation of calcium status because of the ease of use of automated 
spectrophotometric techniques (30, 31 ). Free or ionized calcium, although affected by pH 
(32), may be the more precise indicator of clinical calcium status. Through the use of 
calcium sensitive electrodes free calcium is now being used more frequently (30). If 
severe enough, both low blood calcium (i.e. hypocalcemia) and high blood calcium (i.e. 
hypercalcemia) can result in cardiovascular, neuromuscular, renal, gastrointestinal and 
skeletal complications (33, 34). 
14 
2. The Intestines and Calcium Homeostasis 
The intestines are highly involved in the regulation of calcium, especially during: 
childhood, adolescence, early adulthood, pregnancy and lactation (28). The normal daily 
intestinal absorption of calcium can range from 200 - 1000 mg, depending mainly upon 
dietary calcium intake (28). Two main mechanisms are used to absorb calcium in the 
small intestines of mammals: passive or diffusional, paracellular absorption and active, 
saturable transcellular absorption (28). Both processes are largely dependent upon 1, 25-
dihydroxyviatmin D (28). 
Paracellular absorption is driven by an electrochemical gradient and varies per 
segment of the intestine (28). If dietary calcium intake is low absorption efficiency 
increases to enhance what calcium is available (28). In contrast, if calcium intake is 
beyond its saturation point (i.e.::::; I 000 mg) absorption will plateau (28). Active, 
transcellular absorption, begins with calcium being imported into the intestinal cells via a 
calcium channel created by the calcium transport protein 1 (i.e. transient receptor 
potential vanilloid type 6 (TRPV6)). This process is induced by 1, 25 dihydroxyvitamin D 
and estradiol (28). Subsequently calcium is stored into vesicles containing calcium 
binding protein calbindin 9kDa and is shipped to the basolateral surface of the cell where 
it is then exported into the extracellular fluid and blood via either a sodium calcium 
exchanger or a calcium-magnesium-dependent A TPase (28). A recent study showed that 
calbindin D9k null mice were fully able to absorb calcium from the intestine in response 
to 1 ,25-dihydroxyvitamin D3 (35). These authors concluded that calbindin D9k is not 
required for vitamin D-induced intestinal calcium absorption in the small intestine (35). 
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3. The Kidneys and Calcium Homeostasis 
The kidneys also play an important role in delivering adequate calcium to the 
growing fetus and neonate ( 4-7, 28, 36, 3 7). Approximately 10 grams of calcium are 
filtered by the kidneys each day in humans ( 4-7, 28, 36, 3 7). The mechanisms responsible 
for calcium reabsorption vary depending upon the segment of kidney involved (28, 36 -
38). The vast majority of calcium is reabsorbed passively via a sodium dependent 
paracellular pathway (28, 36 - 38). Active calcium transport, in contrast, is controlled by a 
transcellular pathway that involves three processes: entry of calcium across the luminal 
membrane via the transient receptor potential (TRP) super family channels (i.e.TRPV5 
and TRPV6), transfer through the cytoplasm where the calcium is buffered by calcium-
binding proteins (i.e. calbindin-D28K and calbindin D9K), and active transport of calcium 
across the basolateral membrane by the Na+/Ca2+-exchanger and Ca2+-ATPase (28, 36-
38). TRPV5 and TRPV6 have been found to be controiied by I, 25 dihydroxyvitarnin D, 
dietary calcium intake and estrogen (38). Renal calcium handling is also controiied by 
PTH, calcitonin, parathyroid hormone-related protein (PTHrP), fibroblast growth factor-
23 (FGF-23) and KJotho, a recently discovered gene that is prominently expressed in the 
kidneys (28, 38-42). 
Ninety-eight percent of the calcium that enters the kidneys is reabsorbed from the 
tubular system back into blood, which maintains blood calcium levels within a narrow 
physiological range (28, 36, 37). Hypercalcemia results in an increase in renal calcium 
filtration whereas hypocalcemia results in a decrease in renal calcium fi ltration (28, 33, 
34). Tubular reabsorption may be stimulated by PTH, PTHrP, phosphate, thiazide 
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diuretics, alkalosis, etc (28, 36, 37). Reabsorption may decrease as a result of 
hypercalcemia, phosphate deficiency, acidosis, etc (28, 36, 37). 
4. Bone and Calcium Homeostasis 
Two morphologically distinct types of bone exist in the skeleton, compact (i.e. 
cortical bone) and spongy (i.e. cancellous or trabecular bone) (3). Both types ofbone 
assist in maintaining calcium homeostasis through functioning as a vast pool of mineral 
that can be drawn upon in times of need (3 , 5). These types of bone will be referred to as 
cortical and trabecular bone for consistency within this research paper. Cortical bone 
consists of tightly packed haversian systems containing blood vessels (3). Trabecular 
bone, in contrast, consists of plates (trabeculae) adjacent to irregular cavities that contain 
bone marrow (3). Trabecular bone has a higher degree of porosity relative to cortical 
bone (3). This porosity provides a vast amount of free surfaces and subsequently more 
cellular components. As a result, trabecular bone is considered more metabolically 
responsive to stimuli than cortical bone (3). 
5. Hormones and Calcium Homeostasis 
Through the kidneys, intestines and bone, the following hormonal players help 
maintain normal calcium homeostasis in the adult: PTH, 1, 25-dihydroxyvitamin D3, 
PTHrP, the sex steroids and calcitonin. 
Parathyroid Hormone 
One of the predominant honnonal players involved in the regulation of 
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mammalian calcium homeostasis is PTH ( 43). PTH, in mammals, is secreted by the chief 
cells of the parathyroid glands (43). Secretion ofPTH is regulated by the extracellular 
calcium concentration (Ca2+) and the calcium receptor (CaR), a G protein-coupled 
receptor located on the chief cells of the parathyroid glands ( 44). Activation of the CaR 
on the parathyroid cells, by small increases in blood ionized calcium, cause an immediate 
inhibition of PTH secretion followed by decreases in PTH gene expression and 
parathyroid cellular proliferation (43, 44). In contrast, low calcium levels result in 
reduced binding of Ca2+ to the CaR (i.e. a negative feedback-loop), and thus PTH is then 
released from the parathyroids (43, 44). These actions help sustain extracellular calcium 
levels within an acceptable physiological range (43, 44). The physiological significance 
ofPTH can be illustrated by considering studies on human hypoparathyroidism (45), as 
well as mice null for the PTH gene ( 46 - 50). Hypocalcemia and hyperphosphaternia have 
been found in both PTH null mice and individuals with hypoparathyroidism, both which 
require supplementation with calcium to restore normocalcemia ( 48-50). 
Within the kidneys PTH: stimulates the reabsorption of calcium within the 
proximal tubule , inhibits the reabsorption of phosphorus in the distal tubules and directly 
stimulates the }-a-hydroxylase (1-a-OH) enzyme in the formation of 1, 25-
dihydroxyvitamin D (47). All of these action help increase the normal physiological 
range of calcium in the serum. 
Within bone, the pharmacological actions ofPTH are multifaceted and complex, 
resulting in both anabolic (i.e. bone building) and catabolic (i.e. bone breaking down) 
effects (47, 51-56). Most recently the anabolic affects ofPTH have been noted and 
confirmed using intermittent administration of exogenous PTH (51 -53). Daily 
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administration ofPTH has been found to increase bone mass and reduce fracture risk (53, 
54). PTH has been confirmed to stimulate ofpreosteoblast proliferation, reversal of 
quiescent lining cells to active osteoblasts, increased osteoblast activity, and increased 
osteoblast life span by the prevention of apoptosis (53). This anabolic effect of pulsatile 
PTH has validated its use in the clinical treatment of post-menopausal osteoporosis. More 
research is needed to explore the molecular and cellular mechanisms underlying the 
anabolic effects ofPTH, and whether it may be involved in physiological processes such 
as the rapid remineralization of the maternal skeleton post-weaning. 
Within bone, the catabolic effects ofPTH are well documented (55, 56). PTH 
binds to the PTH 1 receptor on the bone forming osteoblast cells and the marrow stromal 
cell precursors (55, 56). Upon activation of these cells, PTH causes an increase in the 
expression of receptor activator of nuclear factor kappaB ligand (RANKL) and 
macrophage colony-stimulating factor (M-CSF) (55, 56). Both RANKL and M-CSF are 
expressed in preosteoblastic cells (56). RANKL is a member of the tumor necrosis factor 
(TNF) ligand super family. In the presence ofM-CSF, RANKL binds to RANK receptors 
on the osteoclast precursor cells and promotes the differentiation, survival of mature, 
multinucleated bone digesting osteoclasts cells (55, 56). RANKL has also been shown to 
increase the resorptive capacity of the osteooclast cells, thus aiding in the release of 
calcium into the blood (55, 56). At the same time chronic administration ofPTH also 
causes osteoblasts to decrease the expression of osteoprotegerin (OPG) a soluble "decoy" 
receptor for RANK (55, 56). Decreased OPG results in less competition for binding to the 
RANK receptor and thus RANKL can bind more often (55, 56). In summary, more 
RANK/RANKL binding equals more calcium released into the blood. This work will 
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focus more on the physiological and not pharmacological effects ofPTH through the 
assessment of circulating PTH levels throughout reproduction. Given that PTH can have 
catabolic (i.e. bone-resorbing effects), it is reasonable to consider that PTH over activity 
might contribute to the lactational losses of bone mass that support milk production and 
neonatal growth. 
1, 25-dihydroxyvitamin D3 
1, 25-dihydroxyvitamin D3 is the biologically active form of vitamin D (i.e. 
calcitriol) formed in the kidneys after hydroxylation by the 1-aOH enzyme (57, 58). 1, 
25-dihydroxyvitamin D3 binds to its intracellular hormone receptor, the vitamin 03 
receptor (VDR) where it interacts with DNA on a multitude oftarget cells to produce an 
array ofbiological effects (57). 
1, 25-dihydroxyvitamin D3 aids in the maintenance of blood calcium primarily 
through its actions in the intestine and bone (57). Within the small intestine, 1, 25-
dihydroxyvitamin D3 enhances calcium entry into the epithelial calcium channels 
(ECaC). Once in the intestinal cells, 1, 25 dihydroxyvitamin D3 activates several calcium 
transport proteins (e.g. calbindin 9K, calmodulin) which help to shuffle calcium across 
the cytoplasm. 1, 25 dihydroxyvitamin D3 then activates Ca2+ -A TPase which actively 
pumps calcium across the basal lateral surface of the intestine into the circulation. In 
addition, 1, 25-dihydroxyvitamin 03 also aids in the release of calcium into the blood by 
stimulating the maturation of osteoclasts, and thus subsequent resorption of mineral (57). 
Vitamin D deficient patients may present with normal to low blood ionized 
calcium, elevated PTH and possibly low phosphorus levels (57). Vitamin D deficiency 
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may occur as a result of lack of a functional VDR, dietary deficiency or lack of adequate 
sunlight (57). Several metabolic bone diseases may result from vitamin D deficiency, 
such as rickets and osteomalacia (57). Mice null for the VDR experience hypocalcemia, 
rickets and alopecia (58). Provision, however, of a high-calcium, high-phosphorus, 
lactose-supplemented diet by the third week of life in these mice prevents abnormalities 
in mineral ion homeostasis indicating that absence of the VDR does not have to have 
adverse physiological effects, if the diet is modified accordingly (58). 
Parathyroid Hormone-Related Protein 
PTHrP is also involved in calcium and bone homeostasis in both humans and 
rodents (59). Both PTH and PTHrP share amino terminal regional homology as well as a 
common receptor, the PTHlR (59). PTHrP is present in an array of cells including: bone, 
mesenchymal, smooth muscle, mammary, parathyroid, intestinal, pancreas and placenta 
(60- 67). PTHrP has shown to be important in: endochondral bone formation, mammary 
gland development, placental calcium transfer, tooth development, smooth muscle 
functioning as well as being responsible for most cases of humoral hypercalcemia of 
malignancy (HHM) (60- 67). PTHrP is having an increasingly appreciated role in calcium 
homeostasis during reproduction, as will be explained in Section I and M. 
Sex Steroids 
The gonadal steroids, including the estrogens, androgens and progesterone, play 
an important role in calcium and bone homeostasis in animals and humans (68, 69). 
Removal of the gonads in both men and women is associated with bone loss due to 
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increased bone resorption, and a decrease in bone formation. Studies in mice with knock 
out of the estrogen receptor or androgen receptor have provided supporting data regarding 
the in vivo actions of sex steroids on bone (69). Sex steroid effects on bone are likely 
multifaceted and complex, including possible prolongation of the osteoblast lifespan and 
control of osteoclastogenesis (69). Low estrogen is linked with an increase in the 
secretion ofvarious cytokines (e.g. interleukin (IL) -1, IL-6, M-CSF and RANKL (69). 
Increased cytokine activity causes the recruitment and activation of more bone resorbing 
osteoclast cells, and a decrease in the antiresorbing agent, OPG (69). Minute-to-minute 
regulation ofblood calcium in humans and rodents is unlikely to be affected by the 
gonadal steroids (69). 
E. Calcitonin in the Adult 
Another hormonal player involved in calcium homeostasis is calcitonin, a 32 
amino acid peptide discovered in 1962 as a hormone postulated to regulate the ' normal 
level' or' tone' of calcium in the circulation (70-73). Initial investigators perfused blood 
containing high levels of calcium into the thyroid and parathyroid glands of dogs and 
sheep and discovered the subsequent release of a substance that lowered the blood 
calcium (71-75). At first it was believed that this hypocalcemic agent was produced by 
the parathyroid glands (71- 73). Shortly thereafter, however, it was demonstrated that 
calcitonin was produced specifically within the parafollicular cells (' C ' cells) of the 
thyroid gland giving rise to the name ' thyrocalcitonin' (74, 75). More recent studies have 
shown calcitonin is also produced by the brain, breast, placenta and other neuroendocrine 
cells (76 - 80) (Figure 5). 
22 
Calcitonin has been postulated to help regulate normal calcium homeostasis 
mainly through its biological actions on the bone and kidneys (70, 76, 77). Calcitonin 
binds to the calcitonin receptors (CTR) on the osteoclast cells to directly inhibit both the 
number and resorptive capacity of these bone resorbing units, thus decreasing the amount 
calcium released into the circulation (77, 81 ). This property of calcitonin has resulted in 
its use in the treatment of conditions characterized by intensified bone resorption, such as 
osteoporosis, Paget's disease, and hypercalcemia of malignancy (70). Calcitonin also 
inhibits tubular reabsorption of calcium by the kidneys and thus increases the amount of 
calcium lost in the urine (70, 76). Although calcitonin is often referred to as being part of 
the triad of important calcium regulating hormones, along with the aforementioned 1, 25-
dihydroxyvitain D3 and PTH, most of the effects of calcitonin are seen only at 
pharmacological doses and thus it has been speculated by many that calcitonin may be 
physiologically unimportant in mammals (1). Supporting this theory is the fact that there 
is no significant deficiency syndrome linked solely to the absence of the thyroid, a major 
source of calcitonin ( 1, 82 - 84). This lack of an effect is illustrated in those who have had 
their thyroid glands surgically removed, thus eliminating a significant source of 
calcitonin. These individuals appear to have non-significant alterations in calcium 
metabolism (83, 84). Furthermore, individuals with medullary thyroid carcinoma (MTC), 
and thus increased circulating levels of calcitonin (i.e. > 100 pg/ml), do not appear to 
exhibit any alterations in calcium regulation (85, 86). 
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Figure 5: Location of Calcitonin and the Calcitonin Receptor within Human 
Physiology. Calcitonin is released in the systemic circulation after being produced by the C-
cells of the thyroid gland. Calcitonin is also produced in the breast during reproduction, as 
well as in the pituitary lactotrophs of the brain (78 - 80). Calcitonin receptors (CTR) are 
located in the brain, breast, and on the osteoclasts in bone (78- 81). Image by C.S. Kovacs, 
2005. 
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There are, however, several studies that suggest calcitonin is important within 
mammalian physiology (70, 76, 85-90). Some of these suggested functions include: 
acting as an antiresorption agent for the management of bone resorping conditions (86-
90), a gastrointestinal regulator/satiety controller (87, 88), a hypocalcemic agent/calciuric 
hormone (76), a tumor marker (85, 86), a regulator of acid-base balance to prevent 
dehydration (70), and finally, a regulator of the maternal skeleton during reproduction (1 , 
89, 90), just to name a few. The latter potential function, being the focus of interest, will 
be discussed in detail in Section J (Pregnancy), Section N (Lactation) and Section R (the 
Post-Weaning Period). First, however, an introduction to the calcitonin gene family, 
calcitonin receptors, and an overview of what is known about the physiological role of 
calcitonin based on genetic ablation studies in mice. 
1. The Calcitonin Gene Family 
The calcitonin gene super-family includes calcitonin, calcitonin gene-related 
peptide (CGRP- a), amylin, adrenomedullin (AM), as well as the recently described 
adrenomedullin 2 (AM2) (also referred to as intennedin (IM)) and calcitonin receptor-
stimulating peptide (91, 92). For the purposes ofthis review emphasis will be placed on 
calcitonin and CGRP-a only. 
Calcitonin and CGRP-a are derived from the Calca or CALCA gene. The older 
nomenclature 'ctcgrp' will be used to denote the gene throughout this dissertation 
(Figure 6), which is encoded on Chromosome 7 and 11 in mice and in humans 
respectively (70, 91 - 94). Alternative processing of the initial 6.5 kb gene transcript 
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Thyroidal C-Cells Hypothalamic Cells 
1 2 3 4 1 2 3 5 6 
Calcitonin mRNA CGRP-a mRNA 
Figure 6: The Calcitonin Gene. Calcitonin and CORP-a are derived from the Calcitonin gene. 
Alternative processing of the initial gene transcript results in the production of a 141-residue 
calcitonin-specific precursor and a 128-residue CORP-a specific precursor. Post-translational 
modification of these pro-hormones results in the thyroidal C cells producing primarily calcitonin 
transcript and the hypothalamus producing mainly the transcript for CORP-a. Of the 6 exons 
spanning the ctcgrp gene, 1-3 are present in both calcitonin and CORP-a mRNA, exon 4 contains 
the calcitonin-coding sequence and exon 5 encodes the CORP-a form sequence. 
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results in the production of a 141-residue calcitonin-specific precursor and a 128-residue 
CGRP-a specific precursor (70, 91 - 94). Post-translational modification of these pro-
hormones result in the thyroidal C cells producing mainly calcitonin transcript 
and the hypothalamus producing the transcript for CGRP-a (Figure 6) (70, 91 - 94). 
CGRP and its receptors in the nervous system and in peripheral tissues are mainly 
involved in maintaining vascular tone, ingestive behavior, modulation of the autonomic 
and endocrine systems and possibly in the etiology of migraine (95- 97). Of the 6 exons 
spanning the ctcgrp gene, 1-3 are present in both calcitonin and CGRP-a mRNA 
(although exon 1 is not translated), exon 4 contains the calcitonin-coding sequence and 
exon 5 encodes the CGRP-a form sequence (70). There also exists a CGRP-~ gene, 
however there is no calcitonin mRNA produced from the~ gene (70, 91, 92). 
2. Calcitonin Receptors 
The peptides within the calcitonin family interact with two main seven 
transmembrane G protein-coupled receptors -the CTR and the calcitonin receptor- like 
receptor (CRLR) (70, 92, 98- 1 02). Calcitonin receptors are located within osteoclasts, 
mammary tissue during lactation as well as the nervous system (70, 92, 99 - 1 03). Partial 
homologous members of the CTR family including: CGRP, adrenomedullin and amy1in, 
show some cross-reactivity to the CTR (1 00, 101 ). Receptor modulating proteins (RMPs) 
include a family of proteins that heterodimerize with the CTR or the CRLR to generate 
different receptor phenotypes (98, 1 02). Known RMPs include CORP-receptor 
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component protein and a family of receptor-activity-modifying proteins (RAMPs) (98, 
102). 
3. Genetic Ablation of Genes within the Calcitonin Family 
To better understand the physiological role of the genes within the calcitonin 
family, several mouse models have been genetically engineered in which the coding 
sequences for the following alleles: ctcgrp-a, CGRP-a, CTR, amy/in, AM and CRLR have 
been deleted via homologous recombination (91 - 93). Each genetically engineered 
colony produces WT, Heterozygous (HET) and Homozygous (HOM) mice. In the ctcgrp-
a mouse model, for example, genetically manipulated colonies include WT mice that 
have two normal ctcgrp alleles (i.e. these animals are genetically nonnal), HET mice that 
have one ctcgrp allele plus one mutant allele (i.e. neomycin cassette) and HOM mice 
(referred to as the 'null') that have 2 mutant ctcgrp alleles. It is important to note that null 
mice are completely void of the resulting peptide from conception onward (i.e. calcitonin, 
CGRP, CTR, etc) (91 -93, 103- 108). In some genetic knockout mouse colonies, the 
absence of a particular gene results in null embryonic lethality (e.g. the CTR null). A 
summary of the findings on these models is summarized in Table 1. 
In the original published report on ctcgrp nulls, mice were described as having 
significantly greater trabecular bone volume and increased bone formation at 1 and 3 
months of age, versus WT mice (1 03). Ctcgrp nulls were found to be more responsive to 
exogenous human PTH, responding with greater increases in serum calcium and bone 
resorption markers, an effect that was completely reversible with calcitonin 
supplementation (1 03). In addition, it was found that ctcgrp null mice maintained BMC 
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Table 1: Summary of Calcitonin Gene Ablation Study Findings 
Mouse Model Reference No. Summary of Findings 
(versus that seen in the normal, WT sibling) 
Calcitonin/ calcitonin Initial p henotype: 
gene related peptide-a 103 Unique inbred homozygous colony created in a 
( ctcgrp) ctcgrp null high bone mass mouse background (C57BU6). F3 
generation were compared to unrelated WT mice 
and were found to: 
- have greater trabecular bone volume and 
increased bone formation at 1 and 3 month of 
age 
- be more responsiveness to exogenous human 
PTH 
- maintain BMC post ovariectomy 
Revised phenotype: 
104, 105 F3 generation knockout model (1 03) backcrossed 
into a pure C57BU6 mouse background (F1 0 
generations). C57BU6 ctcgrp null when compared 
to WT littermates were found to have: 
- no increase in bone mass with age 
- high bone turnover with age 
106 increased trabecular thinning and cortical 
remodeling at 3 & 6 months of age as well as 12 
and 18 months of age in females 
Calcitonin gene related 106 mice suffer from osteopenia at all ages 
peptide-a (CGRP-a) 
null 
Calcitonin Receptor 107 no CTR null embryos present after 10.5 days post 
(CTR) null coitum 
CTR HET mice have increased bone mass due to 
increased bone formation 
Amylin null 108 enhanced bone resorption resulting in bone loss 
Calcitonin Receptor- 109 CRLR null embryos die between 13.5 and 14.5 
Like Receptor (CRLR) days of gestation. 
null 
CRLR null embryos have cardiovascular 
abnormalities 
Adrenomedullin (AM) 110 AM nulls experience vascular abnom1alities and 
null elevated blood pressure 
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post-ovariectomy, versus WT mice, which lost 36% of their trabecular bone volume after 
two months (1 03). The authors concluded from this initial study that the ctcgrp gene 
reduces bone resorption in hypercalcemic states and assists in the regulation of bone 
formation (1 03). 
It is important to note, however, that the aforementioned study on ctcgrp null mice 
(1 03) was fraught with significant confounders that limit the interpretation of the results. 
More specifically, mice were created in a high bone mass background strain 
(i.e.C57BL/6), inbred to each other, and then compared to unrelated WT mice from 
background strains with inherently lower bone mass (1 04). Also, considering that the 
mouse strain was created by homozygous matings, results simply may have been due to 
spontaneous mutations created through generations of inbreeding. 
After these initial studies, it was noted, that ctcgrp nulls, when compared to 
related WT littermates did not exhibit the same increase in bone mass with age (1 04). The 
ctcgrp knockout mice (F3 generation) (103) were subsequently backcrossed into a pure 
C57BL/6 mouse background (F 10 generation) (1 05). These mice demonstrated a striking 
phenotype characterized by increased trabecular remodeling, trabecular and cortical 
thinning, and cortical porosity (1 05). The cortical thinning lead to morphophological 
changes of vertebral bodies characterized by a 5% reduction of the height/width ratio in 
12 and 18 month-old animals (1 05). The earliest indication of increased remodeling was 
presence in 3 and 6 month-old animals. By 12 months of age a striking phenotype had 
emerged characterized by trabecular and cortical thinning with evidence of cortical 
tunneling and collections of osteoclasts. The authors concluded that, contrary to initial 
findings (1 03) ctcgrp nulls had a profound and progressive phenotype characterized by 
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increased trabecular thinning and cortical remodeling versus that of the WT. These mice, 
however, did retain the greater calcemic response to PTH (1 05) as described earlier ( 1 03). 
Consistent with R.F. Gagel's findings (105) Huebner and colleagues (106) also 
found that ctcgrp null mice experienced a high bone turnover with age. 
Histomorphometric analysis performed at the age of 12 months revealed significant 
increases in not only bone formation, but also bone resorption (1 06). Huebner also 
studied a mouse model lacking only CGRP-a (1 06). In the CGRP-a null mouse model 
ex on 5 of the calcitonin gene, which encodes the sequence of CGRP-a, was replaced with 
a neomycin resistance gene (1 06). Mice missing only CGRP-a showed an osteopenic 
phenotype at all ages studied ( 1 06). The authors concluded that in addition to the 
previously described increase of bone formation in the ctcgrp-a null mice, there is also 
increased bone resorption with age (1 06). This suggests that calcitonin and/or CGRP may 
have a dual action as an inhibitor of bone remodeling, which may explain why alterations 
of serum calcitonin levels in humans do not result in major changes in BMD (1 06). 
To study the consequences of the complete ablation of the murine CTR gene, 
exons E6 and E7 of the mCTR gene were deleted (1 07). Deletion of those exons 
effectively disabled all CTR isoforms. CTR null mice were found to be embryonic lethal 
( 1 07). CTR HET mice, however, were shown to have increased bone mass due to 
increased bone formation (1 07). This again could possibly be the result ofbackcrossing 
with mice with a naturally high BMC or possibly an effect subsequent to lack of 
calcitonin and/or CGRP-a because there is no dominant functional receptor for the ligand 
to act upon. 
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Both calcitonin and amylin are ligands for the CTR. Mice with deletion ofthe 
amylin gene, exhibit bone loss due to enhanced bone resorption (1 08). Also a gene-
targeted knockout model of the CRLR gene has also been generated and studied (109). 
Mice HET for the targeted CRLR allele appear normal, survive to adulthood, and 
reproduce normally (1 09). However, HET matings fail to produce viable CRLR null 
pups. CRLR null embryos die between embryonic day 13.5 and 14.5 of gestation (109). 
These embryos have multiple cardiovascular abnormalities, including thin vascular 
smooth muscle walls and small hearts also previously shown to be exhibited by AM null 
mice (11 0). 
Thus, to summarize from the above studies, absence of calcitonin (and other genes 
from the calcitonin family) has been linked with increased bone turnover ( 104 - 11 0). 
Some of these results, however, remain unpublished and evidently more work needs to be 
completed to confirm inconsistencies and to factor in the effects of animal background on 
resulting bone mass. Understanding of the role of the calcitonin family ofpeptides is 
certainly not complete, manipulation of the mouse genome and production of knockout 
models has certainly contributed information about the physiological roles of peptides 
from the calcitonin family. More information, however, is required to fully extrapolate 
the role of calcitonin in bone biology. To date the role of calcitonin or CGRP-a during the 
reproductive period has not been examined. This will be the particular focus ofthis 
research. 
F. Rodent Calcium Homeostasis versus Human Calcium Homeostasis 
Due to the highly invasive nature of many experiments (e.g. biomechanical 
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testing, tissue biopsy, etc) involved in exploring calcium homeostasis and the 
pathogenesis ofbone disease, animal models are often used instead ofhumans. Rodents, 
in particular, are a promising model because of; their relative cheap cost and availability, 
our awareness of their biological properties and ability to manipulate their genome, their 
fast generation time, and the relative ease in which we can experimentally control their 
environment and behavior (111). Unfortunately, however, there are also possible 
limitations with these models in studying calcium and bone metabolism, including the 
difficulty of accurately assessing the microstructures of the skeleton (i.e. due to the small 
size ofthe bones), obtaining adequate sample sizes of tissue and blood for analysis, 
anatomical differences in the skeletal structure, number of offspring, etc. 
Rodents, however, do experience similar physiological alterations in calcium and 
bone metabolism during reproduction (e.g. loss ofBMC during lactation, and subsequent 
restoration of mineral post-weaning) and share significant gene homology to hwnans (6-
8). Thus, rodents provide a sound starting point for molecular biological experimentation. 
G. Unique Periods of Bone Mineral Loss and Accretion 
Studies in both animals and humans have revealed several unique physiological 
periods in which substantial bone mass can be lost at a rapid rate, yet completely regained 
afterwards. These unique periods include: antler mineralization (112), egg shell 
formation (113), as well as lactation and post-weaning (5-8, 114-124). 
During these periods mineral is temporarily borrowed from the adult skeleton to 
provide for the immediate needs (e.g. mineralization of antlers, formation of egg shell, 
formation of milk, etc). After the requirements have been met, the skeleton completely 
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and rapidly rebuilds itself, returning to its former state (5-8, 114-124). The mechanisms 
underlying these processes have been largely unexplored. For the purpose of this review, 
bone alterations during pregnancy, lactation and the post-weaning period will be the 
focus. 
1. Pregnancy, Lactation and the Post-Weaning Period 
Pregnancy, lactation and the post-weaning period are accompanied with 
significant alterations in bone mass (5-8, 114-117, 119, 122-125). To accommodate the 
rapidly growing fetus, the production of milk for the neonate, and the reconstruction of 
the maternal skeleton post-weaning, respectively, maternal calcium and bone homeostasis 
must undergo major physiological adjustments (Figure 7) (5-8, 11 4-125). Perhaps the 
most remarkable of these alterations is the ability of the maternal skeleton to rapidly and 
fully remineralize itself after such a significant bone loss during lactation (5-8, 29-40, 
114-125). Changes during reproduction occur at the cellular level as well as systemically 
(5-8, 29-40, 114-125). The metabolic alterations required for the attainment/utilization of 
mineral during these unique periods varies, and is different from the non-pregnant state 
(5-8, 29- 40, 114-131 ). More detail regarding the specific systemic alterations that 
accompany pregnancy, lactation as well as the post-weaning period will be discussed in 
subsequent sections regarding each of these time periods. 
H. Maternal Calcium and Bone Metabolism during Pregnancy 
Pregnancy is a time of incredible demand on maternal calcium and bone 
metabolism, as mineral must be actively transported across the placenta to support the 
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Figure 7: C alcium homeostasis during human pregnancy, lactation a nd the post-
weaning period versus normal. Arrow thickness indicates relative increase or decrease 
versus normal. Image adapted from: Kovacs CS and Kronenberg HM, Maternal-Fetal 
Calcium and Bone Metabolism during Pregnancy, Puerperium, and Lactation, Endocrine 
Reviews, 1997 Dec; 18(6):832-72. Copyright, The Endocrine Society. Permission for use 
can be seen in Appendix A. 
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growing fetus (6-8, 29-36). The specific biological strategies that the maternal skeleton 
has adapted to meet the mineral needs ofthe growing fetus, are only partly understood (6-
8). At birth the average human fetus contains 20- 30 grams of calcium, the vast majority 
of which is accreted during the last trimester (121- 125). In fact, the daily calcium 
requirement of the growing human fetus increases from approximately 50 mg/day during 
the 22nd week of gestation up to 330 mg/day at 35 weeks of gestation 
(121- 125). To help meet these rising demands for mineral the fetus has adapted its own 
mechanisms for calcium regulation through unique adaptations within the placenta, 
kidneys, bone, and intestine. Calcium is not only required for fetal skeleton mineralization 
but also cellular growth, signal transduction and neurotransmitter release (6-8). The 
dominant biological mechanism in place to meet the increased calcium demands of 
pregnancy appears to be a doubling in maternal intestinal calcium absorption, facilitated 
at least in part by the actions of 1, 25-dihydroxyvitamin D (Figure 7) (126-129). 
Alterations in the hormonal regulators of pregnancy will be reviewed first. 
I. Alterations in Hormonal Regulators of Calcium Homeostasis during Pregnancy 
The hormonal milieu of pregnancy is different than that seen in the non-pregnant 
state (6-8, 122-131 ). Normal pregnancy induced alterations in: PTH, 1, 25-
dihydroxyvitamin D, PTHrP, the gonodal steroids and calcitonin are discussed below. 
1. Parathyroid Hormone 
In human studies using intact immunochemical assays, serum PTH levels have 
been shown to decrease during early pregnancy and then return to mid-nonnal range by 
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the end of gestation (6-8, 130, 131 ). Older studies suggested pregnancy was a time of 
hyperparathyroidism (132, 133). These studies, however, were flawed by the use of 
assays that measured non-biologically active fragments ofPTH in the circulation (132, 
133). Women who suffer from hypoparathyroidism during pregnancy may have fewer 
hypocalcemic symptoms, and require less calcium supplementation (6-8). This implies 
lack of a role for PTH during pregnancy and suggests the normal increase in intestinal 
calcium absorption and circulating 1, 25-dihydroxyvitamin D at this time. 
In contrast to humans, a few reports in rats suggest that pregnancy is a time of 
hyperparathyroidism (134, 135). Preliminary studies show that mice lacking the PTH 
gene are generally hypocalcemic and hyperphosphatemic at baseline line when compared 
to their WT littermates (48-50). PTH null mice have a low fertility rate and appear to be 
more susceptible to spontaneous death from anesthetic (an effect that was reduced when 
the diet was supplemented with additional calcium). During pregnancy PTH null mice 
receiving a 1% standard calcium chow experienced a slightly lower blood ionized 
calcium levels when compared to PTH null mice receiving a 2% fortified calcium chow 
and to the WT siblings (48-50). Despite these mineral alterations at baseline no apparent 
difference was observed in the cycling of BMC during pregnancy versus that experienced 
that of the WT littermates (48-50). 
2. 1, 25-dihydroxyvitamin D 
In humans 1, 25-dihydroxyvitamin D levels double beginning at early pregnancy 
and this level is maintained until term (126, 127, 134, 136-138). Increases in 1, 25-
dihydroxyvitamin D may be attributed primarily to upregulation of the renal 1 a-OH 
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enzyme (126). Renal 1a-OH stimulates formation of 1, 25 dihydroxyvitamin D. PTH 
typically stimulates 1 a-OH, completing the last hydroxylation in the formation of active 
vitamin D (i.e. 1, 25-dihydroxyvitamin D3) in the kidneys (126). During pregnancy in 
humans, however, it is unlikely that PTH is the cause of the doubling in 1, 25-
dihydroxyvitamin D because the rise in 1, 25-dihydroxyvitarnin D begins while the PTH 
levels have fallen to the low-normal range (126). The maternal kidneys are speculated to 
be the dominant source as shown by an anephric woman who had no increase in 1, 25-
dihydroxyvitamin D during pregnancy and the evidence that renal 1 a-OH is upregulated 
( 6-8). Also contributing to the rise in 1, 25-dihydroxyvitamin D3 are the placenta and 
fetal kidneys (6-8). 
Preliminary experiments in mice null for the VDR showed that pregnancy rescued 
low bone mass and normalized intestinal calcium absorption (139). Vdr null mice entered 
pregnancy with a lower total body BMC (0.381 ± 0.003 grams versus 0.519 ± 0.004 
grams in WT, p<0.02) (139). Vdr null mice, however, experienced a relatively greater 
increase in BMC during pregnancy versus that seen in the WT mice when compared to 
the respective baseline BMC value (i.e. Vdr nulls increased to 158% of the baseline BMC 
versus WT mice that increased to 122% of their baseline BMC value (p<0.02)). Findings 
indicated that duodenal 45 calcium was 78.7%± 3.8% in non-pregnant WT mice and 
94.1% ± 8.8% in Vdr null mice during pregnancy (139). Thus, based on these findings it 
appears that 1, 25 dihydroxyvitamin D and the associated VDR are not the only 
mechanisms responsible for increasing calcium absorption, because in the absence of the 
VDR calcium absorption is still increased during pregnancy. It appears that the increase 
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in calcium absorption seen during pregnancy also occurs via pathways independent of the 
VDR and/or 1, 25 dihydroxyvitamin D. 
3. Parathyroid Hormone-Related Protein 
Studies in humans and rodents have shown that serum PTHrP levels begin to 
increase towards late pregnancy (6-8, 121-124, 140 -144). PTHrP is produced by a vast 
number of both maternal and fetal tissues (including the mammary glands, placenta, fetal 
parathyroids, osteoblasts in bone, amnion and umbilical cord) and thus the exact source of 
PTHrP during pregnancy is hard to determine (6-8, 121-124, 140-144). In rats and in 
humans PTHrP has been suggested to regulate myometrial tone, blood flow and the 
relaxation of smooth muscle during pregnancy and delivery (121-126, 140-144). The 
amino-terminal portion of PTHrP has been shown to stimulate the renal 1 a-OH enzyme 
and skeletal calcium resorption (59, 60). The mid-molecular portion ofPTHrP 
specifically in the fetus has been shown to stimulate placental calcium transfer (145), and 
the carboxy-terminal portion, also known as 'osteostatin', has been shown to inhibit 
osteoclastic bone resorption and may protect the maternal skeleton from excessive 
resorption of mineral (146). 
Thus, from the above studies it can be concluded that there are several theoretical 
mechanisms by which PTHrP could serve a functional role during pregnancy. Despite 
these findings, however, low circulating maternal PTHrP levels throughout most of 
gestation suggest that, ifPTHrP does play a role during pregnancy it is most likely local 
and not systemic. 
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4. Sex Steroids and Other Hormones of Pregnancy 
Substantial increases in circulating prolactin (PRL) and placental lactogen (PL) 
(also called chorionic somatomammotrophin) are seen during pregnancy in both humans 
and rodents (5-7, 147). Prolactin (PRL) stimulates the glandular production of colostrum 
and milk proteins (147). The secretion ofGnRH and the gonadotropins (i.e. follicle 
stimulating hormone (FSH), leutinizing hormone (LH)) are inhibited during pregnancy, 
thus eliminating menstrual cycles at this time (5-7, 147). The involvement of these 
hormones in the regulation of calcium metabolism during pregnancy is largely unknown 
( 4-7, 14 7). Some studies suggest that PRL and placental lactogen may stimulate intestinal 
calcium absorption and the synthesis of PTHrP at this time (5-7). 
J. Calcitonin during Pregnancy 
Serum calcitonin levels are increased during pregnancy in rodents and humans 
versus that ofnon-pregnancy (5-7, 124, 138, 148, 149). Contributions to this rise in 
circulating calcitonin could include the C-cells of the thyroid, the placenta and breast. 
Elevations in calcitonin during pregnancy provided the early rationale behind the 
scientific speculation that calcitonin may protect the maternal skeleton during 
reproduction, and perhaps during other times of greater physiologically need (5-7, 124, 
138, 148-154). 
Thyroidectomy (TX) was the method of choice to investigate the possible 
physiological role of calcitonin in early studies (82-84, 150-154 ). Considering the fact 
that the thyroid is a major source of calcitonin production, it was thought at the time that 
removal ofthe thyroid would result in production of a 'calcitonin deficient state' (150-
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152). Investigators used sheep, rats and goats that had undergone TX with subsequent 
thyroid replacement to examine bone mass changes throughout reproduction (150-152). 
Some of the studies found that these animals had lower BMC/BMD values after periods 
of pregnancy and lactation versus their sham operated counterparts whereas other 
investigators found no effect of TX (150-152). These results were inconclusive as to 
whether or not calcitonin may be involved in protection of the maternal skeleton from 
excessive losses of mineral during pregnancy, and more significantly during lactation. 
Unfortunately, however, extrathyroidal calcitonin sources, found in the breast, brain 
placenta and throughout the vast neuroendocrine system were not appreciated at this time 
(78-80), and thus these early studies were flawed by lack of a truly calcitonin deficient 
model. Whether or not calcitonin plays a critical role in calcium metabolism during 
pregnancy was unanswered by these particular animal studies. 
K. Systemic Adaptations to Pregnancy 
The large demands for mineral throughout pregnancy are met primarily through 
the following systemic alterations in the maternal intestines, kidneys and skeleton (Figure 
7). 
1. Intestinal Adaptations during Pregnancy 
Mineral balance studies, as well as kinetic studies using calcium isotopes (48Ca, 
44Ca, 42Ca) have shown an increase in intestinal calcium absorption by as much as 50-
80% compared to non-pregnant controls during human and rodent pregnancy (Figure 7) 
(5-8, 118, 123 -127, 129, 149, 153 -158). This increase in intestinal calcium absorption 
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has been shown to begin during early pregnancy and to continue until the end of 
gestation, providing an important mechanism by which the maternal skeleton adapts to 
meet its own mineral needs, as well as the needs of the growing fetus. 
Up-regulation of intestinal calcium absorption during pregnancy may be in part 
due to increases in: calcium ATPase, calcium binding protein mRNA levels or TRPV6 
mRNA expression in the intestine (126, 156, 157). These increases could lead to more 
calcium pumped out of the intestinal cell into the circulation. This rise in intestinal 
calcium absorption during pregnancy may allow the maternal skeleton to store calcium in 
advance of the fetal demands later in pregnancy. The increased intestinal calcium 
absorption appears to be a major maternal adaptation to meet the fetal need for calcium 
(126, 156, 157). 
2. Renal Adaptations during Pregnancy 
Urinary calcium excretion is increased during pregnancy (i.e. absorptive 
hypercalciuria caused by increased gastrointestinal absorption of calcium) (Figure 7) 
(158, 159). Glomerular filtration rate (GFR) and renal plasma flow (RPF) have been 
found to be upregulated by 40-65% and 50-85%, respectively in normal women with 
uncomplicated pregnancy (158, 159). Hypercalciuria occurs throughout all trimesters 
with the exception, in some circumstances, such as under fasting conditions (73, 158, 
159). 
3. Skeletal Adaptations during Pregnancy 
Pregnancy is characterized by alterations in maternal calcium metabolism at the 
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level of the skeleton (5-7, 117, 119, 124, 160-169). Studies in humans mainly focus on 
markers of bone turnover with scant data considering BMC/BMD measurements during 
the pre and post partum periods (155, 160, 164, 165). Studies in rodents, in contrast have 
considered BMC/BMD alterations throughout the full reproductive period (162, 168). 
Data is also available for bone markers as well as alterations in bone volume (161 , 162). 
On rare occasions fragility fractures may occur during pregnancy (165). Specific details 
pertaining to skeletal adaptations during pregnancy are noted below. 
Markers of Bone Turnover during Pregnancy 
In healthy pregnant women serum markers of bone formation, including: OC, 
BSAP and PICP showed a biphasic pattern with decreases in bone formation in early 
pregnancy, followed by a significant increase in the third trimester and postpartum (122, 
124, 125, 141). It is important to note, however, that these variables are often difficult to 
interpret due to the increased GFR of pregnancy, the effect of hemodilution during 
pregnancy, fetal and placental contributions to the markers in the urine and absence of 
pre-pregnancy (baseline) values for comparison (5-7). Thus, one may carefully conclude 
that bone turnover is increased during pregnancy, but more data is needed in this area. 
Flux in Bone Mass during Pregnancy 
Due to fetal exposure to x-rays DXA is typically avoided during human pregnancy 
(5-8). In contrast, animal studies commonly use DXA as a rapid and precise method to 
assess bone status throughout reproduction (5-8, 161, 162 -173). It is important to note, 
however, that DXA measurements may be confounded by drastic alterations in maternal 
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weight, soft tissue composition, and fluid shifts during pregnancy (166). These 
physiological changes could result in artifactual alterations in BMD (166). Despite the 
lack of sequential BMD measurements throughout full gestation periods in humans, there 
are a few studies that have considered pre-pregnancy and/or the post-partum period (122, 
155, 164, 167). 
Findings using DXA analysis pre and post pregnancy in humans have shown 
variable results from losses in total body and vetebral BMD during pregnancy (122), to 
no significant change (164). Numbers in these studies were generally low and baseline 
BMD measurements were often obtained at inconsistent time periods. Problems may also 
arise when baseline BMC measurements are taken before the individual has reached their 
peak bone mass, and thus post-pregnancy bone mass assessment may falsely represent 
general growth and not bone mass accretion due to reproduction. One human study 
suggested that pregnancy effects the maternal skeleton by producing a fluctuation in 
cancellous bone volume in which early temporary bone loss through trabecular thinning is 
restored in its entirety through the addition of trabeculae that produce a modestly more 
complex system of thinner more numerous bars by the end of gestation (174). Increases in 
bone volume may also be adaptive mechanisms to accommodate the weighted fetus and 
neonate (174). 
Data in Black Swiss (BLKSW) mice suggest gains in bone mass during gestation 
up to 10-15% above baseline (Figure 8) (168). With larger litter sizes, bone mass gains in 
rodents during pregnancy could possibly be an adaptive mechanism to protect the 
maternal skeleton and prepare for the mineral requirements of the developing fetus and 
later for milk production for 12 or more suckling pups (168). Gains in bone mass and 
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Figure 8: Bone Mineral Content (BMC) pattern throughout reproduction in normal, 
Blackswiss mice. Normal Black Swiss (BLKSW) mice gain BMC during pregnancy, peaking 
at < 48 hours post-partum (168). These gains have not been noted in human studies (155, 
156). During lactation in BLKSW mice BMC levels drop -12% from baseline, and as much as 
-35% from peak BMC levels at < 48 hours post-partum (168). Remarkably, there is full 
recovery, and in fact a temporary overshoot, ofBMC post weaning (168). Serial BMC 
measurements in humans have shown losses of -5 to -10% in BMC during lactation from 
immediate postpartum also a complete regain after weaning (5-8). Losses may be more 
significant in mice due to significant litter sizes. BLKSW data obtained from Sharpe and 
Kovacs IBMSIJSBMR 2003. 
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volume during pregnancy have also been seen in rats (161). In one study in rats, at the 
end of pregnancy there was an increase in cortical periosteal bone formation and an 
increase in cortical volume (161). Up to a 40% increase in cancellous bone volume has 
been observed in the lumbar spine of rats during pregnancy compared with age-matched 
virgin controls (163). More research is needed in this area to fully understand the effect of 
pregnancy on bone mass. Reviews of epidemiologic studies in both humans and animals 
have shown that the alterations in bone mass during pregnancy do not have negative 
effects on long-term fracture risk, likely because of the reversibility of these alterations 
(122, 155, 163, 164). On rare occasion, a woman may suffer from fragility fractures 
during or immediately after pregnancy (165). Alterations in mineral metabolism during 
pregnancy (i.e. increased bone resorption) may exasperate complications related to a pre-
existing low bone mass (165). Baseline (i.e. pre-pregnant) bone mass measurements are 
often unavailable, and thus problems associated with a pre-existing low bone mass may 
be unforeseen. This 'pregnancy-associated osteoporosis' may be due to other systemic 
causes such as viral infections, ischemia or trauma. 
L. Maternal Calcium and Bone Metabolism during Lactation 
Following parturition the mammalian system promptly shifts its metabolic priority 
from providing the growing fetus with its mineral needs to supplying copious amounts of 
calcium for transfer across mammary epithelial cells into the milk (5-7). The calcium 
content of human breast milk has been shown to range anywhere from 25 -36 mg/1 OOml 
(169-171). This translates into a typical maternal loss of21 0-400 mg of calcium into the 
breast milk each day, although losses of up to 1000 mg a day have been observed (172). 
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These lactational demands impose a challenge to the maternal calcium regulatory system 
ofboth humans and animals, which is even greater than the demands of pregnancy. 
Unlike pregnancy, however, the main maternal adaptation to meet the demands of 
lactation is not a doubling of intestinal calcium absorption, but rather an increase in 
skeletal resorption of calcium from the maternal skeleton (5-8, 155, 168, 173-175). Proof 
of increased bone resorption comes from histomorphometric analysis of bone in animals 
(5-8, 156, 168). In humans, serum and urine markers ofbone formation and resorption 
have been used to assess bone turnover during lactation (because of the invasive nature of 
bone biopsy). Markers of bone resorption (TRAP, Dpd/creatinine) are increased 2-3 fold 
during lactation (5-8, 141, 116, 119). Thus, despite the proportional metabolic 
requirements during pregnancy and lactation, the mechanism by which mineral is 
obtained varies quite significantly (5-8). It has been noted that PTHrP, in the context of 
low estrogen, may be the primary mediator of skeletal calcium mobilization during 
lactation (Figure 9) (175). 
M. Alterations in Hormonal Regulators of Calcium Homeostasis during Lactation 
The hormonal milieu of lactation varies from that of pregnancy, as well as from 
the non-pregnant state (5-8, 149, 154, 155, 175 - 183). Lactation induced alterations in: 
PTH, 1, 25-dihydroxyvitamin D, calcitonin, PTHrP and the gonadal steroids are discussed 
below. 
1. Parathyroid Hormone 
Older studies in humans, which used assays that also measured biologically 
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J, GnRH 
Figure 9: Maternal Calcium and Bone Adaptations during Lactation. High circulating prolactin 
levels during lactation and suckling suppress the gonadotropin-releasing hormone (GnRH) pulse centre in 
the hypothalamus, resulting in suppression of the pituitary gonadotropins (i.e. luteinizing hormone (LH) 
and folicle-stimulating hormone (FSH) (175). This cascade of events causes a suppression of the ovaries, 
ovulation and production of estradiol. Hypoestrogenernia continues throughout lactation. PTHrP, produced 
by the breast during lactation, along with low circulating estrogen, may be the primary cause of skeletal 
calcium mobilization during lactation. Image by C.S. Kovacs, 2005. 
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inactive fragments ofPTH, have shown increases in PTH during lactation (176). In 
contrast, however, newer intact PTH assays, clearly show a decrease in serum PTH levels 
by as much as 50% during lactation (5-8, 149, 155, 164, 177, 178). Consistent with this 
finding is the fact that lactating hypoparathyroid women have been shown to have 
normalized blood calcium and phosphorus levels and thus do not require additional 
calcium and calcitriol supplementation (179). As well, hypoparathyroid women have 
shown to lactate successfully (179). This suggestion oflack of a role ofPTH during 
lactation directed many researchers towards the potential role ofPTHrP at this time. PTH 
levels in rats and mice also decrease during lactation. Preliminary experiments in mice 
lacking the PTH gene have shown that BMC losses during lactation in PTH null mice are 
no different than in the WT littermates ( 48-50). 
2. 1, 25-Dihydroxyvitamin D 
In humans 1, 25-dihydroxyvitamin D levels are typicallyunaltered by lactation 
(5-7, 124, 127). Levels of1,25-dihydroxyvitamin D decrease from that ofpregnancy 
lactation to that ofnon-pregnancy during lactation (5-7, 124, 127). In one study, however, 
women nursing twins were found to have higher 1, 25-dihydroxyvitamin D levels than 
women nursing singletons (184). 
Studies in lactating rats, in contrast, have shown elevated levels of 1, 25-
dihydroxyvitamin D (180). These elevations in circulating 1, 25-dihydroxyvitamin D 
have been prevented by supplementing the diet with additional calcium (180). 
Furthermore, the specific role of 1, 25 dihydroxyvitamin D in regulating the cycling of 
BMC during lactation has been tested using a genetically engineered mouse model 
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lacking the VDR (139). During these studies Vdr null mice were switched to a 2% 
calcium chow at 10 weeks of age to increase fertility (139). The Vdr null BMC dropped 
by 0.137 grams (36%) from pregnancy to late lactation and the WT mice BMC dropped 
by 0.188 grams (36.2%) during the same period. Although these values did not vary 
significantly from each other (i.e. the bone mass lost during lactation was of a similar 
magnitude), the V dr null still had a BMC of 0.465 grams (122% of the respective baseline 
BMC versus 85% percent in the WT siblings) compared to the respective pre-pregnancy 
baseline BMC values (138). Due to the fact that VDR deficient mice have an increase in 
BMC during pregnancy suggests that during lactation calcium absorption may occur 
independently of the VDR and 1,25 dihydroxyvitamin D (139). 
3. Parathyroid Hormone-Related Protein 
Despite the decline in circulating PTH during lactation in both rodents and 
humans, increased urinary cAMP excretion, as seen hypoparathyroidism, provided 
indirect evidence of another PTH-like hormone functioning at this time (184, 185). The 
peptide is thought to be PTHrP. In humans, PTHrP mRNA expression is increased in 
mammary tissue during lactation (185 - 189) (Figure 9). Furthermore, an abundant 
amount ofPTHrP is secreted into the milk (191, 192). It is currently unknown ifPTHrP, 
present in the milk, plays an important role in the developing neonate (191, 192). 
Studies in mice have suggested that PTHrP is part of a lactational mammary-bone 
feedback loop (Figure 9) (186 - 193). Proof of a role of PTHrP is illustrated in studies 
using mice that have been genetically engineered to lack mammary gland PTHrP mRNA 
and milk PTHrP (193) (i.e. mice carrying afJ-lactoglobulin promoter-driven Cre 
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transgene, one null PTHrP allele, and onejloxed PTHrP allele). Mammary epithelial 
expression of Cre during late pregnancy and lactation resulted in efficient deletion of the 
PTHrP gene. Findings illustrated that mice with PTHrP absent from the mammary tissue 
during lactation had significantly lower circulating PTHrP levels versus their WT 
littermates (193). These mice were found to lose less BMC as assessed by DXA by day 
11 oflactation versus their WT litter- mates (i.e. control mice had a BMC of0.044 ± 
0.001 g/cm2 versus BLG-Cre/PTHrP1ox!- mice had a BMC of0.048 ±0.002 g/cm2 , p<O.Ol) 
(193). Thus, these finding suggest that the mammary tissue is a major contributor to 
circulating PTHrP levels and that mammary PTHrP levels positively correlate with bone 
resorption rates at this time (193). Thus, mammary tissue PTHrP is a contributor to 
lactational bone loss, but not all bone loss is contributed to PTHrP, as BLG-
Cre/PTHrP1ox!- mice still experienced lactational BMC losses (193). 
Studies in mice have also demonstrated that the CaR, which becomes expressed 
on mammary epithelial cells at the transition from pregnancy to lactation, regulates 
PTHrP production and calcium transport (188, 189). Increasing concentrations of calcium 
and neomycin suppressed PTHrP secretion by mammary epithelial cells in vitro (188). In 
vivo, however, it was shown that systemic hypocalcemia increased PTHrP production. 
( 189). Authors of this work concluded that, in mice, PTHrP is required to stimulate the 
osteoclastic bone resorption needed to induce the normal loss of BMC during lactation 
(189). 
4. Sex Steroids and Other Hormones of Lactation 
In both humans and rodents prolactin stimulates lactogenesis, or milk production, 
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by acting together with cortisol and insulin to stimulate the transcription of the genes that 
encode milk proteins (194- 196). As lactation is being established prolactin levels are 
consistently elevated (Figure 8). After this period, however, prolactin levels increase in 
response to the suckling reflex stimulus (194-196). Elevated circulating prolactin levels 
during lactation suppress the gonadotropin-releasing hormone (GnRH) pulse centre in the 
hypothalamus, resulting in suppression of the pituitary gonadotropins (i.e. luteinizing 
hormone (LH) and folicle-stimulating hormone (FSH) (194). This cascade of events 
causes a suppression of the ovaries, and thus ovulation, ultimately decreasing production 
of estrogen (194-196). 
Hypoestrogenemia has been widely assumed as an important trigger leading to 
increased bone resorption during lactation. Studies in mice, however, have shown that low 
estradiol explains only part of lactational bone loss (175). Mice treated with estrogen 
during lactation experience a 50-60% reduction in the amount of bone lost by DXA when 
compared with untreated mice (175). It is important to note, however, that treatment in 
this study provided estrogen doses that were 4-fold higher than in normal circulation, thus 
providing results for pharmacological overtreatment, and not simply physiological 
replacement. Even with pharmacological doses of estrogen mice still continued to lose 5-
7% of their bone mass between days 4 and 12 of lactation (175). Thus, the lactational 
bone phenotype is likely due to other factors in addition to low estrogen levels. 
In rats, high circulating prolactin levels of lactation have been shown to stimulate 
PTHrP production in vivo thus reinforcing the brain, as a physiological contributor to the 
mammary-bone feedback loop, and ultimately skeletal bone loss (Figure 8) (140). 
Reinforcing this link is the fact that PTHrP has been shown to be elevated in states of 
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hyperprolactinemia other than lactation (197). Both prolactin and PTHrP are induced by 
suckling and prolactin has been shown to upregulate its own receptors (140, 197). As a 
consequence, increased prolactin may possibly perpetuate PTHrP's bone resorbing effects 
on the maternal skeleton (Figure 8) (140, 187, 197). One study in rats also suggested that 
PTHrP production from the lactating mammary gland is suppressed by progesterone 
(185). Progesterone dramatically falls after delivery, thus possibly disinhibiting PTHrP 
production by lactating mammary glands and resulting in considerable amounts ofPTHrP 
secreted into the milk (189, 190). Furthermore, skeletal losses during lactation occur 
irrespective of ovariectomy, adrenalectomy, or subsequent pregnancy (5-8). 
N. Calcitonin during Lactation 
Studies in lactating humans and animals have shown elevated calcitonin levels in 
the serum during lactation, even in the absence of the thyroid (150, 152, 153, 184). High 
circulating calcitonin levels during lactation, like that of pregnancy, have been speculated 
to have a role in the protection of the maternal skeleton at this time (150, 152, 153, 184). 
Several lines of evidence exist to suggest a possible role for calcitonin during 
lactation in addition to the aforementioned studies on post-thyroidectomized sheep, rats 
and goats (refer to section J. Calcitonin during Pregnancy). Levels of calcitonin in the 
breast milk of humans have been found at concentrations significantly higher then that in 
the maternal serum (153 ), as well mothers nursing twins have been found to have slightly 
higher calcitonin levels verses their singleton nursing counterparts (122). In rats calcitonin 
has been found to be expressed in the gonadotropes of the anterior pituitary gland (78) 
and when administered intravenously it has also shown to inhibit prolactin release from 
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rat anterior pituitary cells (198- 200) which may directly affect milk production. As well, 
targeted overexpression of calcitonin in gonadotrophs of transgenic mice leads to chronic 
hypoprolactinemia (20 1 ). In rodents, CTR mRNA expression is induced in the mammary 
epithelium during pregnancy and lactation, suggesting that calcitonin may have paracrine 
regulatory activity in this tissue at that time (79, 202). As well, calcitonin and the CTR are 
also expressed in T47D and MCF7 breast cancer cell lines. 
Whether or not calcitonin or the CTR has an essential role in calcium metabolism 
during lactation was largely unanswered by the aforementioned studies in sheep, rats and 
goats (150, 152, 153, 184). This research was carried out before targeted strategies to 
manipulate the mammalian genome were created, and many before extrathyroidal sources 
of calcitonin were appreciated. Therefore, a true model of calcitonin deficiency during 
lactation has not been examined until now. Studies of calcium metabolism in the 
complete absence of calcitonin could reveal possible physiological roles of calcitonin 
during lactation. 
0. Systemic Adaptations to Lactation 
The large demands for mineral throughout pregnancy are met by several systemic 
alterations in the maternal intestines, kidneys and skeleton (Figure 6). 
1. Intestinal Adaptations during Lactation 
In humans intestinal calcium absorption falls to a level that is no different than 
that of non-pregnancy during lactation (Figure 6) (5-8, 117, 119, 121 - 123, 136, 149, 
156). This translates to approximately 30% of dietary calcium intake. This decline in 
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calcium absorption from pregnancy to that of lactation is thought to occur mainly as a 
consequence of the respective decrease to normal in 1, 25-dihydroxyvitamin D levels at 
this time (5-8, 117, 119, 121 - 123, 136, 149, 156). This decrease in intestinal absorption 
may suggest that calcium needs are being met primarily through other homeostatic 
mechanisms (i.e. increased skeletal reabsorption) (5-8, 117, 119, 121 - 123, 136, 149, 
156). In addition, clinical studies of calcium supplementation show evidence that suggests 
that optimal lactation and maternal bone health does not depend on an increase in calcium 
intake by the breastfeeding mother ( 6-8). 
Unlike humans, intestinal calcium absorption in rats, however, appears to remain 
elevated 2-fold above non-pregnancy levels (Figure 6) (5-7). This elevated intestinal 
absorption may be maintained to support a large litter size, or to accommodate a short and 
intense lactation period. 
2. Renal Adaptations during Lactation 
In humans, urinary calcium excretion decreases during lactation versus that seen 
during pregnancy (Figure 6)(5-8, 117-123, 136, 149, 156). This occurs as a result of a 
rise in renal tubular reabsorption of calcium (5-8, 118-123, 136, 149, 156). Low urinary 
calcium in the setting of high calcium in the blood suggests that tubular reabsorption of 
calcium might be increased to account for the reduction in calcium excretion and this is 
likely due to the increased physiological demand for calcium at this time. Renal calcium 
excretion has been shown to be similarly reduced in the lactating rat (5-7, 118 -123). 
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3. Skeletal adaptations during Lactation 
Perhaps the most profound of all systemic changes are those that have been seen 
in the skeleton during lactation (Figure 6) (5-8, 117-123, 149, 156). The metabolic 
alterations are in place during lactation to ensure that adequate mineral is available for the 
production ofbreast milk and the survival of the growing neonate. On rare occasion the 
mineral demands of lactation may be significant enough to cause a woman to suffer from 
fragility fractures (203 - 206). 
Markers of Bone Turnover during Lactation 
In humans, histomorphometric data is unavailable during lactation due to the 
invasive nature of bone biopsy. Serum and urine markers ofbone resorption and serum 
makers of bone formation are therefore used at this time to evaluate bone turnover. 
Markers of bone resorption (e.g. TRAP, Dpd/creatinine) are clearly elevated 2- to 3-fold 
during lactation and especially above values ofpregnancy (5-7, 114, 115, 122, 123,207, 
208). Bone formation (e.g. OC, BSAP and PICP) markers have also been found to be 
generally elevated during lactation above that of pregnancy (5-7, 114, 115, 122, 123,207, 
208) but not as markedly increased as the resorption markers, thus there is net uncoupling 
of turnover. 
Bone turnover is also elevated in rodents during lactation. Histomorphometric 
analysis has revealed an increase in osteoclast number during lactation as well as losses of 
up to 30% of bone mineral after a full lactation cycle ( 154, 168). Bone markers have 
shown a greater increase in bone resorption than bone formation (152, 168). In addition, 
studies in rats have shown that the large demands for mineral during successive lactation 
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periods is associated with a decrease in cortical and trabecular bone strength as well as a 
decrease in cancellous bone volume (163). 
In summary, bone turnover is increased during lactation in both humans and 
rodents. The net effect, however, appears to be that of bone resorption. 
Flux in Bone Mass during Lactation 
BMC losses of3- 10% have been found at trabecular sites (e.g. lumbar spine and 
hip) with smaller losses are seen at cortical sites, after 2-6 months of exclusive lactation 
in humans (5-7). This translates to a BMC loss of 1-3% per month while breastfeeding (5-
7). BMC losses associated with post-menopausal osteoporosis are considered rapid at 
> 1% per year in humans. Thus, losses of 1-3% per month seen during lactation are 
quantitatively more profound (5-7). 
Rats and mice, in contrast, have shown BMC losses amounting to 25-30% of 
BMC via DXA at trabecular rich sites after 3 weeks of exclusive lactation (Figure 7) (6-
8, 168) with smaller losses at cortical sites. These losses are likely more exaggerated 
because of the significant demands of 8-12 suckling pups (6-8, 168). These tissue density 
decreases in rodents have also been confirmed using J..!CT (6-8). Cortical periosteal bone 
formation and bone volume has also been shown to increase from early gestation to the 
end of pregnancy in rats (161 , 162). It has been suggested that this early increase in bone 
formation, as well as the increase in bone volume may be a mechanism for storing 
mineral for the subsequent decrease in bone volume and BMC that results from milk 
production during lactation (161, 162). 
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Lactational BMC losses in both human and rodents are obligatory and occur 
irrespective of dietary calcium intake (6-8, 156, 183, 209, 21 0). In several randomized, 
placebo-controlled trials, women that received calcium supplementation daily throughout 
lactation lost amounts of mineral that were no different than their placebo receiving 
counterparts (156, 183, 209, 21 0). Authors concluded that calcium supplementation does 
not prevent bone loss during lactation (156, 183, 209, 21 0). Even in a study of lactating 
Gambian woman where calcium intake is relatively low (i.e. 283 mg/day), randomized 
supplementation with almost triple the amount of calcium had no effect on breast-milk 
calcium concentration or changes in maternal BMC (209, 21 0). This study suggested that, 
in women with low calcium intakes, there was no direct benefit from increasing calcium 
intake during lactation, and that physiological mechanisms operate regardless of dietary 
intake to supply calcium for breast-milk production. Opposing results, however, have 
been noted. One particular study showed that increased dietary calcium intake was 
associated with improved calcium balance in women with habitual intakes of <500 mg 
calcium per day (116). 
The mechanisms underlying the bone loss that occurs during lactation are not 
completely understood (5-7). Hypoestrogenemia is well established as the primary 
contributor to the bone loss associated with post-menopausal osteoporosis (11 , 12, 17, 
203-208, 211). During lactation, however, low estrogen is thought to be only part of the 
honnonal milieu resulting in bone loss (Figure 8) (5-8). Treatment of lactating mice with 
pharmacological levels of estrogen has shown to decrease histomorphometric parameters 
and urinary markers of bone resorption, reducing the amount ofbone loss by 50-60%, but 
not completely preventing it (175). It is important to note that this study may not show the 
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contributions of physiological levels of estrogen to bone loss, but perhaps an exaggerated 
model of estrogen effects based on a pharmacological dosage. Additional proof, regarding 
the role of estrogen in preventing bone loss lies in studies of women who have been 
rendered estrogen deficient through the use of GnRH agonist therapy, for the treatment of 
medical conditions such as endometriosis and uterine leiomyomata (212, 213). After six 
months ofGnRH agonist therapy, women lost about 1-4% of their BMC at trabecular-
rich sites (212, 213). Lactation, in contrast, is accompanied with only moderate estrogen 
deficiency, yet BMC losses amount to 5-10% at trabecular-rich sites after six months (5-
8, 161, 163, 164, 167, 183). 
Studies in mice have illustrated that BMC loss during lactation is attributed to 
both high levels of mammary-derived PTHrP and low levels of circulating estrogen (175, 
193) (Figure 8). More specifically, the relative contributions of estrogen and PTHrP can 
be highlighted through studies that show that: 1) circulating estrogen levels have been 
found to be low during mid-lactation and correlated negatively with bone resorption 
markers (175), 2) treatment of lactating mice with estrogen lowers urinary CTx levels and 
histomorphometric parameters of bone resorption, and reduced the amount of bone lost 
significantly but not completely (175) and 3) mice lacking mammary derived PTHrP lose 
significantly less bone mass during lactation versus the normal siblings (193). Thus, it is 
likely that mammary derived PTHrP during lactation acts synergistically with 
hypoestrogenemia to trigger accelerated bone resorption during lactation. 
Although rare, osteoporosis may present itself during lactation (201-204). The 
occurrence is quite rare, and may arise from an unrelated condition or an exacerbation of 
a pre-existing low bone mass (203 - 206). These women may present clinically with 
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vertebral crush fractures during or after breastfeeding (203 - 206). At this time, PTH and 
calcitriol are typically normal or slightly reduced (203 - 206). In one known case of 
lactational osteoporosis, PTHrP levels were found to be elevated for months after weaning 
(205). The extent, however, to which PTHrP contributes to the reduction of bone density 
during lactation is only now being appreciated (5-7, 201-204). 
In the long-term, for the vast majority, the consequence of lactation-induced bone 
loss does not appear of clinical concern (5-7). Most epidemiological studies of pre- and 
postmenopausal women have found that a history of lactation has no adverse effects on 
bone health (6-8, 183,203,208, 214). In fact, some studies suggest that breastfeeding 
may reduce the risk of spinal and hip fracture after menopause (173, 214 ). 
4. Mammary Gland Adaptations during Lactation 
Lactation is the primary physiological function of the mammary gland. Many of 
the unique adaptations underlying lactation still remain an enigma (8). Lactating 
mammary tissue has been shown to express: calcitonin, CTR, CaR and PTHrP mRNA (5-
8, 79, 80, 174, 186 -191 ). During lactation the breast becomes a calcium-sensing organ 
(188). PTHrP acts through the CaR in response to extracelullar calcium levels to control 
the calcium, and possibly water content of milk (Figure 8) (187). PTHrP appears to 
mimic the normal bone resorbing actions of PTH, by acting through the PTH 1 receptor 
(5-8, 189). In addition, suckling, as well as prolactin, has been shown to stimulate PTHrP 
production during lactation (Figure 8) (197). PTHrP levels are found to be extremely 
high in the milk of humans and animals (191, 192). This research suggests several 
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important pathways in which the breast, brain and bone are linked during lactation 
(Figure 8). 
P. Maternal Calcium and Bone Metabolism during the Post-Weaning Period 
Despite losses of up to 5-l 0% of total body BMC after 6 months of exclusive 
lactation in humans, and losses of up to 3 5% of total body BMC after 3 weeks lactation in 
rodents, mineral is completely and rapidly restored after weaning. Within 3-6 months in 
humans and 3 weeks in mice BMC values via DXA have shown to be no different than 
that of pre-pregnancy (38-40, 215- 217). 
It is notable that the adult skeleton is normally able to regain little of the mineral 
that it has lost (e.g. after periods of weightlessness, prolonged corticosteroid therapy, 
estrogen withdrawal, etc) (11, 12, 19-21) and thus, the post-lactation period is a unique 
interval in which the skeleton can accrete substantial mineral during adulthood (5-7). A 
clearer understanding of the mechanisms underlying this rapid post-weaning skeletal 
remineralization may help to isolate molecular pathways and specific factors involved in 
bone mineral accretion. These factors may be important in the establishment of novel 
phannacological therapies for the treatment of metabolic conditions characterized by 
excessive bone loss (e.g. osteoporosis). 
Weaning is typically defined as the gradual process of replacing breast milk 
feeding with an increasing amount of ingested nutrients. In animal studies, weaning is 
often the direct removal of suckling offspring from the presence of the mother (38-40, 
119, 208, 215-217). In spite of the potential information that the post-weaning skeleton 
may reveal about the molecular biology of bone mineral accretion, limited data is 
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available that considers the actual mechanisms underlying the anabolic actions of the 
maternal skeleton at this time (215- 217). Below is a summary of what is currently known 
about calcium metabolism during the post-weaning period. 
Q. Alterations in Hormonal Regulators of Calcium Homeostasis during the Post-
Weaning Period 
Weaning has also been shown to affect some of the hormonal players involved in 
calcium homeostasis (119, 208, 215-217). Studies considering PTH, PTHrP, VDR, the 
sex steroids and calcitonin in both humans and rodents are noted below. 
A few studies in humans have shown elevations in PTH during the post weaning 
period (up to 6 months) versus that of pregnancy and lactation (119, 183). It is important 
to note, however, that these studies were based on single measurements at only one 
selected time point during the post-weaning period. A study in mice found contrasting 
data, in that, PTH levels returned to the non-pregnant level 7 days post-weaning (217). 
Furthermore, preliminary studies in mice null for the PTH gene suggest that PTH is not 
required for BMC remineralization, as the skeleton return to its pre-pregnant state post-
weaning, despite lacking PTH ( 48-50). 
PTHrP may be involved in the remineralization of the maternal skeleton post-
weaning through its actions on bone or mammary tissue (215-217). Within bone PTHrP is 
produced by cells of the osteoblast lineage and acts through the PTHlR on mature 
osteoblasts (60). Six week old mice with osteoblast-specific targeted disruption ofPTHrP 
were found to have an increase in marrow space, reduced BMD and bone volume, 
scattered thin spicules of trabecular bone and decreased trabecular number, when 
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compared to age matched control mice (219). It is possible that PTHrP produced by 
osteoblasts may stimulate the recovery after weaning in the absence of the hormonal 
milieu of lactation (i.e. high prolactin and low estradiol) (218, 219). This possibility is 
currently being explored in our lab. Mammary derived PTHrP could also be considered a 
possible candidate in aiding in skeletal recovery post-weaning. The breast is powerful 
source ofPTHrP during lactation and might remain so during recovery. Rapid mammary 
tissue involution after lactation, may however over-ride this explanation. Furthetmore, 
circulating PTHrP levels have been shown to correlate with levels of prolactin during 
lactation and the post weaning period (187, 217). 
Preliminary studies in genetically engineered mouse models have shown that the 
VDR may not be required for skeletal remineralization during the post-weaning period 
(138). More specifically, mice lacking the VDR gene completely regain BMC levels post 
weaning, as per normal WT mice (139). 
During weaning, or possibly earlier, ovarian function resumes causing estrogen 
levels to return to normal (215). This return of estrogen to the pre-pregnancy level may 
assist in the remineralization of the maternal skeleton (215). Physiologically, estrogen 
acts by inhibiting the bone resorbing osteoclasts cells, and thus it seems possible that 
post-weaning rise in skeletal bone mass may in part be contributed to this effect (222-
224). Additional support for the anabolic effects of estrogen on bone comes from the 
post-menopausal period (11 , 12). Estrogen receptors are present on the bone forming 
osteoblast cells (II , 12). At the cellular level estrogen has been shown to have an anti-
apoptotic effect on osteoblasts (68, 222). It has also been demonstrated that osteoclast 
formation from mononuclear hematopoietic stem cells and bone resorption activity of 
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mature osteoclasts is inhibited by estrogen, which leads to reduced depth of resorption 
lacunae (223). Most estrogen effects are thought to be mediated via nuclear estrogen 
receptors alpha (ERa) and beta (ER~) (222). 
There are, however, a multitude of additional calcium regulating hormones and 
factors that have not been explored in detail during weaning. The ratio of RANKL to 
OPG in controlling osteoclastogenesis, and thus bone loss should be considered during 
weaning, as a decrease in this ratio could possibly contribute to the bone formation post-
weaning. Supporting this theory is a recent finding in mice that suggested that RANKL 
expression is decreased during the post-weaning period (217). 
Recovery of the maternal skeleton to its pre-pregnant state post weaning likely 
involves a number of complex metabolic pathways (215-218). It is also important to note 
that many rodents undergo post-partum estrus, and thus can conceive the day immediately 
following delivery. Thus, rodent calcium metabolism is particularly challenged, as many 
of these animals are concurrently pregnant and lactating. Despite the simultaneous 
demands for mineral, the rodent skeleton can completely remineralize after weaning. 
R. Calcitonin during the Post-Weaning Period 
Despite the lack of evidence that elevated or depressed calcitonin levels may have 
any major physiological effect in humans, a recent study in rats has implicated calcitonin 
in the synchronization of mineral prior to, during and post lactation (216). In this 
particular study, rats were shown to have a five-fold increase in maternal calcitonin levels 
at 24 hours post-weaning (216). These changes were concurrent with a finding of rapid 
inactivation and apoptosis ofosteoclasts (216). The authors concluded that these changes 
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were similar to the reversal phase of a bone remodeling cycle, where bone formation 
begins and resorption slows down (216). More research is needed to investigate if 
calcitonin is involved during the weaning process. 
It is also relevant to note that pituitary lactotrophs express the CTR (75) and 
pituitary calcitonin has been shown to inhibit PRL gene transcription, and lactotroph cell 
proliferation (78). Studies in mice have also shown that targeted overexpression of 
calcitonin in the pituitary gonadotrophs leads to chronic hypoprolactemia (201). Due to 
the fact that PRL is a key player in milk production and possibly bone turnover during 
lactation, a sharp increase in calcitonin post-weaning could possibly provide the 
necessary signaling required, initiating the anabolic cascade of events at the time. 
S. Systemic Adaptations to Weaning 
Much less is known about the systemic alterations in the maternal intestines, 
kidneys and skeleton during weaning (Figure 6). The few finding that exist, are noted 
below. 
1. Renal and Intestinal Adaptations during the Post-Weaning Period 
In humans, the renal and intestinal handling of calcium has not been explored in 
detail during the post-weaning period. Fractional calcium absorption was found to be 
higher in lactating women after weaning (0.37+/-0.02) compared with non-lactating 
postpartum control subjects (0.31 +/-0.02) (120). The authors concluded that lactation 
stimulates an increase in fractional calcium absorption, but the response is only apparent 
after weaning or the resumption of menses ( 120). It is also important to note that this 
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small difference in calcium absorption may not prove to be clinically significant. No 
rodent data is available reading the renal or intestinal handling of calcium during the post-
weaning period. 
2. Skeletal Adaptations during Post-Weaning 
Limited data on bone turnover markers or histomorphometry is available post-
weaning in humans. A study considering changes in bone metabolism in 10 women from 
pre-pregnancy through post-weaning found no significant difference in osteocalcin versus 
that of pre-pregnancy (226). A slight increase in BSAP was found post-weaning 
compared to pre-pregnancy. Another group found increases in serum osteocalcin post-
weaning (227). 
In comparison, a study in rats, immediately following weaning found there was a 
profound increase in the osteoblast population in maternal cancellous bone (216). In 
contrast, a more recent study in mice concluded that serum markers of bone formation 
stayed the same as that seen during lactation (i.e. elevated above pregnant and non-
pregnant levels) (217). In this study, although no change was seen in osteoblast number or 
bone formation rates, there was a significant increase in osteocalcin and numbers of 
osteoblast colonies found in culture (217). This suggested that osteoblast signaling may 
indeed vary during the post-weaning period, despite no significant alteration in osteoblast 
number. Another study in rats showed that after lactation all indices of bone formation 
rates were significantly greater versus those observed in the controls, which is indicative 
of higher bone turnover rates (161). At 8 weeks after weaning, none of the indices of bone 
formation and turnover were significantly different from the controls (161 ). 
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Few studies have also considered bone resorption changes that occur in maternal 
osteoclasts during the transition from lactation to post-lactation. A study in rats assessed 
skeletal samples during and after lactation. Findings showed a rapid change in the 
osteoclast population after weaning, resulting in less resorptive surfaces (216). 
Osteoclasts were found to detach from their bone surfaces, losing their ruffled borders, 
and becoming fragmented, showing apoptosis within 24 hr after lactation (216). A more 
recent finding in mice suggested that RANKL expression is decreased during the post-
weaning period (i.e. RANKL being involved in osteoclast differentiation and function) 
(217). More research is needed to explore the post weaning period. 
Studies in humans have shown a rapid increase in femur, spine and total body 
BMC/BMD during the weaning period (208, 225). This has been found to be equal to a 
gain of 0.5-2% in BMD per month after lactation. A study in humans showed that during 
the weaning period women gained significantly more bone in the lumbar spine than did 
non-lactating women (5.5% versus 1.8%) (208). Authors concluded that earlier 
resumption of menses was associated with a smaller loss of bone during lactation and a 
greater increase of bone after weaning (208). A study in mice showed that after a 28-day 
period, BMD had increased by 37% within the spine, 27% within the femur and 25% for 
the total body (215). In another study at 8 weeks after weaning, the amount of cancellous 
bone volume had increased and there was no significant difference from controls (161). 
It can be concluded based on limited findings, that the post-weaning period is 
accompanied with a significant anabolic phase in the skeleton versus that seen at other 
time points during reproduction or adult life. Recovery of the maternal skeleton to its pre-
pregnant state appears to occur independent ofPTH and 1, 25- dihydroxyvitamin D. 
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Possible hormonal changes in the microenvironment that may assist in skeletal anabolism 
include increases in estrogen and calcitonin. It is likely that the post-weaning period is 
accompanied by a number of unknown metabolic pathways. More studies are needed to 
determine the mechanisms that trigger these rapid BMC gains. 
In summary, weaning as well as the previously mentioned periods of pregnancy 
and lactation, are accompanied with unique systemic and skeletal adaptations (5-8, 114-
117, 119, 122-125). Of key interest is the role of the calcitonin gene and its pep tides 
during these time points. This will be the focus of the work in this thesis. 
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II. Project Purpose, Hypothesis and Description 
Research over the past 30 years has largely concluded that mammalian calcitonin 
at physiological doses is not required for survival (1, 2, 70, 6-8). Proof, of this theory, lies 
in physiological studies that have illustrated no harmful effects of calcitonin excess or 
deficiency (82-85). Thus, it has been speculated that calcitonin may only remain 
physiologically important in lower vertebrates that dwell in the calcium rich sea (1, 2, 6-
8, 94). 
A few studies, nevertheless, have persisted in suggesting that mammalian 
calcitonin is required during times of increased calcium demand, such as that seen during 
pregnancy and lactation (89, 90). It is important to note, however, that these older animal 
studies were based on surgical models of calcitonin deficiency and were fraught with 
confounding variables, such as side-effects of thyroid ablation and the Jack of awareness 
of the extra-thyroidal sources of calcitonin. In light of this work and the possibility that 
calcitonin may have a physiological role in mammals, this doctoral research was carried 
out to re-test the hypothesis that calcitonin is required to protect the maternal skeleton 
from excessive resorption during pregnancy and lactation. Assuming this hypothesis to be 
true, our secondary hypothesis was that calcitonin acts at the level of the pituitary, 
mammary tissue and osteoclasts to regulate skeletal metabolism during lactation. 
These hypotheses were approached by using a genetically engineered mouse 
model in which the ctcgrp gene has been ablated. In these genetically manipulated 
colonies, WT mice have both calcitonin alleles (i.e. these animals are genetically normal), 
HET mice have one calcitonin allele plus one mutant allele (i.e. neomycin resistant copy) 
and ctcgrp null mice have 2 mutant alleles. Ctcgrp null females, versus their WT sisters 
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were studied during pre-pregnancy, pregnancy, lactation, and during the post-weaning 
period. Studies examined BMC, bone microarchitecture, biomechanics, as well as the 
levels of various hormones and minerals in the serum, urine, milk and breast tissue. 
Differences seen in the null mice could then be attributed to a direct or indirect 
consequence of calcitonin and or CGRP-a ablation. 
These studies were anticipated to provide definitive evidence about the role of 
calcitonin during reproduction in mice within the breast, brain and bone (Figure 10), 
which in tum could lead to confirmatory studies in hwnans that lack physiological levels 
of calcitonin. A clearer understanding of the mechanisms underlying the rapid 
demineralization of the maternal skeleton during lactation and the subsequent restoration 
of mineral during the post-weaning period could lend invaluable information regarding 
the etiology of bone diseases and the creation of anabolic based therapies for the future. 
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Figure 10: Does Calcitonin have a role within the Breast, Bone and Brain during 
Reproduction? Elevated prolactin (PRL) levels during lactation stimulate PTHrP production 
by mammary tissue, and suppress the GnRH pulse center in the hypothalamus, in turn 
suppressing the pituitary gonadotropins (LH and FSH) and then the ovaries [ovulation, 
estradiol, and progesterone (PROG) production]. Low estradiol and high mammary-derived 
PTHrP act together to enhance osteoclast-mediated bone resorption. The presence of calcitonin 
and its receptors (CTR) within these key areas of calcium regulation (i.e. osteoclast , mammary 
tissue, and the pituitary lactotrophs) during reproduction suggests at least three pathways by 
which calcitonin could modulate BMC cycling during reproduction. 
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III. Materials and Methods 
A. Animal Husbandry 
1. Animals 
Ctcgrp-null mice were obtained from Dr. Robert F. Gagel ' s group at the 
University of Texas, M.D. Anderson Cancer Centre. These mice were created with 
targeted ablation of exons 3-5 of the murine calcitonin gene and genotyped by PCR, as 
previously described (1 03). Chimeras were originally crossed with C57BL/6 mice to 
produce germ line transmission of the targeted allele. The original strain was 
subsequently back-crossed into BLKWS mice (Taconic, Germantown, NY) (this is an 
outbred stock (NIH Swiss) with the exception of homozygosity for the non-agouti allele 
that gives black fur) for at least six generations, and the colony was maintained by 
breeding heterozygous-deleted mice together. 
2. Scheduled Mating and Litter Sizes 
Virgin first degree relative pairs of WT and ctcgrp null females were selected for 
study after 10 weeks of age (i.e. after peak bone mass was achieved). Experimental 
female mice were placed with heterozygous-deleted breeder males at approximately 
17:00 hours. Mice mated overnight and then were manually checked for the presence of a 
vaginal mucus plug at approximately 9:00 hours (i.e. the morning after mating). The 
presence of a mucus plug marked gestational day 0.5. Both pregnant and non-pregnant 
experimental mice were removed from the presence of the breeder male. Pregnant mice 
were subsequently placed in separate labeled cages. Non-pregnant mice were mated again 
the next evening. Normal gestation for these mice was 19 days. Weaning normally 
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occurred by 21 days oflactation, and was ensured by removing the pups from the mother 
on this day. At this stage the pups typically had started eating solid food and drinking 
water. All mice were given a standard chow (1% calcium, 0.75% phosphorus) and water 
ad libitum. 
Litters (i.e. number of pups from one mouse pregnancy) were counted at weaning 
(i.e. day 21 oflactation). 
3. Housing 
Mice were housed with regular light /dark cycles (9:00 am-9:00pm light). Non-
pregnant mice were housed 4 per cage. Nestlets (Ancare) were used for nesting in 
addition to standard bedding. All studies were performed with the prior approval of the 
Institutional Animal Care Committee of Memorial University. 
B. Reproductive Cycles 
Full reproductive cycles lasted approximately 70 days. Pre-pregnancy was defined 
as the 5-10 days prior to being placed with a breeder male and after the female mice had 
reached 12 weeks of age and during which time the BMC was stable. Pregnancy spanned 
19 days and for experimental purposes was further subdivided into 3 time points (early 
pregnancy: 7 days gestation, mid-pregnancy: 12-14 days gestation, and late pregnancy: 17 
- 19 days gestation). Lactation spanned 21 days and day 1 was noted as soon as the pups 
latched on the mother for suckling. Like pregnancy, lactation was also further subdivided 
into 3 time periods (i.e. early lactation: 7 days, mid-lactation: 12-14 days, late-lactation: 
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19-21 days). Weaning was defined as the day in which the suckling pups were manually 
removed from the mother (day 21 of lactation), and post-weaning (also referred to as 
'recovery') spanned 21 days even ifBMC had recovered prior to that date. Weaning was 
subdivided into 3 time periods (early weaning: 7 days, mid-weaning: 12-14 days, late-
weaning: 19-21 days). An additional time point for data collection included 24-48 hrs of 
lactation (see Figure 11 for a Schematic of this reproductive time line). 
C. Genotyping 
1. Mice Identification 
At weaning (i.e. 21 days of age) pups were separated into cages ( 4 mice per cage) 
based on gender. After brief anesthesia with isoflurane ™ (CDMV) mice ears were 
pierced with individual identification tags (i.e. the calcitonin colony was denoted with the 
letter ' S'). 
2. Tail Collection 
Using sterile razor blades (Smith Brand®), mouse's tail samples (approximately 1 
em) were clipped and collected at the time of weaning. Samples were then placed in 
microcentrifuge tubes (Fisher Scientific) containing 500!lL of lysis buffer (1 OOmM Tris 
HCL, pH 8.0 I 500 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0 I 0.2% sodium 
dodecyl sulfate (SDS)I 200 mM sodium chloride (NaCl)) containing 100 11g/ml 
proteinase K (Invitrogen). Tubes were subsequently incubated in an isotherm oven 
(Fisher Scientific) at 55° C overnight to digest. 
74 
Week 1 
Week2 
Week4 
Week 5 
Week6 
Week? 
Week8 
Week9 
Week 10 
Pre-pregnancy - baseline data was collected in virgin mice 
starting at 12 weeks of age 
Pregnancy- female mice were placed with male mice until a 
vaginal plug was observed indcating day one of gestation 
Early Pregnancy was denoted as the first week of gestation 
Late Pregnancy was denoted as 17-19 days gestation, as 
referred to as the 'peak of pregnancy' 
Partuition - after 18.5 days of gestation mice delivered pups 
24-48 post-partum 
Early Lactation was denoted as the 7th day of lactation 
Mid-Lactation was denoted as day 12-14 oflactation 
Late Lactation was denoted as 19-21 days of lactation 
Weaning (day 1) - the day the pups were removed from the 
mother 
Early Weaning- denoted as day 7 post-weaning 
Mid-Weaning - denoted as day 12-14 post-weaning 
Late Weaning- denoted as day 21 of post-weaning 
Figure 11: Schematic Time Line of Data Collection through Full Reproductive Cycles in 
Mice. Samples of tissue and serum as well as DEXA scans were collected at key time points 
throughout reproduction. 
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3. DNA Extraction 
After overnight incubation tail tissue was shaken by hand for 3 minutes and spun 
on a microcentrifuge (Thermoelectron!Fisher) for 10 minutes at a maximum speed (i.e. 
13,000 rpm). The supernatant was then decanted into fresh microcentrifuge tubes 
(Fisher Scientific) (Fisher Scientific) containing 0.5 ml isopropanol and inverted to 
precipitate the mouse tail DNA. DNA was then collected using small pipette tips, placed 
into microcentrifuge tubes (Fisher Scientific) containing 0.5 mL water and shaken for 5 
minutes to dissolve the DNA. Next 0.5 mL of phenol/ chloroform/ isoamyl alcohol 
(100:100:1) was then added and shaken vigorously for 60 seconds. The resulting turbid 
solution was then centrifuged for 2 minutes at 13,000 rpm. Then a pipette was used to 
remove the supernatant and it was placed into fresh eppendorftubes. 1 ml of0.12 M 
sodium acetate (NaOAc) in ethanol (ETOH) was added. The tubes were then inverted 
several times until the DNA was clearly seen in the solution. Samples were subsequently 
centrifuged for another 10 minutes (13,000 rpm) to precipitate out the DNA, supernatant 
was discarded and 1 ml of70% ETOH was added. Finally the samples were spun for a 
final I 0 minutes, ETOH discarded, and pellets were allowed to air dry. DNA pellets were 
resuspended in 50 - 200 f.!L ofTris EDTA buffer (TE) and stored at 4 o C. 
4. Polymerase Chain Reaction (PCR) 
PCR was performed on mouse tail DNA samples to establish the presence of the 
ctcgrp gene. WT, HET and ctcgrp null animals were identified by PCR analysis using a 3-
primer system specific to the ctcgrp gene sequence and the neomycin cassette. More 
specifically, the CT1 forward primer (sequence: CAG GAT CAA GAG TCA CCG CT) 
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was used to detect the retained portion of the WT allele, the CT3 primer (sequence: GGA 
GCC TGC GCT CCA GCG AA) was used to detect the deleted portion of the WT allele, 
and the CTN primer (sequence: GGT GGA TGT GGA ATG TGT GC) was used to detect 
the neomycin cassette (Figure 12). 
PCR cocktail was made using 1 OX PCR buffer ([Invitrogen] 20rnM Tris-HCl, pH 
8.4, 50 mM KCl), dNTPs ([Invitrogen] 0.2 mM of each dGTP, dTTP dATP, dCTP,), 
primers (CTl, CT3 and CTN), 50 mM MgCh (Invitrogen), Taq DNA polymerase 
([Invitrogen] 0.02 U/~J.L) and deionized water. Cocktail was aliquoted into PCR tubes 
(Fisher) ( 49 J.!L) and DNA (1.5 f.lL or 500 ng) was carefully added to this mix. Each tube 
was labeled with the mouse identification code and placed into the Peltier Thennal 
Cycler-Dual Alpha Blocks (PT-200 DNA Engine Thermal Cycler). 
The following PCR program was used: Step 1: 94 oc for 4 minutes, Step 2: 94 oc 
for 1 minute, Step 3: 63° C for 1 minute (-0.5° C per cycle), Step 4: 72° C for 1 minute, 
Step 5: back to Step 2 repeat lOX, Step 6: 94 °C for 1 minute, Step 7: 62 o C for 1 minute, 
Step 8: 72 ° C for 1 minute, Step 9: back to Step 6 repeat 30X, Step 10: 94 ° C for 1 
minute, Step 11: 62 ° C for 1 minute. Step 12: 72 ° C for 5 minute, Step 13: 4 ° C forever. 
5. Gel Electrophoresis 
Electrophoresis was performed on PCR products using a 1.2% agarose gel (2 g 
agarose [Invitrogen], 10 mL of lOX TAE [pH 8.0, 0.12M EDTA, 0.40 M Tris, 11.5% 
Glacial Acetic Acid] and 90 mL of deionized water, 0.06% ethidium bromide [Invitrogen] 
or 0.20% SYBR ®Safe). The gel solution was microwaved for 1 minute, briefly mixed 
and microwaved again for 1.3 minutes. Next, the solution was poured into a gel mold 
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Figure 12. Schematic of the Alignment of Primers used to distinguish the Retained and 
Deleted Portion of the ctcgrp gene. WT, HET and ctcgrp null animals were identified by 
PCR analysis using a 3-primer system specific to the ctcgrp gene sequence and the 
neomycin cassette. The CTl forward primer was used to detect the retained portion of 
the WT allele, the CT3 primer was used to detect the deleted portion of the WT allele, 
and the CTN primer was used to detect the neomycin cassette. 
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with well inserts and cooled for 10 minutes. Gel buffer (630 mL deionized water and 70 
mL 1 OX TAE) was added and gel inserts were carefully removed. Two microliters of 
Orange G (1 0 mL 1 Ox T AE, 50 mL Glycerol, 500 mg Orange G powder) was then added 
to each of the tubes of DNA and mixed. Ten microliters of each DNA/dye solution was 
then loaded into each of the wells. The power supply was then connected (200 volts) and 
the gel timed to run for approximately 30 minutes. After this time the gel was then 
exposed to UV light and an image was captured using Chemi-Imager Software and 
printed on Mitsubish Thennal paper (Perkin Elymer). 
The presence of a single 250 base pair (bp) band indicated that the mouse was 
WT, a band at 150 bp indicated that the mouse was a NULL, and finally a mouse with 
both the 250 bp and 150 bp bands was a HET (Figure 13). 
D. Data Collection and Storage 
1. Litter Sizes 
At the time of weaning (21 days) litter numbers were counted for WT and ctcgrp 
null mice. Due to normal losses of pups after birth, this number is nonnally lower than the 
number of pups that would have been observed at 24-48 hours after birth. 
2. Serum 
Serial blood samples were taken by either bleeding the tail vein or by cardiac 
puncture. Tail vein blood was collected by cutting the tip of the mouse tail with a sterile 
razor blade and manua1ly 'milking' blood down the tail vein into 1.5 mL micro-
centrifuge tubes (Fisher Scientific). On several occasions multiple bleeds were required 
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WT NULL HET 
~ 250 bp 
~ 150 bp 
Figure 13: Genotyping by Polymerase Chain Reaction (PCR) and Gel 
Electrophoresis. The presence of a single 250 base pair (bp) band indicated that the 
mouse was WT, a band at 150 bp indicated that the mouse was NULL for the ctcgrp gene 
(i.e. ctcgrp null), and finally a mouse with both a 250 bp and 150 bp band was HET for 
the ctcgrp gene. Wild-type = WT, Heterozygous= HET and Homozygous = HOM. 
80 
to obtain adequate volumes of tail blood for analysis. Cardiac puncture was performed, 
prior to euthanization, to obtain larger blood volumes. For this procedure, mice were 
anesthetized with a single intraperitoneal (i.p.) injection of a combination ofketamine 
hydrochloride (Wyeth~ and Xylazine (Bayer). Mice were then held with one hand 
firmly holding the scapular region together, to prevent limb or head movement. Sterile 5 
cc syringes (LuerLOK®) were attached to 22 gauge needles (PrecisionGlide®) and skin 
was pierced beneath the mouse ribcage (approximately 2 centimeters under the xiphoid 
process) at a slight angle until the heart was penetrated. Blood from the heart was 
subsequently drawn into the syringe, emptied into 1.5 mL microcentrifuge tubes (Fisher 
Scientific) (after needles were removed from the syringes to prevent red blood cell 
damage) and spun on a microcentrifuge (Thermoelectron) for approximately 5 minutes at 
a maximum speed (i.e. 13,000 rpm) to separate out serum (i.e. the clear liquid separated 
from clotted blood). Serum was then pipetted into clean 1.5 mL microcetrifuge tubes 
(Fisher Scientific), labeled and placed at -20° C. 
3. Plasma 
Aprotinin solution (0.0133 g Aprotinin [Sigma] in I mL 0.5 EDTA) was used to 
rinse syringes, needles, and microcentrifuge tubes (Fisher Scientific) prior to collection of 
plasma. Whole blood was drawn via cardiac puncture (as per above method) into syringes 
containing 10 J.!L of aprotinin solution and transferred to microcentrifuge tubes (Fisher 
Scientific) containing 3 J.!L of aprotinin. The samples were immediately spun on a 
microcentrifuge (Thermoelectron) for approximately 5 minutes at a maximum speed (i.e. 
13,000 rpm) to obtain plasma (i.e. the liquid component of blood with suspended blood 
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cells). Plasma was then pipetted into clean 1.5 mL microcetrifuge tubes (Fisher 
Scientific), labeled and immediately placed at -70° C. 
4. Urine 
Urine was collected by allowing the mice to void into autoclaved, empty cages. 
Clean capillary tubes (Fisherbrand) were then used to gather the pools of urine. A 
capillary tube bulb (Drummond Scientific Co.) was then used to void the urine out of the 
capillary tubes into clean microcentrifuge tubes (Fisher Scientific) for storage at -20° C. 
5. Milk 
Pups were separated from their mothers 1 hour before milking. Mothers were 
provided with a subcutaneous injection of 1 IU of Oxytocin (in 1 00 f..lL of solution) 
(Hospira) to stimulate milk let down. A milking apparatus was assembled using a 
laboratory vacuum attached to rubber tubing (Figure 14). A disposable pipette tip (Fisher 
Scientific) was inserted into the end of the rubber tubing (pointed side inward). Mouse fur 
was dampened with water and alveolar area was cleared for the ease of pumping milk. 
The round open end of the pipette tip was then inserted over the alveolar area of each 
manunary gland and light suction was applied by turning on the vacuum. A pumping-like 
action was simulated with the pipette to promote the ejection of milk. Sterile capillary 
tubes were used to collect the milk droplets from the inside of the disposable pipette tips. 
A capillary bulb was used to empty the milk from the capillary tubes into microcentrifuge 
tubes (Fisher Scientific). Tubes were labeled and milk was stored at -20 ° C. 
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Milk was corrected for variations in protein content using a Bovine Serum 
Albumin Standard (BSA) protein assay kit 23227 (Pierce). Samples were diluted (1 f.l.L 
milk in 100 f.l.L deionized water) for the protein concentration of the milk to fall within 
the range of the standard curve (i.e. 25 f.l.L- 2000 f.l.L). Assay was performed according to 
the kit instructions. 
6. Mammary Glands 
Mammary glands were harvested from WT and ctcgrp null mice after a rapid 
cervical dislocation during mid-lactation, and late lactation (prior to this time they were 
not clearly visible). A lower abdominal incision was made with small surgical scissors 
and a clean cut was continued directly up through the mid-line of the mouse. Additional 
incisions were made traveling up each hind-limb to allow for full visualization and access 
to the mouse mammary glands. Embedded lymph nodes were removed with scissors and 
forceps. 5 sets of yellow/beige coloured mammary glands were clearly visible: one set 
under each upper-limb extending around the neck, 1 set adjacent to the thoracic region of 
the spine extending around the back, and 2 more sets in the abdominal and groin region 
(Figure 15). Samples were quickly collected using autoclaved forceps and scissors rinsed 
with DEPC h·eated water. Mammary samples were then either snap-frozen in liquid 
nitrogen and placed at -70°C (for RNA extraction and analysis), or placed immediately in 
10% formalin (37% formaldehyde, 10 x PBS pH 7.3, distilled water) to be embedded and 
sectioned for histomorphometry. 
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Figure 14: Apparatus used to Collect Milk from Mice during Lactation 
A pipette tip was inserted into the end of the rubber tubing. The round open end of the 
pipette tip was then inserted over the alveolar area of each mammary gland and light 
suction was applied by turning on the vacuum. A pumping-like action was imulated with 
the pipette until milk ejected. Photo taken by Danielle lngs. 
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7. Pituitary Glands 
Pituitary glands were harvested from WT and ctcgrp null mice after a rapid 
cervical dislocation during mid-lacta6on. To harvest pituitary samples incisions were 
made in the inferior portion of the mandible using small surgical scissors. Then, 
several cuts were made through the midline of the mandible exposing the skull. Using the 
same tools the skull was carefully removed and the brain was shifted to expose the 
underlying pituitary gland (i.e. small white coloured gland in back of brain) (Figure 16). 
Using forceps rinsed with DEPC treated water, pituitary samples were removed, snap-
frozen in liquid nitrogen and placed at -70°C (for RNA extraction and analysis). 
8.Bone 
At various time points (i.e. non-pregnancy, late pregnancy, mid-lactation and late-
lactation) mouse femur, tibia, fibula and spine regions were harvested. After euthanisation 
via cervical dislocation, hindlimb bones from WT and ctcgrp null mice were quickly 
harvested. Initially hair and flesh was removed using forceps and scissors. The heads of 
the femurs were then carefully separated from the ileum and pubis using circular motions 
. . 
(Figure 17). Spine regions were subsequently harvested by making three complete 
incisions with a disposable razor blade (Smith Brand~, one just below the cervical line 
(i.e. where dislocation occurs), the second just slightly above the lumbar region, and a 
third at the centre of this sample (i.e. creating 2 samples). Left hind limb and upper spinal 
regions were stored at -20°C in small labeled vials for biomechanical analysis (Figure 
17). Right hind limbs and lower spinal regions were placed immediately in 10% formalin 
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Figure_lS: Location of Mouse Mammary Tissue. Reprinted from The Anatomy of the 
Laboratory Mouse by Margaret J. Cook. Copyright © 1965, with permission from 
Elsevier (Appendix B). Adapted for the Web by: Mouse Genome Informatics The 
Jackson Laboratory Bar Harbor, Maine, May 2005. 
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(37% formaldehyde, 10 x PBS pH 7.3, distilled water) to be embedded in plastic and 
sectioned for future histomorphometric analysis. 
E. Bone Mineral Content 
BMC was measured using the PIXImus 2 duel-energy x-ray absorptiometer 
(DXA) (GE Lunar). The corresponding software was PIXImus version 2.1 with Microsoft 
Windows 2000. A standard phantom (Fat 11.9% and BMC 0.063 grams) was used to 
perform quality control calibrations (QC) with the PIXImus daily. If QC failed, a field 
calibration was performed. If field calibration did not pass the PIXImus software was 
reinstalled, and global parameters reentered. 
Brief anesthesia was induced using isoflurane (Minrad Inc.). Individual mice were 
placed in a small enclosed chamber (i.e. glass jar with sealed lid, containing a paper towel 
soaked with a small volume of anesthesia). After this time, anesthesia was maintained 
anywhere from 15 minutes to several hours with a single intraperitoneal (i.p.) injection of 
either thiopental sodium (Abbott Laboratories) or a combination ofketamine 
hydrochloride (Wyeth~ and Xylazine (Bayer). 
Mice were subsequently placed on holding trays. Orientation of the mouse on the 
PIXlmus tray was critical to maintain BMC reproducibility with <1% precision error. 
Spine regions were manually straightened, and the head and ear tags were excluded from 
active scanning regions of the DXA because of inconsistency ofBMC in this area 
(Figure 18). In addition, as pregnancy progressed the expanding size of the mouse's body 
surpassed the capacity of the holding tray, and thus only the body and limbs could be 
included. 
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Figure 16: Location of mouse pituitary gland in the brain. Image obtained from 
Mouse Atlas of Gene Expression (www.mouseatlas.org). This work is licensed under 
a Creative Commons Attribution 2.5 License (www. creativecommons.orgllicenses 
/by/2.5/). 
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Total body (minus head) and regional (spine, hind limb) BMC (grams) measurements 
were obtained for each mouse. Absolute values were normalized to the non-pregnant 
baseline BMC measurements (e.g. ctcgrp null BMC measurements for the peak of 
pregnancy were expressed as a ratio of the respective BMC measurement for each ctcgrp 
null mouse at baseline) (Figure 18). 
Initially, to determine the pattern of BMC, mice were scanned every day 
throughout full reproductive cycles. During this time anesthesia overdose caused deaths 
in a few cases. Later it was decided that mice would be scanned every other day, and 
eventually only at representative time points (i.e. baseline, late pregnancy, late lactation, 
post weaning) to ensure that the expected BMC changes were occurring (Figure 18). Due 
to the x-ray exposure dams were euthanized at the end of the post- weaning, recovery 
phase as well as all pups from these pregnancies after they were weaned at 21 days of 
age. 
Previous quality control studies were conducted in the Calcium Research Lab to 
determine fetal contributions to total body BMC. Mice on day 18.5 of pregnancy were 
scanned immediately before and after a C-section in which the pups were removed; this 
determined that the fetal skeletons contributed 1% or less to the apparent maternal BMC 
and was, therefore, negligible (data not shown). 
F. Micro Computed Tomography 
Both WT and ctcgrp null mice were euthanized at baseline and late lactation via 
cervical dislocation. Right femurs were immediately harvested and adjacent flesh was 
carefully taken off using forceps. Femur samples were then fixed in paraformaldehyde for 
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Figure 17: Collection of mouse hind limbs. The heads of the femurs were carefully 
separated from the ileum and pubis using a circular motion. Reprinted from The Anatomy 
of the Laboratory Mouse by Margaret J. Cook. Copyright © 1965, with permission from 
Elsevier (Appendix B). Adapted for the Web by: Mouse Genome Informatics The 
Jackson Laboratory Bar Harbor, Maine, May 2005. 
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18 hours. After this time bones were rinsed, stored in 1 0 x phosphate-buffered saline at 
room temperature, and labeled until analysis. 
The quantitative and qualitative ~CT analysis for each femur was completed at the 
Centre for Bone and Periodontal Research at McGill University using the SkyScan 
1072 (SkyScan,Vluchtenburgstraat 3, B-2630 Aartselaar, Belgium). This instrument has a 
20-100 keV/0-250 ~A sealed, air-cooled, microfocus x-ray source with a polychromatic 
beam derived from a tungsten target with a spot size ofless than 5 t-tm at 4 W. For these 
analyses, the x-ray source was operated at 100 kV and at 98 t-tA (maximum power). 
Images were captured using a 12-bit, cooled CCD camera (1 024 x 1 024 pixels) coupled 
by a fiber optics taper to the scintillator. 
Samples were scanned at a magnification resulting in a pixel size of 10.94 tJ.m. 
Using a rotation step of0.9 degrees and an exposition time of2240 ms for each step, a 
total of 206 images was generated giving a scanning time of 30 min. The cross-sections 
along the specimen axis were reconstructed using Cone-Beam Reconstruction Software 
(SkyScan), with a distance between each cross-section of27.371 tJ.m. Each cross-section 
was reduced in half size to facilitate the analysis, giving of a voxel of 27.371 x 27.371 x 
27.371 t-tm3. CT-analyzer and 3D Creator software (both from SkyScan) were used to 
analyze and to do 3D rendering respectively. Data produced included mean trabecular 
thickness, mean trabecular spacing, total volume, anisotropy, volume fraction(%), 
volume (cubic mm), surface (square mm), surface/ volume(%) and structure model index 
(SMI) (Figure 17). See Appendix D for detailed protocol. 
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(a) 
(b) 
Figure 18: Bone Mineral Content (BMC) Assessment via PIXImus Bone 
Densitometry. (a) Sample PIXImus image at baseline (non-pregnancy), (b) Sample 
PIXImus scan at late pregnancy (17.5 days gestation). 
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G. Biomechanical Testing 
Specimens were kept frozen until a few hours before testing and were then thawed 
to room temperature prior to biomechanical analysis (Instron Series 3340 
electromechanical single column test instrument). Several biomechanical fixtures were 
subsequently attached to assess the strength ofWT and ctcgrp null mouse bones. Each 
fixture is described below. 
1. Three-Point Bend Test 
Cortical bone strength was assayed using a 3 point-bend fixture (3PBF) attached 
to an Instron Series 3340 electromechanical single column test instrument (Instron) 
(Figure 20a). Instron Series IX/s software package was used for the data acquisition, 
control and analysis. A compression test was selected from a list of standardized methods. 
Tibias were carefully separated from fibulas and femurs at room temperature. Each tibial 
sample was carefully and evenly placed across the lower part of the 3 PBF (i.e. the 2 point 
end). Sample specifications (e.g. thickness, identification number and the corresponding 
reproductive time point (e.g. baseline, lactation) was entered into the software. The 
length) were measured with the millimeter (tmn) side of a ruler. Values were 
subsequently entered into the software, along with the sample identification machine was 
balanced (i.e. zero force, zero distance) and the cross-head was lowered so that thel OkN 
load cell with the anterior component of the 3PBF was approximately 2-3 em above the 
mid-shaft of the tibia. The crosshead speed was set to 10 mm/ minute and the start button 
was manually activated. The cross-head proceeded to descend onto the specimen until it 
could no longer tolerate the force applied to it. This break point (i.e. point of failure, or 
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Figure 19: MicroComputed Tomographic (J.1CT) Image of a Mouse Femur. Sample 
SkyScan 1072 image of mouse femur showing trabecular thickness distribution and 
trabecular separation distribution (McGill University, Centre for Bone and Periodontal 
Research). 
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spike on the curve) was recorded, as well as the load-displacement curve from which 
other biomechanical parameters were derived. The bone fragments were then discarded. 
Values for load (kN), displacement (em) and slope were then placed in a spreadsheet for 
analysis. 
2. Crush Test 
To provide a more extensive analysis of both cortical and trabelcular bone, a 
'crush fixture' was conceptualized and designed at Memorial University. Two round and 
flat pieces of metal (2.5 em x 2.5 em x 1 em) were attached to a fixture stem and scaled to 
fit into the lnstron Series 3340 electromechanical testing device (Figure 20b). Single 
thoracic vertebral bodies were cut from intact thoracic regions and used for analysis. The 
superior and inferior endplates were removed from the cortical rims to even the surface. 
Samples were lodged at the centre of the lower fixture plate. As per the 3PBT, 
specifications were measured and values were entered into the software, along with the 
sample identification number and corresponding reproductive time point. The machine 
was balanced and the cross-head was lowered approximately 2-3 em above the vertebral 
sample. The crosshead speed was set to 1 0 mm/ minute and the start button was manually 
activated. The cross-head proceeded to descend onto the specimen until it could no longer 
tolerate the amount of force applied to it, or a maximum force was reached (in this case 
the cross-head would retract at 1 OkN). This break point (i.e. point of failure, or spike on 
the curve) was recorded from the load-displacement curve from which other 
biomechanical parameters were derived. The compressed vertebral bodies were then 
discarded. 
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(a) 
(b) 
Figure 20: Biomechanical Fixtures used to assess bone strength (a) Three-point bend 
fixture used to assess the strength of long bones, and (b) crush fixture used to assess the 
strength of irregular and flat bones. 
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3. Narrow Pointed Fixture Compression Test 
A 3rd fixture was designed to assess primarily trabecular bone strength (Figure 
21a). The conceptualization of this fixture came from Dr. Molgaard from the Faculty of 
Engineering, Memorial University of Newfoundland. The design was executed by the 
Machine shop at the Health Sciences Centre, Memorial University. The descending 
component of the fixture included a long, narrow metal component with a cone shaped 
pointed tip (2.5 em x 3 mm) (Figure 21a). The bottom of the fixture (i.e. the stationary 
component) included a small round incision drilled into it, accommodating the ascending 
portion of the fixture upon descent (Figure 21a). The fixture was intended to penetrate 
through the vertebral cross section, without disturbing the cortical rim. The vertebral 
cross section was lodged directly on top of the insert in the bottom fixture. By readjusting 
the crosshead, the ascending fixture was placed 2-3 em above the vertebral cross section. 
The machine was then balanced (i.e. zero force, zero distance) and the test was initiated. 
The crosshead speed was set to 10 mml minute and the start button was manually 
activated. The cross-head proceeded to descend onto the specimen until it could no longer 
tolerate the amount of force applied to it, or a maximum force was reached. Point of 
failure was recorded (i.e. first spike on graph), as well as the load-displacement curve 
from which other biomechanical parameters could be derived. 
4. Narrow Flat Fixture Compression Test 
Furthermore, a 41hbiomechanical fixture was designed with slight modifications 
from the 3rd fixture (Figure 21b). This fixture was also designed to assess 
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(b) 
Figure 21: Biomechanical Fixtures used to assess bone strength (a) Narrow pointed 
fixture and (b) Narrow flat fixture. Both fixtures were custom designed for the assessment 
of trabecular (cancellous) contributions to bone strength. 
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trabecular strength. This design was executed by the Machine shop at the Health Sciences 
Centre, Memorial University. The descending component of the fixture included a long, 
narrow piece of metal with a flat round tip (2.5 em x 3 mm). The bottom of the fixture 
(i.e. the stationary component) was the same as the lower portion of the 3rd fixture. This 
fixture was intended to penetrate through the vertebral cross section, and evenly penetrate 
the trabecular framework within the cortical shell of the vertebral bodies. The vertebral 
cross section was lodged directly on top of the insert in the bottom fixture. By readjusting 
the crosshead, the ascending fixture was placed 2-3 em above the vertebral cross section. 
The machine was then balanced (i.e. zero force, zero distance) and the test was started. 
Point of failure was recorded (i.e. first spike on graph), as well as the load-displacement 
curve from which other biomechanical parameters could be derived. 
H. Mineral Assessment 
1. Whole Blood Ionized Calcium 
Whole blood ionized calcium was measured on fresh mouse tail blood using a 
Chiron Diagnostics 634 Ca++/pH Analyzer (Chiron Diagnostics) with high, medium and 
low test controls (Bayer HealthCare). Samples were collected directly from mouse tail 
veins at room temperature using heparinized capillary tubes (Bayer). Time points 
assessed included: baseline, late pregnancy, 24-48 hours post-partum, early, mid and late 
lactation, as well as postpartum. 
2. Flame Atomic Absorption Spectroscopy and Milk Calcium 
Maternal milk calcium content was analyzed via flame atomic absorption 
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spectroscopy (Perkin-Elmer 2380 Atomic Absorption Spectrometer). High, medium and 
low calcium standards were made using nitric acid and increasing concentrations of a 
calcium reference solution (Fisher Scientific) (i.e. 0.25 ~g/ml, 0.75 ~g/ml, 1.5~g/ml). 
Whole milk samples were diluted (5 ~I milk: 1000 ~I nitric acid) and assessed in 
duplicate on the atomic absorption spectrometer (Perkin-Elmer 2380 Atomic Absorption 
Spectrometer). Milk was subsequently corrected for variations in protein content using a 
protein assay with Bicinchoninic acid (BSA TM Protein Assay Kit). 
3. Urine Calcium and Creatinine Correction 
Calcium content of maternal urine samples was assessed using a colorimetric 
assay (Sigma-Aldrich) as per kit instructions. Urine was subsequently normalized to 
creatinine concentrations. Creatinine was measured using an alkaline picrate colormetric 
assay (Diagnostic Chemicals Limited, RefN. 221-30). 
I. Hormone Physiology 
1. Parathyroid Hormone (PTH) 
The PTH content of maternal serum was measured at baseline (pre-pregnancy), 
late pregnancy, early lactation, late lactation, and post-weaning (21 days post- lactation) 
in both WT and ctcgrp-null mice using a rat 96 well PTH intact enzyme-linked 
immunosorbent assay (ELISA) kit (lmrnutopics) that is also reactive against mouse PTH. 
Two different goal polyclonal antibodies to rat intact PTH were used in the kit: an 
antibody specific to the mid-region/C-terminal portion (39-84) ofPTH biotinylated (for 
capture), and another antibody specific to the PTH N-terminal region (1-34) conjugated 
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with the enzyme horseradish peroxidase (for detection). The sensitivity of the kit was 1.6 
pg/mL ofPTH. Assay was perfonned according to the kit instructions, with each sample 
being assayed in duplicate when possible. The absorbance of each sample was taken on a 
spectrophotometric kinetic microtiter plate reader (Molecular Devices) capable of reading 
absorbance at 400 nm and 750 nm. 
2. Estradiol (17- beta Estradiol) 
Serum Estradiol was assessed using an enzyme immunoassay (EIA) (Cayman 
Chemical Catalog No.582251 ). The detection limit of the assay was 8 pg/mL. The assay 
was based on the competitive binding of either free estradiol or an estradiol tracer 
(estradiol linked to an acetylcholinesterase (AChE) molecule) for a limited amount of 
estradiol-specific rabbit antiserum binding sites. The amount of estradiol tracer able to 
bind to the rabbit antiserum was inversely proportional to the concentration of free 
estradiol in each well. The assay was carried out according to kit instructions with each 
sample being assayed in duplicate when possible. The absorbance of each sample was 
then taken on a spectrophotometric kinetic microtiter plate reader (Molecular Device~) 
capable of reading absorbance from 400 nm to 750 nm. 
3. Prolactin 
Serum Prolactin was assessed using a RIA by Dr. A.F. Parlow (National Hormone 
and Peptide Program, Harbor, UCLA Med Center, CA, USA). The following immune-
reactants were used in the RIA: antiserum to mouse prolactin (rabbit), highly purified 
mouse prolactin antigen for iodination and mouse prolactin reference preparation ( 1 
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ampoule containing 5 micrograms, lyophilized in 1 ml1% bovine serum albumin in 
PBS). All reactants were added to the RIA tubes at a single sitting, at refrigerator 
temperature, in the sequence of a) buffer, b) standard or unknown, c) radiolabelled 
antigen, and d) antiserum at a final, tube dilution of 1 :400,000. The reactants were then 
incubated at room temperature for 24 hours, prior to the addition of the second antibody. 
Standard curves were then created for mouse prolactin concentrations and unknown 
values were subsequently calculated. 
4. Parathyroid Hormone Related Protein (PTHrP) 
Mouse plasma PTHrP was measured using an in-house PTHrP radioimmunoassay 
(RIA) specific to theN-terminal ofPTHrP designed by Dr. T.J. Martin (St Vincent's 
Institute of Medical Research, Melbourne, Australia) (Appendix C). In brief, on day 1: 
standards, plasma samples and assay buffer were incubated, tracer was added and 
incubated overnight at room temperature. On day 2: anti-goat Sac-Cel was added and 
incubated for 30 minutes at room temperature, 1 ml of distilled water was added to each 
tube, samples were then centrifuged and supernatant was aspirated. Finally pellets were 
counted using a gamma counter (Beckman Coulter ™ LS 6500). Normal human plasma 
(stored at -80° C) was used in lieu of the serum from haemochromatosis patients as per 
the protocol (Appendix C). 
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J. Markers of Bone Turnover 
1. Deoxypyridinoline (Dpd) crosslinks 
Dpd crosslinks, a common bone resorption marker, was quantified in the urine of 
WT verses ctcgrp null mice at baseline, late pregnancy, late lactation and the post-
weaning period using a METRA DPD EIA (Quidel). The limit of the kit was 1.1 nM/L. 
The assay was performed according to the kit instructions, with each urine sample being 
assayed in duplicate. The absorbance of each sample was then taken on a 
spectrophotometric kinetic microtiter plate reader (Molecular Devices) capable of reading 
absorbance at 400 nm and 750 nm. Dpd was then expressed relative to creatinine in order 
to correct for variations in urine concentration. Creatinine was measured using an 
alkaline picrate colormetric assay (Diagnostic Chemicals Limited, RefN. 221-30). The 
assay was based on the reaction between the sample and sodium picrate, where creatinine 
combines with the reagent to form a red-orange complex. Final calculations involved 
dividing the Dpd value (nmol/L) by the creatinine value (mmol/1) of each sample 
(creatinine mg/dl x 0.088 = mmol/1). The assay was performed according to kit 
instructions with final results were expressed as nmol Dpd/mmol creatinine 
2. Osteocalcin 
Serum osteocalcin, a common bone formation marker, was quantified in the serum 
of ctcgrp null mice verses WT at: baseline, late pregnancy, early lactation, late lactation 
and during the post weaning period (21 days post-lactation). A two- site IRMA 
(Immutopics) was used for this analysis. The IRMA utilized two different antibodies 
specific to mouse osteocalcin; a polyclonal goat antibody recognizing the mid-region C-
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terminal region (immobilized onto a plastic bead for capture) and a polyclonal goat 
antibody recognizing the amino terminal region (radiolabeled for detection). The assay 
was performed according to the kit instructions with each sample being assayed in 
duplicate. The assay sensitivity was 0.1 ng/mL. Each tube was counted for 1 minute on 
a1480 WALLARD Wizard™ automatic gamma counter (PerkinElmer) and counts were 
subsequently recorded. 
K. Immunohistochemistry 
Immunohistochemistry was completed to immunolocalize PTHrP in the mammary 
epithelium during lactation in the WT versus ctcgrp null mice. A peroxidase 
antioperoxidase protocol was used (Appendix E). In brief paraffin embedded mammary 
tissue were dewaxed with xylene, rehydrated in ethanol, submerged in methanol with 1% 
hydrogen peroxide to block endogenous peroxidase activity of the sections. These 
sections were then incubated with a primary antiserum of rabbit anti PTHrP. This 
antiserum was denoted 'r87' and was obtained from Dr. Jack Martin's lab at the 
University of Melbourne. The 'r87' antiserum was specific to the amino terminal region 
of PTHrP. For each sample duplicate a separate negative control slide containing non-
immune rabbit serum at the same dilution was also used. All sections were then rinsed 
and incubated with a secondary antibody (i.e.goat anti rabbit immunoglobulin) for 30 
minutes. Sections were again rinsed and incubated in diaminobenzidine, tris and water, 
tris buffer, rinsed and stain with Mayer's haematoxylin for 30-60 seconds and dehydrated 
through graded absolute ethanol ethanol 75% , 90%, 100% x 2. Finally samples were 
rinsed in xylene and mounted in p-xylene-bis-pyridinium bromide (DPX). 
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L. RNA Extraction 
Total RNA was extracted from whole mammary glands using an RNeasy Midi Kit 
(Quiagen). Approximately 100 g of mouse mammary gland yielded 0.6-1.3 llg of RNA 
per ~-tl of solution. 
M. eDNA Synthesis 
eDNA synthesis was performed on mouse mammary gland RNA samples using 
the Superscript III First-Strand Synthesis System (Invitrogen). 
N. Real- Time Quantitative RT-PCR 
Quantitative real-time RT-PCR data and analysis were obtained using the ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems). For the calcitonin 
receptor (CTR), the calcium receptor (CaR), and the Vitamin D receptor (VDR) 
Taqman® Gene Expression Assays were used that included pre-designed primers and 
probes for optimal amplification {Applied Biosystems) along with Taqman® Universal 
PCR Master Mix (Applied Biosystems). All gene expression assays have a F AM reporter 
dye at the 5' end of the TaqMan MGB probe and a non-fluorescent quencher at the 3' end 
of the probe. Other gene specific primers used for this study were as follows; for 
parathyroid hormone related peptide (PTHrP) (forward) 5' -
TCCACACAGCCGAAATCAGAGCTA -3'; (reverse) 5'-
TTCTCCTGTTCTCTGCGTTTCCCA-3 ', fori-alpha hydroxylase, (fotward) 5', 
CCAGAGCGCTGTAGTTTCTCATCA-3 ', (reverse) 
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5' ATGAAGGTTICTGTGTCAGGAGGG-3 ',for calcium transport protein subtype 1, 
(forward) 5' ATCGATGGCCCTGCGAACT 3', (reverse) 5' 
CAGAGTAGAGGCCATCTTGTTGCTG 3'(20), for epithelial calcium channel, 
(forward) ATTGACGGACCTGCCAATTACAGAG 3', (reverse) 5' 
GTGTTCAACCCGT AAGAACCAACGGTC 3' (20). These primers were used along 
with SYBR® Green PCR Mastermix. The real-time PCR thermal cycler protocol 
included 1 cycle at 50 °C for 2 minutes, 1 cycle at 95 °C for 10 minutes, and 40 cycles of 
95 oc for 15 seconds and 1 minute at 60.0 °C. For primers using SYBR® Green PCR 
Mastermix the real-time PCR program was the same, but without the first cycle at 50 °C 
for 2 minutes. All samples were performed in triplicate and expression ratios were 
calculated from differences in threshold cycles (CT), which represents the PCR cycle at 
which the an increase in reporter fluorescence above the baseline signal can first be 
detected. GAPDH was used as a control gene. 
0. Duodenal Calcium Absorption 
Duodenal calcil!m absorption was measured in non-pregnant versus mid-lactating 
WT and ctcgrp null mice as previously described (228). In brief, fasted mice were 
anesthetized with an i.p. injection of a combination ofketamine hydrochloride (Wyeth~ 
and Xylazine. After animals were anesthethized a closed duodenal loop of approximately 
1.5 em in length was created using surgical suture material and closed tied loops at each 
end of the segmented area. Next 16uCi/mL ofCalcium45 (in 40 J..ll ofbuffer containing 
NaCl 150mM, CaC12 2mM (the calcium carrier) and Tris-HCl 30 mM) was injected into 
this loop. After 1 0 minutes the loop was excised and mice were subsequently euthanized. 
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The duodenal sections were immediately solubilized in glass vials containing Scintigest 
and stored at 65°C overnight. The next day radioactivity was counted on a liquid 
scintillation counter to determine the amount of calcium absorbed. Non-viable loops were 
detected and discarded. 
P. Calcitonin and CGRP-a Dose Finding and Rescue Experiment 
Dose finding experiments were conducted to determine the amount of salmon 
calcitonin (SCT) (Rhone-Poulenc Rorer) was required to prevent losses ofBMC during 
lactation. A mean intramuscular (i.m.) dose of 0.067 ~moles or 10 IU of SCT (Rhone-
Poulenc Rorer) was provided daily in 60~1 of saline (vehicle) beginning on the day of 
delivery and throughout 21 days of lactation to representative WT and ctcgrp null mice. 
In addition other WT and ctcgrp null mice received equimolar doses (0.067 ~moles or 
255 ~gin 60 ~Ll of saline) of rat CGRP-a. (American Peptide Co Lot: S02011A1). Control 
mice received once daily i.m. injections of either 100 ~1 of 0.9% saline. 
Mice were briefly anesthetized with isoflurane (as per method previously 
described) in order to receive the injection. A small area on the hindlimb was sterilized 
with 70% ethanol prior to i.m. injection. Bone densitometry was used every second day 
throughout the experiment to precisely determine the excursion ofBMC. Mice and pups 
were euthanized post rescue experiment. 
Q. Statistical Analysis 
Data was analyzed using SYSTAT 5.2.1 for Macintosh (SYSTAT Inc, Evanston, 
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IL). ANOVA was used for the initial analysis; Tukey's test was used to determine which 
pairs of means differed significantly from each other. Real-time quantitative RT-PCR 
results were analyzed by the TMCT method where the target and reference are amplified 
in separate wells (21 ). Two-tailed probabilities are reported, and all data are presented as 
mean± SE._ Where statistical significance between pairs of means exists, this is indicated 
on the respective figure or table. If no pairs of means have a notation to suggest that they 
were statistically significant from each other, this means that they were not. 
Furthermore, planned group sizes were based on several power calculations. 
Power is the probability of finding a statistically significant difference at a given "P" 
value with a specific number of subjects in each group. Calculations revealed that for 
DEXA experiments, to obtain a power of 95% (p < 0.1 0) with an anticipated difference 
between means of 20%, 5 mice were required in each group. The actual group size of 
mice in a few cases was more than 5 due to the fact that initially we thought we needed 
more mice for these experiments. Unfortunately, mice were not always readily 
available and some died during or after anesthesia and some ate their pups and 
therefore could not be studied during lactation. In fact, the observed BMC difference was 
100% between the two groups (the doubling of BMC loss) so that the group size of 5 for a 
predicted 20% difference was more than adequate. In contrast, for the biomechanical 
testing, we later learned that due to the variability of expected results with this technique 
that colleagues often use a sample size of 15-20 per group, and thus we had 
underestimated the numbers required for that particular procedure. Also, 
108 
biomechanical testing was a new procedure for our lab and we didn' t know all of its 
inherent problems. 
IV Results 
A. Litter Sizes in WT, HET and Ctcgrp Null Mice 
Initially, the number oflive pups present at the time of weaning (i.e. day 21 of 
lactation) was counted to determine if absence of calcitonin would affect postnatal litter 
size. Results indicated that there was no difference in litter size between the WT, ctcgrp 
HET and ctcgrp null female mice at the time of weaning (Figure 22). Mean litter sizes 
were as follows: WT 8.8 pups ± 0.6 (n=9), HET 7.9 pups± 0.6 (n=11) and ctcgrp null 7.6 
pups ± 0.5 (n=18) (p=0.33). Only WT and ctcgrp nulls were used for subsequent 
experiments. 
Previous findings, in contrast, showed that the number of viable fetuses in utero of 
ctcgrp null females was significantly lower (7.9 pups ± 0.4) than the number of ctcgrp 
HET females (9.1 pups± 0.3) (p<0.02) when assessed on embryonic day 17.5 or 18.5 post 
cessarian section (233). Variations in litter sizes between genotypes before birth versus 
that seen at weaning may result from unfavorable changes in calcium metabolism in the 
ctcgrp null in utereo. Possible reasons for lack of a significant difference in litter size 
between genotypes at weaning could be: potential survival advantages after birth for the 
ctcgrp null or selected culling of the WT pups after birth. It is also possible that this result 
is simply a chance occurrence or the difference persisted but couldn't be detected with 
smaller numbers counted post-natally. A larger sample size might have been needed to 
detect a difference in litter size between genotypes. 
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Figure 22: Litter Sizes in WT, HET and Ctcgrp null mice. At weaning the litter sizes 
(mean ± SE) were not significantly different between ctcgrp null, HET and WT female 
mice. Numbers in parentheses represent the number of mice studied. 
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B. Bone Mineral Content 
Mice were taken, and serially scanned by DXA every second day throughout 
reproduction to determine if loss of calcitonin would affect the normal cycling ofBMC 
during reproduction compared to the normal siblings. Calcitonin normally suppresses 
bone resorption by directly inhibiting the number and function of the bone digesting 
osteoclast cells (77). Therefore lack of calcitonin, in the ctcgrp nulls, was hypothesized to 
cause uninhibited bone resorption and a subsequent decrease in BMC during 
reproduction, a time of increased calcium demand. 
Findings indicated that at the baseline age of 10-12 weeks, ctcgrp null mice had a 
higher mean BMC (0.397 g ± 0.016 g) (n= 15) by DXA versus that seen in the WT 
siblings (0.383 g ± 0.021 g) (n=8) (Figure 23). Baseline BMC values, however, were not 
statistically significant between genotypes. Previous research using contact x-rays of 
vertebral bodies and tibias also showed that baseline bone density trended higher in l-
and 3-month-old female ctcgrp null mice versus WT mice of the same age (103). Within 
this particular study by Hoff and colleagues (1 03), ctcgrp null mice were also found to 
have a higher trabecular bone volume in vertebral bodies at 1 and 3 months and in the 
proximal tibia at 3 months (1 03 ). 
After 18.5 days of pregnancy whole body BMC in WT mice increased by 15.9% ± 
3.4% above baseline (i.e. an increase of0.06lg) (n=5). In ctcgrp null mice, gains in total 
body BMC during pregnancy increased by 9.9% ± 2.6% above the respective pre-
pregnancy baseline values (i.e. an increase of0.039 g) (n=7). Thus, mean gains in mineral 
during pregnancy were no different in ctcgrp nulls versus that seen in the normal WT 
siblings (p=0.365) (Figure 22). 
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Figure 23: Baseline BMC (grams) in WT and Ctcgrp null mice. At the baseline age of 
10-12 weeks ctcgrp null mice had a BMC (mean ± SE) that was not significantly different 
than in the WT siblings (p = 0.605) Numbers in parentheses represent the number of mice 
studied. 
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After 7 days oflactation, however, ctcgrp null mice were found to have lost 
significantly more total body BMC via DXA ( -10.1 % ± 3.1 %, i.e. a decrease of 0.0401 
grams) (n=7) when compared to the loss experienced by the WT sisters (-4.5% ± 3.7%, 
i.e. a loss of0.017 g) (n=5) (p=O.OOO) and the respective pre-pregnancy baseline BMC 
values. After 14 days oflactation this significant result was seen again, with Ctcgrp null 
mice having lost significantly more BMC (-29.6% ± 3.1 %, i.e. a loss of0.118 g) (n=7) 
versus WT mice (-15.7% ± 3.7%, i.e. 0.060 g) (n=5) (p=O.OO). Most noticeable, however, 
were BMC values at 21 days oflactation (i.e. at the end or 'trough' oflactation). At this 
time, ctcgrp null mice were found to have lost almost double the amount of total body 
BMC (-32.3% ± 2.3%, i.e. a loss of0.128 g) (n=7) by DXA versus that seen in the WT 
siblings at this time (-19.9% ± 3.0%, i.e. a loss of 0.076 g) (n=5) with respect to the 
respective pre-pregnancy baseline BMC values (p<0.020) (Figure 24). 
Regional BMC measurements (i.e. hind limb and cervical spine) were also 
assessed by DXA at baseline and throughout reproduction in WT and ctcgrp null mice. 
Baseline hindlimb BMC values were as follows: WT 0.075 g ± 0.003 g (n=5) and ctcgrp 
null 0.068 g ± 0.002 g (n=7). During pregnancy hindlimb BMC increased by 0.05% ± 
3.4% (i.e. an increase of0.004 g) (n=5) and 7.2% ± 2.9% (i.e. an increase of0.005 g) 
(n=7) in the WT and ctcgrp null mice respectively, when compared to the baseline BMC 
values. These values were not significantly different (p=0.530) (Figure 25). After 21 days 
oflactation, however, losses in the hind limb of ctcgrp null mice (i .e. -28.4 % ± 2.9 %) 
(n=7) were significantly greater than that in the hind limb of the WT siblings 
(-12.9% ± 3.4 %) (n=5) (p=O.OO) when compared to the respective pre-pregnancy 
113 
WT D Ctcgrp null 
20 
~ 
~ 10 
......_.., 
uu (7) ~~ 0 
t:Ot:O 
q ~ 
-10 (5) (7) (5) (7) . ...... q 
~ ...... 
b!} .......... 
q ~ 
-20 ro ro 
..Cp:) 
us 
-30 LJ ~ 0 . ...... c!:: ~ 
-40 .......... 
~ 
* ~ 
-50 
-60 
Pregnancy Lactation Post-weaning 
Figure 24: Total Body BMC changes in WT and Ctcgrp null mice throughout 
reproduction relative to Baseline BMC. Gains in total body BMC (mean ± SE) during 
pregnancy were not significantly different between WT and ctcgrp-null mice. During 
lactation, however, ctcgrp null mice lost significantly more total body BMC compared to 
the WT siblings (*p=0.002). Despite these losses during lactation, both WT and ctcgrp-
null mice completely regained BMC levels post-weaning. Numbers in parentheses 
represent the number of mice studied. 
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baseline BMC values (i.e. lactation BMC losses: WT 0.010 g, ctcgrp null 0.019 g) 
(Figure 25). 
Baseline spine BMC values were as follows: WT 0.075g ± 0.003 g, ctcgrp null 
0.076 g ± 0.003 g. During pregnancy spine BMC levels decreased by -4.0%± 5.4% (i.e. a 
loss of0.003 g) (n=5) and -12.6% ± 4.6% (i.e. a loss of0.010 g) (n=7) in the WT and 
ctcgrp null mice, respectively, when compared to baseline BMC values. These values 
were not significantly different. Again, during lactation, however, losses in the lower 
spine in the ctcgrp nulls (-51.6% ± 4.6%) (n=7) were over double that seen in the WT 
(-24.4% ± 5.4%) (n=5) (p=O.OO) at that time (i.e. lactation BMC losses: WT 0.018 g, 
Ctcgrp null 0.039g) (Figure 26). 
Despite the significant losses of BMC seen during lactation in the WT and more 
significantly in the ctcgrp nulls, both genotypes restored their BMC to their respective 
baseline values after weaning (Figure 24). Full recovery, however, took several 
additional days in the ctcgrp null mice (18.1 ± 0.8 days) (n= 7) compared to the WT 
siblings (13.1 ± 1.1 days) (n=4) (p=0.0065). This finding was not surprising considering 
the degree ofBMC loss in the ctcgrp null. 
It is important to note that for most of these experiments there were notable 
discrepancies in the group sizes of mice. Sample numbers did not turn out as consistent as 
expected due to unanticipated deaths during experiments, as well as challenges with 
timed pregnancies and therefore mice being available at the same time for comparison. 
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Figure 25: Hindlimb BMC changes in WT and Ctcgrp null mice during Pregnancy 
and Lactation relative to Baseline BMC. Gains in hindlimb BMC (mean ± SE) during 
pregnancy were not significantly different between WT and ctcgrp null mice. During 
lactation, however, ctcgrp null mice lost significantly more hindlimb BMC compared to 
the WT siblings (*p=0.005). Numbers in parentheses represent the number of mice 
studied. 
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C. Calcitonin and CGRP-a Supplementation during Lactation 
In an effort to prove that lack of calcitonin, and not lack of CGRP- a, was the 
cause of the significant BMC losses during lactation, a peptide rescue experiment was 
performed. Initially a series of dose-finding experiments were completed to determine if 
provision of salmon calcitonin (sCT) could prevent excessive losses ofBMC in the ctcgrp 
null (i.e. 'rescue' the BMC loss to a level that was no different than that seen in the WT 
siblings) (Figure 27). Initially, i.m. injections of 50 IU of sCT (in 250J.ll of solution) was 
provided daily as a 'maximum dosage' based on a calculation of 50% of the concentration 
that has been found in previous studies to suppress lactation (i.e. approximately 100 IU) 
(234-236). It was found that this dosage resulted in no lactational loss in BMC, and in fact 
a slight BMC gain was observed in the ctcgrp null when compared to the peak of 
pregnancy BMC (i.e. 103.0% ± 4.2%) (Figure 27). In contrast, a mean daily i.m. dose of 
both 10 IU and 1 IU (in 60J.ll and 35J.ll solution respectively) was found to prevent 
excessive losses of BMC during lactation in ctcgrp null mice to a level that was no 
·different than that seen in the WT siblings. 
Based on these findings, 1 0 IU of sCT was selected as the concentration of sCT 
that could reduce the lactational BMC loss in the ctcgrp null mice to a level that was no 
different than that seen in the WT. Equimolar doses ofrat CGRP-a were calculated and 
117 
20 
WT D Ctcgrp null 
10 
,.---. (7) (5) (7) ~ 0 
..__., 
0 uu 
::;E::;E 
-10 coco 
s:: (l) 
...... s:: 
-20 (l) ...... co-
s:: ~ 
C'j C'j 
..s::co -30 
u s 
~ 0 
-40 
·.p ctl 
C'j 
.......... 
(l) 
0::: -50 
-60 
* Pregnancy Lactation 
Figure 26: Spine BMC changes in WT and Ctcgrp null mice throughout Pregnancy 
and Lactation relative to Baseline BMC. Spine BM!= (mean ± SE) losses during 
pregnancy were not significantly different between WT and ctcgrp null mice. During 
lactation, however, ctcgrp null mice lost significantly more spine BMC compared to the 
WT siblings (*p=O.OOJ). Numbers in parentheses represent the number of mice studied. 
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subsequently a rescue experiment was carried out to determine which peptide (or both) 
would rescue the ctcgrp null BMC phenotype during lactation. 
In the rescue experiment it was found that daily injections of 10 IU of sCT 
prevented the excess loss ofBMC in ctcgrp null mice to levels that were not significantly 
different than that seen in the WT siblings after 21 days (-24.0% ± 2.7% in ctcgrp null vs. 
-25.0% ± 3.5% in the WT) (Figure 28). All experimental BMC values were based on 
respective peak BMC values during pregnancy. If once-daily injections of peptide hadn't 
worked, twice-daily injections would have been provided in experiments. If this did not 
suffice, subcutaneous pumps could have been used. We wanted to avoid the use of 
surgically implanted subcutaneous pumps, however, as they could have potentially 
interfered with lactation as well as the behavior of the mice. 
Next to determine if absence of CGRP-a was also contributing to the exaggerated 
loss ofBMC during lactation in the ctcgrp null versus WT equimolar dosages of rat 
CORP-a were provided in the same manner throughout lactation. Finding indicated that 
rat CORP-a did not blunt the loss of mineral seen during this time period in the ctcgrp 
null as did the injections of sCT. Ctcgrp null mice that received the equimolar dose of 
CORP-a, lost the same amount as saline treated animals, which was significantly more 
BMC than the ctcgrp null mice receiving sCT treatment (-54.3% ± 2.7%) {n=3) (Figure 
28). 
The lower number of experimental animals in the CGRP-a treated group should 
be noted. This was due to several factors: the high cost of the custom CGRP-a peptide 
meant that only a few mice could be afforded this treatment, as well one mouse died,. 
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Figure 27: BMC Changes during Lactation in WT and Ctcgrp null Mice upon 
Administration of Varying Doses of Salmon Calcitonip (sCT) and Saline (controls). 
60J...Ll (lOIU) ofsCT administered i.m. once daily throughout lactation resulted in a loss of 
BMC (mean± SE) in the ctcgrp null that was no different than that seen in the WT 
siblings receiving saline. In contrast, ctcgrp null mice that received 250!-ll (50 IU) of sCT 
were found to gain BMC during lactation. Numbers in parentheses represent the number 
of mice used in this dose finding experiment. 
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bringing the number from 4 to 3. Also, a dose finding experiment was not completed for 
CORP-a because an equimolar dosage of calcitonin was considered 'equal'. 
A limitation of this experimentation was the fact that there was no positive control 
for CORP. The rat CORP peptide could have been tested independently in cell culture to 
see if it indeed was biologically active by stimulating adenylate cyclase activity in 
striated muscle cells. This would have independently eliminated the possibility that 
CORP was a biologically inactive batch. However, with the quality controls implemented 
by the company who manufactured the rat CORP-a, and with our diligent handling, it is 
unlikely that it was a defective peptide. 
It should also be noted as well that neither salmon calcitonin or rat CORP-a are 
100% homologous to mouse calcitonin and CORP- a peptide and therefore caution 
should be used in interpreting the results. 
D. Bone Microarchitecture 
Considering the significant BMC loss seen in the ctcgrp null versus WT by DXA 
during lactation, bone microarchitecture was next assessed at the Centre for Bone and 
Periodontal Research, McGill University, to determine if there were any corresponding 
alterations in the trabecular structure. At baseline and throughout reproduction there were 
several notable micro architectural differences in the femora and vertebrae of ctcgrp nulls 
mice versus that seen in the WT siblings (Table 2). Ctcgrp null mice were found to have 
greater femora mean trabecular thickness (MTT) (Figure 29) and significantly lower 
mean trabecular spacing (MTS) (Figure 30) within the femora at baseline compared with 
the WT littermates at this time. In addition, ctcgrp null mice experienced significant 
12 1 
trabecular thinning in both the femora and vertebrae from baseline to late lactation, a 
trend that was not seen within WT mice (Table 2). Interestingly, despite obvious thinning 
in the trabecular region, MTT and MTS values in the ctcgrp null at late lactation were no 
different than that seen in the WT mice at this time (Figure 29, 30). !lCT results 
indicated that ctcgrp null mice had a greater femora trabecular bone volume at baseline 
(0.47 mm3 ± 0.07mm3) (n=3) versus that seen in the WT (0.19 mm3 ± 0.07mm3) (n=3) at 
this time. WT trabecular bone volume, however, increased significantly from baseline to 
late lactation (this is a normal finding during this phase of reproduction (161)). These 
bone volume changes were blunted in ctcgrp null bones in the femora from baseline to 
late lactation. In the ctcgrp null vertebrae, however, no significant increases were seen in 
bone volume from baseline to late lactation (Table 2). To summarize, the normal change 
for WT mice is to increase bone volume during pregnancy perhaps to compensate for 
trabecular thinning. The ctcgrp null may not have needed to increase bone volume 
because of a higher baseline bone mass. After lactation, ctcgrp null mice had a bone 
volume and MTT that was no different than that seen in the WT siblings. 
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Figure 28: C alcitonin but Not CGRP-a R escued the Ctcgrp null Phenotype. sCT 
admi:listered i.m. once daily throughout lactation resulted in a loss ofBMC (mean ± SE) 
in the ctcgrp null that was no different than that seen in the WT. In contrast, ctcgrp null 
mice that received equimolar doses of CGRP-a , or saline (controls) lost significantly 
more BMC than the ctcgrp null mice receiving calcitonin treatment. Numbers in 
parentheses represent the number of mice studied. 
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E. Bone Strength 
Bone strength was next assessed to determine if significant BMC losses in the 
ctcgrp null mice, along with increased trabecular thinning and separation was associated 
with an increased risk of fracture (i.e. decreased load until failure) versus that of the WT. 
A standard 3-point bend test was first completed using femurs from ctcgrp null and WT 
mice at baseline and late lactation. This particular biomechanical testing method assesses 
primarily the cortical contributions to total strength, the fraction of bone that changes the 
least during lactation. The ultimate load required to cause bone breakage showed an 
apparent decrease from pregnancy to late lactation in both WT and ctcgrp null mice 
hindlimbs, but was not significantly different within or between groups (Table 3). Not 
included in the calculations were two ctcgrp null femurs that broke upon bring placed into 
the device and thus could not be subjected to the 3-pont bend test. Results from this 
biomechanical test are shown in Table 3 which illustrate that cortical bone strength was 
not significantly different between WT and ctcgrp nulls at any time point. 
Next, using what others have considered to be a test of trabecular strength (i.e. the 
vertebral crush test), we found no difference in the ultimate load until failure using a 10 
. 
kN descending crush fixture at 10 mrnlminute (1.86 kN± 0.20 kN WT, 1.78 kN ± 0.26 kN 
ctcgrp null) p=NS (Figure 32). However, due to the strength of the walls of the cortical 
shell of the vertebral body (see methods and discussion) we designed two additional 
fixtures to focus on trabecular bone that could potentially bypass the strength of the outer 
cortical shell. This test proved very difficult to do because there was so little trabecular 
bone present at the end of lactation that the device encountered little or no resistance to its 
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Table 2: Micro Computed Tomographic Changes in WT and Ctcgrp null mice throughout reproduction 
Femora MTT(J..lm) MTS(J..lm) BV (mm3) TV(mm3) BV/TV (%) BS (mm2) 
Baseline WT {n=3) 53 .3 ± 5.1° 413 ± 26° 0.19 ± 0.07° 3.11 ± 0.22° 6.2 ± 1.8°'0 15.0 ± 4.3° 
Lactation WT {n=S) 47.7 ± 3.6° 363 ± 26a,c 0.42 ± 0.05 3.70±0.16 11.6 ± 1.3° 29.7 ± 3.0° 
Baseline Ctcgrp null (n=3) 72.7 ± 5.3a,O,c 277 ± 26°'0 0.43±0.07° 3.34 ± 0.22 12.8± 1.8° 28.5 ± 4.3 
Lactation Ctcgrp null {n=6) 47.7 ± 3.6° 363 ± 26a.c 0.42 ± 0.05 3.70±0.16 11.6 ± 1.3° 29.7 ± 3.0° 
Vertebrae MTT(J..lm) MTS(J..lm) BV(mm3) TV (mm3) BV/TV (%) BS (mm2) 
Baseline WT (n = 3) 49.0 ± 2.0 225 ± 11 0.56 ± 0.05°'0 2.92 ± 0.13c 19.0 ± 1.1a,o,c 29.5 ± 2.1 c,a 
Lactation WT (n = 5) 44.6 ± 1.8° 217 ± 11 0.77 ± 0.04° 3.54 ± 0.12a,b,c 23.3±1.1c 42.1 ± 1.9°'0 
Baseline Ctcgrp null (n = 3) 54.5 ± 2.0°'0 213 ± 12 0.65 ± 0.05 2.71 ± 0.15° 23.7 ± 1.1 a 31.4 ± 2.1 a,o 
Lactation Ctcgrp null (n = 6) 46.2 ± 1.6° 201 ± 9 0.82 ± 0.05° 2.93 ± 0.12° 25.2 ± 0.9° 38.2 ± 1.7b,C 
J.!CT analysis revealed higher trabecular bone volumes, greater trabecular thickness, and more densely packed trabeculae at 
baseline (mean ± SE) in the ctcgrp nulls. Ctcgrp null mice underwent more pronounced thinning of trabeculae than WT by the 
end of lactation but did not increase trabecular bone volumes. Lumbar spine showed a similar pattern of changes. Lumbar spine 
values include results from both the first and second lumbar vertebrae. MTT- mean trabecular thickness, MTS-mean trabecular 
spacing, BV- trabecular bone volume, TV - total volume including trabecular bone (but excluding cortical bone), BV /TV-
trabecular bone volume relative to total volume; BS trabecular bone surface. a-d Shared letters within columns indicate 
statistical significance (i.e. p< 0.05). 
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passage. Ultimate load results indicated no difference in load until failure (kN) between 
WT and ctcgrp null mice during late lactation using these 2 specialized fixtures (i .e. 
pointed tip, and flattened tip fixtures) (Figure 33, Table 4). Thus, despite significant 
BMC differences during lactation in the WT and ctcgrp null, no difference was seen in 
bone strength. 
F. Bone Turnover 
To investigate if the enhanced skeletal demineralization during lactation in the 
ctcgrp null versus WT, was associated with increased bone resorption, markers of bone 
turnover were assessed. Consistent with DXA results was the finding that urinary 
excretion of deoxypyridinoline (Dpd) I creatinine (Cr) (i.e. a marker of bone resorption 
corrected for creatinine concentrations) was increased significantly in ctcgrp nulls 
(8.9±1 .02 nmol Dpd/rnmol Cr) (n=7) versus that seen in the WT siblings (1.4 ± 1.3 nmol 
Dpd/mmol Cr) (n=4) during late lactation (p=0.003) (Figure 34). Significant differences 
were also seen from early lactation (2.5±1.02 nmol Dpd/rnmol Cre) (n=7) to late lactation 
(8.9 ±1.0 nmol Dpd/mmol Cr) (n=7) within the ctcgrp nulls ((p=_0.0023) and between late 
lactation and post-weaning (3 .3 ±1.2 nmol Dpd/mmol Cr) in the ctcgrp nulls (p=0.03). 
In contrast, however, no difference was observed in the serum level of osteocalcin 
(a marker of bone formation) between the ctcgrp null and WT at any time point (p=0.413) 
(Figure 35). The lack of change in osteocalcin is consistent with what others have 
observed about lactation, that there is little change in bone formation parameters but 
instead a large increase in bone resorption parameters (6-8).Thus it appears that lactation 
is dominated by bone resorption, and not bone formation. 
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Figure 29: Mean Trabecular Thickness (MTT) in WT and Ctcgrp null mice Femora and 
Vertebrae at Baseline and Lactation. Ctcgrp null mice had a significant decrease in femoral and 
vertebral MIT (mean ± SE) as assessed by micro computed tomography from baseline to late lactation. In 
contrast, WT mice had a MIT value at baseline that was no different than that seen during lactation in 
both the femora and vertebrae. Numbers in parenthesis represent the number of mice studied. 
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G. Whole Blood Ionized Calcium 
Ionized calcium is normally unchanged during pregnancy and lactation in both 
humans and mice (5-8). Ionized calcium was found to be normal in WT and ctcgrp null 
throughout reproduction with the sole exception being 24 hrs post lactation. Transient 
hypercalcemia was experienced during the first 24 to 48 hours postpartum in the ctcgrp 
null (1.40 ± 0.02 mmol/1) versus WT (1.26 ±0.02 mmol/1) (p<O.OOl) (Figure 36). Our 
findings indicated, however, that after lactation was fully established both WT and ctcgrp 
null mice maintained a normal ionized calcium at throughout the remainder of lactation 
and the post-weaning period, as well at baseline and throughout pregnancy (Figure 36). 
This hypercalcemia likely occurred as a result of the significant increase in bone 
resorption, and subsequent pooling of mineral within the blood before lactation was 
completely established. 
H. Urine Calcium 
Normally urine calcium decreases during lactation, likely due to the effect of 
PTHrP to stimulate renal tubular calcium reabsorption (6-8). Increased losses of calcium 
in the urine could have been one mechanism resulting in increased bone resorption in the 
ctcgrp null versus WT during lactation. Findings, however, indicated that both WT and 
ctcgrp null mice showed the same trend towards decreased urinary calcium excretion 
during lactation with no significant differences between the genotypes and reproductive 
stage (p=NS) (Figure 37). Thus, the increased bone resorption seen in the ctcgrp null 
versus WT during lactation does not result in renal calcium wasting. Alternatively, it 
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Figure 30: Mean Trabecular Spacing (MTS) in WT and Ctcgrp null mice Femora and Vertebrae 
at Baseline and Lactation. Ctcgrp null mice had a significant increase in both femoral 
MTS (mean ± SE) as assessed by J.!CT from baseline to late lactation. In contrast, ctcgrp null vertebrae 
did not have the same increase in MTS from baseline to late lactation mice. WT mice had a MTS value 
that was no no different in both femora and vertebrae from baseline to lactation. Numbers in 
parentheses represent the number of mice studied. 
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appears that the skeletal resorption in the absence of ctcrrp was not due to excess renal 
calcium losses. 
I. Duodenal Calcium Absorption 
Normally duodenal calcium absorption doubles during pregnancy primarily due to 
an increase in circulating 1, 25-dihydroxyvitamin D3. Intestinal calcium absorption 
subsequently returns to non-pregnant levels during lactation. A decrease in intestinal 
absorption of calcium (below normal) could be one way to cause increased bone 
resorption. Results indicated that duodenal 45Ca absorption was significantly increased 
when comparing the non-pregnant WT (79.7 ± 3.1 %) to mid-lactation in both the WT and 
ctcgrp null mice. 45Ca absorption, however, was no different between WT and ctcgrp null 
at mid-lactation, when the BMC losses were significantly greater in the ctcgrp null 
(Figure 38). Thus, increased calcium losses seen in the ctcgrp null versus WT during 
lactation did not occur as a result of decreased intestinal calcium absorption. 
J. Milk Calcium 
Due to the increase in bone resorption in the absence of a subsequent increase in 
urine Ca excretion, milk calcium content was examined to determine if calcium was 
going out in significant amounts into the milk supply. The calcium content of milk, 
corrected for protein, was assessed during early lactation (day 2-7) and again during mid-
lactation (2 weeks). Initial findings during the first week of lactation indicated that ctcgrp 
nulls had a higher mean milk calcium value versus that of the WT mice during mid 
lactation (Figure 39). This value, however, did not show statistical significance and the 
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Figure 31: Ultimate Load until Failure using a Standard 3-Point Bend Test Fixture in WT 
and Ctcgrp null mice during Late Lactation. Ultimate load required to cause breakage showed an 
apparent decrease from baseline to the end of lactation in both WT and ctcgrp null mice (mean ± SE) 
but was not significa1tly different within or between groups. Not included in the calculations were two 
ctcgrp null femurs that were evidently fragile because they broke upon being placed into the device 
and thus could not be subjected to the three-point bend test. Numbers in parentheses represent the 
number of mice studied. See Table 3 for details. 
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variability between samples was quite large (Figure 39). Initially milk was collected and 
assayed in several different lots, leading to problems of combining data which in turn may 
have accounted for wide error bars on the first data set (Figure 39). In contrast, during 
mid-lactation milk calcium levels were significantly higher in ctcgrp nulls versus that seen 
in the WT siblings (Figure 40). Differences between early and mid-lactation could have 
been attributed to a variety oflocal or systemic mechanisms including increased bone 
resorption. As well, during mid-lactation milk samples were assayed and collected at same 
time, which may explain the tighter error bars and statistical significance being achieved. It 
is possible that increased milk calcium in the ctcgrp null versus WT could explain the cause 
(or consequence) of exacerbated BMC losses experienced. Increased milk calcium could be 
a consequence of more calcium flooding the mammary tissue from bone, or alternatively if 
absence of calcitonin was somehow stimulating milk production, then perhaps the bone 
resorption is occurring secondarily to a primary abnormality in the mammary tissue. 
K. Serum Prolactin 
Previous studies have shown that pharmacological administration and targeted 
overexpression of calcitonin in the pituitary lactotrophs caused hyperprolactineinia. Thus, 
to acknowledge the brain, as a physiological link potentially leading to significant BMC 
loss and bone resorption, prolactin levels were explored to see if absence of calcitonin 
would contribute to exaggerated BMC losses. As anticipated Prolactin levels were 
increased from baseline to late pregnancy in both WT and ctcgrp nulls in preparation for 
milk production. No significant differences however, were seen between WT and ctcgrp 
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Table 3. Three-point Bend Test Analysis of Bone in WT and Ctcgrp null mice at Baseline and Late Lactation 
Genotype and Stage Ultimate Stiffness Ultimate stress Work to failure Moment of Toughness 
load (g) (N/mm) (mPA) (Nx mm) inertia (mm4) (J /mmJ) 
WT Baseline (n = 3) 1914±266 132 ± 14 208 ± 27 2.64 ± 0.39 0.088 ± 0.001 4.00 ± 0.65 
WT Late Lactation 1737 ± 226 96 ± 18 3.78 ± 0.80 2.78 ± 0.48 0.120 ± 0.001 3.78 ± 0.80 
(n = 5) 
Ctcgrp null Baseline 1678 ± 265 91 ± 14 189 ± 27 2.26 ± 0.39 0.086 ± 0.001 3.56 ± 0.65 
(n = 3) 
Ctcgrp null Late 1430 ± 229 102 ± 14 179 ± 27 2.17 ± 0.39 0.100 ± 0.001 3.46 ± 0.65 
Lactation (n = 6) 
This test of cortical strength showed a non-significant trend (mean± SE) for decreased bone strength between baseline (non-
pregnant) and end of lactation (trough), with no significant difference between groups at any time point. Two Ctcgrp null 
femurs were clearly fragile because they broke upon being placed into the device but could not be included in the data analysis. 
Numbers in parentheses in the first column indicate the numbers of mice studies. 
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nulls at any time point (Figure 41). 
L. Serum Estradiol 
Due to the fact that decreased estradiol levels increase bone resorption, and lactation 
causes a lowering of estradiol in the circulation, it was next explored if absence of 
calcitonin could cause an exaggerated decrease in estradiol levels during this time and 
therefore further stimulate bone resorption. Estradiol levels were subsequently examined to 
determine if levels were elevated in the ctcgrp null, thus exacerbating the BMC loss in the 
ctcgrp null versus WT during lactation. Results indicated that serum estradiol levels were at 
the level of detectability of the EIA used (8 pg/ml) (data not shown). Thus, because the 
levels were below detection, it was impossible to say if estradiol levels were lower in the 
ctcgrp null. 
M. Mammary PTHrP mRNA 
In contrast, real-time quantitative RT-PCR showed that PTHrP was significantly 
upregulated in the mammary tissue of ctcgrp nulls compared to the WT by a fold of3.28 ± 
0.09 SD at 21 days of lactation (p<0.01 ). Tests were performed in triplicate and normalized 
to a GAPDH control (Figure 42). 
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Figure 32: Ultimate Load until Failure using a Crush Test Fixture in WT and Ctcgrp null 
mice during Late Lactation. No significant differences were seen in the ultimate load until failure in WT 
and ctcgrp null mice (mean ± SE) during late lactation using a crush fixture attached to the Instron Biomech 
testing device. Numbers in parentheses represent the number of mice studied. 
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N. PTHrP Mammary Staining 
It was shown via immunohistochemistry that PTHrP expression was visibly 
increased (as indicated by brown staining) in ctcgrp null mammary epitheilial tissue during 
lactation versus that in the WT during mid-lactation. WT and ctcgrp null mammary tissue 
without the primary antibody was used as a negative control (Figure 43). 
0. Plasma PTHrP 
Given the increased skeletal resorption during lactation, we anticipated that plasma 
PTHrP levels may be elevated in the ctcgrp null versus that seen in the WT siblings. 
Plasma PTHrP (1-40) levels, however, were found to be no different in WT and ctcgrp 
nulls at baseline, mid-lactation or late lactation (Figure 44). The mean PTHrP levels, 
however, did appear to be higher in the ctcgrp null versus WT during late lactation, but 
again these values were not significantly different. Thus, circulating PTHrP level were not 
conclusively demonstrated to be elevated but the increased mammary expression ofPTHrP 
indicates that it should have been. Possible explanations for this could have been that 
PTHrP levels were all near the sensitivity of the assay; as well the samples were not drawn 
timed to specific suckling episodes which could have helped ensure that peak levels were 
obtained 
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Figure 33: Ultimate Load until Failure using a Narrow Pointed Fixture and Narrow Flat Fixture iJ 
WT and Ctcgrp null mice dur ing Late Lactation. No significant differences were seen in the ultimate 
load until failure in WT and ctcgrp null mice (mean± SE) during late lactation using (a) Narrow pointed 
fixture or (b) Narrow Flat Fixture (b) attached to the Instron Biomechanical testing device. Numbers in 
parentheses represent the number of mice studied. 
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P. Serum Parathyroid Hormone (PTH) 
Increased PTH could have also contributed to the significant BMC loss in the 
ctcgrp null during lactation. Previous unpublished work in the Calcium Research 
Laboratory at Memorial University, however, has shown that as in humans, WT mice in 
several inbred, outbred and mixed strains have PTH levels that are suppressed to the 
lower end of the normal range during pregnancy and lactation as compared to pre-
pregnancy. In this experiment, serum PTH levels were no different at baseline in WT and 
ctcgrp null mice (Figure 45). Serum PTH was indeed suppressed by the WT mice during 
the study. Notably, however, during early lactation (7 days) PTH became significantly 
elevated in the ctcgrp nulls versus WT and versus all other time points (p=0.05). Also, 
PTH showed a trend for higher levels in ctcgrp nulls in late lactation when compared to 
WT. The elevation in PTH could have contributed to the enhanced skeletal 
demineralization seen in the ctcgrp nulls during lactation. It is important to note that the 
significant increase in PTH in the ctcgrp nulls occurred during the interval of 
normocalcemia, and not during the initial 24-48 hours postpartum in which the ionized 
calcium was transiently elevated. (p<0.04) (data not shown). In a separ~teanalysis of 
serum obtained at 24-48 hrs (to correspond with the transient hypercalcemia), PTH levels 
were suppressed to the limit of detection (1.6 pglml) in both WT and ctcgrp null mice (p = 
not significant). 
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Table 4: Ultimate Load until Failure in WT and Ctcgrp Null Mice Vertebral Bodies at Mid-Lactation 
using Various Novel Fixtures 
Type Fixture Variable Assessed 
Crush Ultimate load (kN) Until Failure 
WT Late Lactation (n = 10) 1.86 ± 0.20 
Ctcgrp null Late Lactation (n = 6) 1.78 ± 0.26 
Pointed Tip 
WT Late Lactation (n = 6) 0.0049 ± 0.0011 
Ctcgrp null Late Lactation (n = 5) 0.0048 ± 0.0012 
Flat Tip 
WT Late Lactation (n =5) 0.0063 ± 0.0013 
Ctcgrp null Late Lactation (n = 5) 0.0052 ± 0.0013 
Assessment of ultimate load until failure (kN) using a crush, pointed tip or flat tipped fixture (mean± SE) showed no 
significant difference (p=NS) between WT and Ctcgrp null vertebral strength at mid lactation. The crush fixture assessed 
mainly the tough outer cortical shell and its contributions to failure, thus explaining the higher numbers with this analysis. The 
pointed fixture and flat tipped fixtures both assessed the inner trabecular contribution to bone strength. Numbers in parentheses 
indicate the numbers of mice studied. 
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Q. Expression of other Calcitropic Genes 
Real-time quantitative RT-PCR results were analyzed using the comparative 
method, also referred to as the 2-MCT method, where the target and reference were 
amplified in separate wells (21 ). In this case, the mean Ct values of the ctcgrp null 
samples were compared to C1 values from normal WT mammary tissue. The Ct values of 
both the WT and ctcgrp null samples were normalized to respective Ct values from the 
GAPDH gene. The following comparisons were made: 
Ctcgrp null late lactation versus WT late lactation. 
Ctcgrp late lactation versus ctcgrp pregnancy. 
WT late lactation versus WT pregnancy. 
Ctcgrp null pregnancy versus WT pregnancy. 
Mammary tissue expression ratios ofmRNAs for: the calcium receptor, calcitonin 
receptor, 1-alpha-hydroxylase, vitamin D receptor, and the epithelial calcium channels 
(calcium transporter 1 and 2 [CaTl and CaT2] were examined in triplicate. No significant 
differences, however, were seen between the WT and ctcgrp nulls during lactation (Table 
5). ANOVA was used for the initial analysis; Tukey' s test was used to determine which 
pairs of means differed significantly from each other. 
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Figure 34: Urinary excretion 9f Deoxypyridinoline (Dpd)/creatinine (Cre) 
throughout reproduction in WT and Ctcgrp null mice. Dpd a marker of bone 
resorption (break-down of collagen) corrected for concentrations of Cre (mean ± SE) was 
increased significantly in ctcgrp nulls versus that seen in the WT siblings during late 
lactation (p=0.0025). Numbers in parentheses represent the number of mice studied. 
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Figure 35: Serum Osteocalcin levels throughout Reproduction in WT an!l Ctcgrp 
null mice. No differences were observed in the serum level of osteocalcin (a marker of 
bone formation) (mean ± SE) between ctcgrp null and WT at any time point (p=0.413). 
Numbers in parentheses represent the number of mice studied. 
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Figure 36: Maternal Whole Blood ionized Calcium in WT and Ctcgrp null mice 
throughout Reproduction. Blood ionized calcium (mean ± SE) remained constant 
throughout reproduction showing no differences between WT and ctcgrp nulls at the main 
time points. At 24 hours post-partum, however ctcgrp nulls experienced transient 
hypercalcemia versus that in WT and every other time point (p<0.01 ). Numbers in 
parentheses represent the number of mice studied. 
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Figure 37: Maternal Urinary Calcium corrected for Creatinine concentration in WT 
and Ctcgrp null mice throughout Reproduction. Ctcgrp null and WT mice both 
experienced a decrease in urinary calcium excretion (mean ± SE) during lactation, but 
with no significant differences between the genotypes at any time point. Numbers in 
parentheses represent the number of mice studied. 
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Figure 38: Intestinal Calcium Absorption in WT and Ctcgrp null mice during 
Lactation. Duodenal 45Ca absorption (mean ± SE) was not significantly different at mid-
lactation in WT and ctcgrp null mice. Efficiency of absorption was greater than 80% in 
both WT and ctcgrp null mice and not significantly different from the non-pregnant WT 
value. Numbers in parentheses represent the number of mice studied. 
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Figure 39: Milk Calcium levels in WT and Ctcgrp null mice Early Lactation. 
Milk calcium, corrected for protein (mean± SE) was not significantly different between 
ctcgrp nulls versus that ofthe WT mice during early lactation (day 2-7). Numbers in 
parentheses represent the number of mice studied. 
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Figure 40: Milk Calcium levels in WT and Ctcgrp null mice during Mid-Lactation 
Milk calcium, corrected for protein (mean ± SE) was significantly higher (p=0.0213) in 
ctcgrp null mice versus that of the WT mice during mid-lactation (week 2). Numbers in 
parentheses represent the number of mice studied. 
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Figure 41: Maternal Serum Prolactin levels in WT and Ctcgrp null mice throughout 
Reproduction. Prolactin levels (mean ± SE) were increased from baseline to late 
pregnancy in both WT and ctcgrp nulls in preparation for milk production. No significant 
differences however, were seen between WT and ctcgrp nulls at any time point. Numbers 
in parentheses represent the number of mice studied. 
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Figure 42: Mammary Tissue PTHrP mRNA in WT and Ctcgrp null mice during 
Late Lactation. Real-time quantitative RT-PCR showed that PTHrP was significantly 
upregulated in the mammary tissue of ctcgrp nulls compared to the WT by a fo ld of3.28 
± 0.09 SD at 21 days of lactation. Tests were performed in triplicate and normalized to a 
GAPDH control. 
149 
Figure 43: Immunohistochemistry of mammary epithelium using a Rabbit Anti-
PTHrP Antibody (1-40). PTHrP staining was visibly increased (dark pink) (iv) in ctcgrp 
null mammary epithelium during lactation compared to that in WT mammary epithelium 
during lactation (ii). WT and ctcgrp null mammary epithelium wa used as a negative 
control without the primary antibody (i , iii) (scale bar, 100 [.tm). 
150 
20 
18 WT D Ctcgrp null 
r---, 16 ,_...., 
---
,_...., 
0 
s 14 
8 
~ 12 
:::r:: 10 ~ 
P-t 
ro 8 s 
en 
ro 6 ,_...., P-t 
4 
2 
0 
(3) (3) (5) (5) (4) (4) 
Baseline Mid-lactation Late Lactation 
Figure 44: Maternal Plasma PTHrP levels in WT and Ctcgrp null mice throughout 
Reproduction. Within the circulation, the plasma PTHrP (mean ± SE) levels showed no 
significant difference was seen between WT and ctcgrp nulls at any time point. Numbers 
in parentheses represent the number of mice studied. 
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Figure 45: Serum PTH levels in WT and Ctcgrp null mice throughout Reproduction. 
During earl y lactation (7 days) PTH (mean ± SE) became significantly elevated in the 
ctcgrp nulls (77.9 ± 17.6) (n=8) versus WT and all other time points (ANOVA p=0.05). 
In a separate analysis of serum obtained at 24-48 hrs (to correspond with the transient 
hypercalcemia), PTH levels were suppressed to the limit of detection (1.6 pg/ml) in both 
WT and ctcgrp null mice (p = not significant), (not included in graph). Numbers in 
parentheses represent the number of mice studied. 
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Table 5: Real-Time RT PCR Relative Cr* Expression Ratio of Calcium Regulating Genes in the M ammary Gland of WT 
and Ctcgrp null mice 
Relative C, * Expression Ratio PTHrP CaR CTR laOH VDR CaTl CaT2 
Ctcgrp null late lactation 3.28±0.095 Undetectable Undetectable 0.766±1 .635 1.82±0.227 Undetectable Undetectable 
relative to WT late lactation 
Ctcgrp null late lactation 4.272±0.072 Undetectable Undetectable 0.834±1 .584 0.567±0.231 Undetectable Undetectable 
relative to Ctcf(rp null Peak 
WT late lactation relative to 1.202±0 .124 Undetectable Undetectable 1.07±0.776 0.391±0.242 Undetectable Undetectable 
WT peak 
Ctcgrp null peak relative to 0.923±0.107 Undetectable Undetectable 0.986±0.662 1.250±0.246 Undetectable Undetectable 
WT peak 
Mammary PTHrP mR A was upregulated over 3-fold in the Ctcgrp null versus WT at late lactation. No differences, however, 
were seen in the relative expression of mammary gland vitamin D receptor (VDR) and 1-alpha- hydroxylase (1aOH). The 
calcitonin receptor (CTR), the calcium receptor (CaR), and the epithelial calcium channels (calcium transporter 1 and 2 [CaTl 
and CaT2] were undetectable within the mammary samples in both normal and Ctcgrp null mice. Samples were examined in 
triplicate and expressed relative to GAPDH as a control. Multiple analysis were completed on triplicate samples, the chart above 
represents one set. 
*C1 (threshold cycle): Threshold cycle reflects the cycle number at which the fluorescence generated within a reaction crosses the 
threshold. It is inversely correlated to the logarithm of the initial copy number. The C1 value assigned to a particular well thus reflects the 
point during the reaction at which a sufficient number of amp/icons have accumulated. 
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V Discussion 
A Foreword 
In this doctoral work, ctcgrp null mice were compared to WT siblings at four 
main time periods: pre-pregnancy (baseline), pregnancy, lactation, and the post-weaning 
period. Of these stages, the most noteworthy phenotypic differences were found in the 
spine region during lactation and during the post-weaning period. Ctcgrp null mice lost 
more than double the amount of skeletal mineral content after 21 days of lactation (i .e. 
51.6%) versus that seen in the WT siblings (24.4%). Despite these significant losses 
ctcgrp nulls regained BMC completely after just 3 weeks. Consequently, this discussion 
will focus on the periods of lactation and post-weaning recovery in the absence of 
calcitonin. The broader context concerning the role of calcitonin in bone metabolism will 
also be discussed. 
B. Thesis Statements 
In light of earlier studies that suggested the possibility that calcitonin may have a 
physiological role in mammals during the reproductive period (89, 90, 150, 153), this 
doctoral research was carried out to test the thesis that: calcitonin is required 
physiologically during reproduction to protect the maternal skeleton against excessive 
resorption of mineral. In addition, because of the location of the CTR within key regions 
potentially responsible for mineral regulation during reproduction (i.e. mammary 
epithelial cells, osteoclasts, and pituitary lactotrophs) and the production of calcitonin by 
thyroidal c-cells and pituitary lactotrophs, the second thesis is that: lactational bone 
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losses, in the absence of calcitonin, involves linked physiological pathways between the 
bone and breast. 
C. Thesis 1: Calcitonin is required physiologically during reproduction to protect the 
maternal skeleton against excessive resorption of mineral. 
The reproductive period clearly illustrates the dynamic nature of the skeletal 
system. Previous reports have indicated that after 6 months of exclusive lactation up to 
5-10% ofBMC can be lost in humans (5-8) and up to 35% ofBMC can be lost after 3 
weeks oflactation in mice (168). Remarkably, despite these significant lactational BMC 
deficits, the postweaning period brings about a rapid regain of all BMC losses with no 
long-term adverse effects on bone health (5-8, 168). The reproductive skeleton has the 
unique capacity to fully gain back what it has lost, an ability that the adult skeleton does 
not have after the achievement ofPBM. By understanding the mechanisms involved in 
BMC cycling during reproduction, one could explore how this relates to BMC loss and 
possible regain during the post-menopausal years when osteoporosis and subsequent 
fracture incidence increase significantly (11 , 12). Current pharmacological therapies help 
sustain exiting BMC values or, at best aid in modest re-gains over time (52, 211 , 218). 
In the past, animal studies suggested that calcitonin, a 32 amino acid peptide 
predominantly of thyroid origin, could possibly play a role in the cycling of BMC during 
reproduction (89, 90, 150, 152). Sheep, rats and goats with total thyroidectomy, 
parathyroid gland autotransplantation and thyroid hormone replacement were used to 
represent calcitonin ' deficiency' in these particular studies (89, 150 -152). Some 
researchers determined that there was a reduction in BMC at the time of weaning in the 
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so-called calcitonin deficient animals. Other investigators, however, did not find such an 
effect (89, 150-152). Therefore, these studies were largely inconclusive and the role of 
calcitonin in skeletal BMC cycling during lactation was left unanswered. It is important to 
highlight also that in these animals, serum calcitonin was not measured to determine if 
they were truly calcitonin-deficient. As well, extrathyroidal sources of calcitonin (e.g. 
breast, pituitary, placenta, etc) were not appreciated at the time and this might have 
possibly confounded the interpretation of the experimental results. Therefore, the use of 
the ctcgrp null model (1 03) in this research provided the first insights into the 
physiological effects of true lack of calcitonin during the reproductive period. 
Using the ctcgrp null model, we found that mice lacking calcitonin lost 
significantly more total body BMC (32.3%) via DXA after a cycle oflactation versus that 
experienced by the WT sibling controls (19.9%). This difference in BMC between the 
WT and null first became apparent after just 7 days of lactation, indicating that ablation of 
calcitonin in mice had an effect early on and was necessary to sustain normal BMC 
cycling during the full duration of lactation. Calcium resorption during lactation is the 
predominant adaptation in which increased requirements for calcium are met (5-8). The 
release of calcium from skeletal storage ensures an adequate supply of mineral to the 
breastmilk for neonatal growth and development (5-8). 
The finding of a significant lactational BMC loss in the ctcgrp null versus that in 
the nonnal WT controls was consistent with some of the earlier studies using surgical 
models (150, 152). Subsequent to this finding the following questions were asked: what is 
driving this significant loss of BMC in the null? Is the loss driven by maternal metabolic 
alterations in the absence of calcitonin (and/or CGRP-a) or fetal demands? Where is the 
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calcium going? Where is the BMC loss primarily occurring from? Is the BMC loss 
predominantly trabecular or cortical in nature? Furthermore, what are the implications of 
losing such a significant amount ofBMC during reproduction? 
To begin addressing these questions, we first explored where the BMC loss was 
occurring in both the WT and ctcgrp null mice. Both the hind limb and spine were singled 
out as key regions of interest to examine iflosses were predominantly cortical or 
trabecular. The trabecular rich spine region has a greater surface area per bone volume 
ratio and thus is considered more metabolically active (i.e. there are more mineral 
fluxuations between the bone and blood in this region) (3).The hindlimb, in contrast, is 
made up a relatively larger proportion of cortical bone, and thus has a lower bone surface 
to bone volume ratio (3). 
Results indicated that the most dramatic of the BMC losses were those seen within 
the trabecular-rich spine region, to the extent that 51.6% of the baseline BMC was lost in 
the ctcgrp nulls versus 24.4% in the WT, relative to the respective pre-pregnancy baseline 
BMC values (Figure 26). Losses within the hind limb were also over double in the ctcgrp 
null (28.4%) versus WT (12.9%), but the degree ofBMC loss was propOiiionately less in 
the hind limb versus that seen in the spine, which is not surprising due to the lower area 
and bone volume ratio. 
These findings indicated that calcitonin, in mice, is indeed required from early 
lactation as well as throughout the full lactation process because, in its absence, BMC 
losses were more profound when compared to WT controls. Also, BMC losses appear to 
be predominantly trabecular in nature, as the trabecular rich spine region lost 
proportionally more mineral versus that seen in the cortical rich hind limb region. This 
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increased loss in the spine is likely due to the metabolically active nature of this region of 
the skeleton. The absence of calcitonin and possibly secondary effects subsequent to this 
genetic alteration (e.g. increased PTHrP) could have also contributed to the increase in 
trabecular BMC loss during lactation. The exploration of these other pathways will also 
be discussed. 
When considering regional decreases in BMC during lactation, it is relevant to 
point-out obvious skeletal differences and potential bone resorption patterns in humans 
versus rodents. Unlike humans, rodents largely remodel their cortical skeletons and their 
growth plates remain open during most of their lifespan (6-8). Also, in rodents and 
humans there are notable postural differences, and thus biomechanicalloading patterns 
and possibly lactational BMC cycling patterns may differ. Thus, significant regional 
lactational losses seen in the rodents may not necessarily reflect what may occur in other 
species. Despite these obvious anatomical and physiological differences, trabecular bone 
is generally more actively resorbed than cortical bone during lactation in all mammals 
that have been studied (6-8). In any instance of increased bone resorption, the loss is 
always detected first in the trabecular compartment because that is the bone with the 
greatest surface area and thus osteoclasts can resorb it quickly. 
To summarize, these findings support the first thesis by showing that calcitonin is 
indeed required physiologically during lactation, because in its absence significant BMC 
losses occur. Furthermore, these results provided the justification for supplementary 
investigation of the ctcgrp null, as compared to WT siblings, in hopes of better 
understanding mechanisms underlying the significant BMC loss during lactation and 
more generally, the role of calcitonin in mammalian physiology. 
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After the aforementioned DXA analysis in which ctcgrp null mice experienced an 
exaggerated BMC cycling pattern during lactation, it was next called into question 
whether these findings resulted subsequent to the absence of calcitonin, CGRP-a or both. 
Because this genetically engineered mouse colony has both calcitonin and CGRP-a 
ablated, absence of either or, or both gene products, could have resulted in the BMC 
pattern observed during lactation. To address this question, a ' rescue' experiment was 
designed in which sCT was provided via daily injections to a level that would result in 
BMC losses that were no different between the WT and ctcgrp null during lactation (i.e 
the null would experience norma/losses). Then, equimolar doses ofrat CGRP- a peptide 
were provided to see if it would have same effect on BMC loss. It was found that daily 
injections of 10 IU of calcitonin peptide prevented significant BMC losses in the ctcgrp 
null to levels that were no different than that seen in the WT siblings (i.e. normal BMC 
lactational losses) (Figure 26). Ctcgrp null mice, however that received equimolar daily 
doses of CGRP-a peptide throughout lactation had BMC losses were no different that that 
seen in saline controls. Thus, based on these findings, replacement of circulating levels of 
calcitonin, and not CGRP- a , prevented the significant loss ofBMC during lactation. 
There were several limitations to this ' rescue' experiment that should be noted. 
First, CGRP-alpha peptide was expensive and therefore could only be tested at a fixed 
dose in 4 mice. Second, the numbers of mice injected with CGRP-alpha were low due to 
the fact that a mouse died during the analysis, leaving only 3 mice. Third, CGRP-alpha 
was not tested independently to confirm if it was indeed biologically active. Such testing 
would have eliminated the possibility that CGRP was a bad batch of peptide. Fourth, it is 
possible that pharmacological doses of sCT could have independently inhibited lactation 
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through the suppression of prolactin gene transcription and secretion (234-236). 
However, this is unlikely as pups were fme and mothers appeared to lactate 
normally. Fifth, pharmacological doses may not be physiologically relevant. Sixth, 
compensatory mechanisms in the absence of calcitonin and CGRP-a may have 
contributed to, or even masked the skeletal phenotype. Such compensatory mechanisms 
could possibly include the upregulation or downregulation of other calcium regulating 
hormones such as PTH, PTHrP, or CaR. 
Nevertheless, experimental results support the first thesis, by further illustrating 
the fact that calcitonin is needed during lactation. Provision of sCT resulted in less BMC 
loss during lactation, whereas provision of CGRP-a had no effect. Absence of calcitonin 
could have resulted in: decreased osteoclast number in the presence of sCT and thus less 
bone resorption (77), decreased osteoclast function (i.e. resorptive capacity) in the 
presence of supplementary calcitonin (77), or possibly the presence of sCT could have 
counteracted the catabolic effects of another peptide on bone (e.g. PTHrP, which has been 
suggested to promote bone resportion during lactation) (146). Exploration of these 
options will be discussed in detail further along. 
There is some evidence that DXA changes are also a measure of changes in bone 
microarchitecture, an important determinant ofbiomechanical strength (229-231 ). 
Considering this, we next examined both the trabecular structure and the relative strength 
ofWT versus ctcgrp null bones at baseline and late lactation. With increased bone 
resorption and significant losses seen by DXA in the ctcgrp null versus WT during 
lactation, we hypothesized that ctcgrp null bones would have significant alterations in 
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microarchitecture (e.g. increased porosity, trabecular thinning, etc) and thus greater 
susceptibility to fracture. 
Consistent with the aforementioned findings and supporting the hypothesis was 
the discovery that ctcgrp null mice underwent more pronounced thinning of trabeculae 
versus that seen in the WT controls by the end oflactation in the femora and lumbar spine 
regions (Figure 27, 28). Also, within the femora there was an increase in spacing between 
trabeculae in the ctcgrp null that was not seen in the WT mice. The main biological effect 
of calcitonin is to inhibit osteoclastic bone resorption (77), and thus the finding of 
increased trabecular thinning and spacing during a time of increased calcium demand, in 
the absence of calcitonin, does not come as a surprise. With less control over osteoclast 
activity and number, one would expect there to be exaggerated bone resportion. Also, in 
the absence of calcitonin the activity of other key calcium regulating hormones may also 
be altered. For example, increases in PTHrP and decreases in estrogen have been 
associated with increased bone resorption (5-8, 60, 175, 193). By removing calcitonin 
from the equation, a key calcium regulating hormone, other calcium regulating hormones 
(e.g. PTHrP and estrogen) could have been altered such that bone resorption was 
increased and subsequently trabecular thinning and spacing were also increased. 
It was observed that despite significant losses in BMC via DEXA during lactation 
in the ctcgrp nulls, J.!CT results showed that the amount of trabecular bone volume 
relative to total volume (BY/TV) did not significantly decrease in the null at this time. In 
fact, the BY/TV slightly increased in the null vertebrae during lactation versus baseline 
(23. 7 ± 1.1% vs. 25.2 ±0.9% respectively). Inconsistencies could reflect differences in the 
two techniques ()lCT performed at McGill University versus DEXA completed at 
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Memorial University) as well as the fact that the samples were drawn at several different 
time points (i.e. samples sent to McGill were obtained a much earlier time point during 
lactation than the DEXA analysis at Memorial University). Also, due to the expense 
associated with performing the )lCT analysis at McGill the sample number for this 
analysis was lower than that used within the DEXA analysis. 
Interestingly, however, )lCT analysis revealed higher trabecular bone volume, 
greater trabecular thickness, and more densely packed trabeculae at baseline in the ctcgrp 
nulls versus that seen in the WT. In fact, the baseline bone volume within the ctcgrp null 
femora was no different than that seen during late lactation in this region in the WT mice 
(Table 2). These baseline results were consistent with Hoffs (1 04, I 05) initial findings 
illustrating higher bone mass in the ctcgrp null (1 03). Interestingly, using much older 
mice Gagel found an osteopenic phenotype with age in the ctcgrp null versus WT mice 
(104, 105). 
The issue of bone mass in the ctcgrp nulls has been an obvious area of scientific 
contention in the past. Using older mice R.F. Gagel (1 04, 1 05) found osteopenia and 
trabecularization in the ctcgrp null mice. The current data, using younger mice, illustrates 
increased trabecular thickness, a baseline BMC that trended higher and 11CT data that 
indicated a higher baseline bone volume in the ctcgrp nulls that was no different than that 
found in the WT siblings during late lactation. The latter ofthese results may suggest that 
ctcgrp nulls lack (or do not require) the ability to naturally increase the bone volume 
during lactation, especially in the cortical rich femur region. Normally, WT mice 
experience a doubling in femoral bone volume from baseline to late lactation, perhaps to 
support the fetus (161-163). This data, however, supports the finding that bone mass is 
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indeed higher in the ctcgrp nulls versus WT. Unlike Hoffs initial experiments (103) 
however, in which ctcgrp nulls were mated to each other, these finding were based on 
matings first-degree relatives generated from the same HET x HET matings, and they 
were mated to the same HET males. Therefore, despite the possibility that the initial 
findings of increased bone mass and volume was an inherited mutation, due to ongoing 
matings of homozygous mice with homozygous mice (i.e. ctcgrp null x ctcgrp null) in 
Hoffs experiments, this data actually supports the suggestion that ctcgrp nulls actually 
have a higher baseline bone mass phenotype in the context of sound animal husbandry 
(i.e. nulls compared to related WT littermates and backcrossed for 10 generations into a 
BLKSW colony). 
Despite the hypothesis that ctcgrp nulls would have weaker bones during lactation 
(i.e. because of significantly lower BMC values at this time) the biomechanical results 
indicated that there were no significant differences in the strength of ctcgrp null bones 
versus that seen in the WT siblings. Several factors may explain why no differences were 
seen in the biomechanical properties. Most standard bone biomechanical tests, such as the 
3PBT, focus primarily on cortical strength. During these experiments lactational bone 
losses via DXA were most exaggerated in the spine, which consists of a large ratio of 
trabecular bone content. BMC alterations in the cortical rich hindlimb were not as 
exaggerated, and thus might explain why there were no significant differences seen 
biomechanically in this area. Another possibility could have been that the test was not 
sensitive enough to detect any biomechanical differences in such small fragile samples. It 
is also quite possible that because the ctcgrp nulls ended up with a bone volume and 
trabecular thickness that was no different than that seen in the WT siblings, this might 
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Figure 46: Break in a Cylinder as Demonstrated in a 3-Point Bend Test on a Long 
Bone. All three points on the fixture initially come into contact with the tough outer 
cortical shell of the long bones because it is the length of the cylinder, not the interior that 
will resist bending and breaking. 
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have accounted for lack of a difference biomechanically at late lactation between 
genotypes. Furthermore, the higher baseline bone volume in the ctcgrp null and the 
increased bone volume changes during pregnancy in the WT may have offset any 
discrepancies that may have been detected in bone strength between genotypes. 
The theory and practical reality ofbiomechanical testing and the novel approaches 
that were taken to overcome existing limitations in these experiments are also relevant to 
discuss. A standard three-point bend test (3PBT) was initially used to examine bone 
strength within the hind limb region. Like many biomechanical tests, this particular 
method is very sensitive to specimen and loading geometry and strain rate (i.e. a material 
property that reflects the change in strain, or displacement of an object, over a specified 
period of time) (24). As well, the 3PBT mainly reflects the strength of cortical bone 
(because all three points on the fixture initially come into contact with the tough outer 
cortical shell ofthe long bones and because it is the shell of the cylinder, not the interior 
that will resist bending and breaking) (Figure 46). Also, cortical bone is relatively 
avascular and undergoes more modest resorption compared to trabecular bone (3). 
During lactation it is likely the trabecular fraction of bone that is more rapidly mobilized 
due to its large surface area and vascularity. These factors enable the spine region to be 
resorbed by osteoclasts on multiple surfaces (5-8, 113, 114, 116, 121). Thus, a vertebral 
test was subsequently deemed as a more appropriate model for determining the strength 
ofWT and ctcgrp null bones during lactation to overcome these limitations. Next a crush 
fixture was constructed in an effort to focus more specifically on the trabecular rich 
vertebral samples (Figure 47). Small, disk-shaped metal plates were crafted, one side 
comprising the lodging surface for the vertebral sample to be centered on, and the other 
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Figure 47: The Vertebral Crush Test Considers Cortical Contributions to Strength. 
As the cross-head compresses a single vertebrae, it comes into contact with high points on 
the surface. These high points are comprised of the outer cortical shell, and not the 
trabelcular framework contained deeper within the bone sample. 
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serving as the attachment site for the moving biomechanical crosshead which compresses 
the sample (Figure 20b). Software was programmed to move the crosshead (10 mm/min) 
until adequate force was provided to serially compress each vertebral body minus the end 
plates (Figure 20b). Samples were carefully centered on the lower fixture. Tests results 
indicated that, regardless of the blinded sample being tested, the maximum load (1 OkN) 
was achieved for every specimen. Thus, the load/displacement curve appeared 
exponential making it challenging to extrapolate any differences in strength between 
samples. It was decided that the second spike on the curve would serve as the ultimate 
failure point for the sample because there was less probability that it represented contact 
with the cortical perimeter and more likely indicated the inner trabecular contributions to 
strength. The first spike occurred when the cross-head contacted the outer spherical 
cortical shell. Thus, the first spike was disregarded because of the probability of a cortical 
contribution. It was observed, however, that despite using the second spike on the curve 
as the selected failure point, that the tough outer cortical shells of the vertebrae were so 
irregular in shape that erratic spikes on the load/ displacement curve made it difficult to 
extrapolate infonnation even from the second peak on the curve. By contacting the 
uneven cortical shell of the bone first and subsequently causing flexion on the standard 
curve, the crush fixture did not accurately assess the trabecular bone contributions to 
strength, yet focused more on the tough outer cortical surface. No differences, however, 
were seen between WT and ctcgrp null at the BMC trough point of lactation. To 
overcome the limitations of the crush fixture, another biomechanical attachment was 
designed. This next fixture was comprised of a generic base that fit into the 
biomechanical testing devise, and a narrow pointed tip (Figure 21a). The metal point 
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Figure 48: Pointed Fixture Testing Trabecular Contributions to Bone Strength. 
As the cross-head compresses a single vertebrae, it bypasses the outer cortical rim and 
compresses the trabecular framework within the bone sample. 
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was created to bypass the cortical shell of the vertebrae and simply pass through 
compressing the trabecular framework until it reached a failure point (i.e. level of 
resistance to a controlled load) of only the inner trabecular fraction of the sample. Results 
however, again showed no difference between the load/displacement curve between 
ctcgrp null and WT bones during lactation. This could be explained simply because of the 
fact that there was so little trabecular bone remaining during late lactation that the fixture 
did not consistently register a signal presence. It was observed that the limitation of this 
fixture was that (because of its narrow pointed tip) it came into contact with only a 
fraction of the trabecular surface as it was lowered onto the bone sample, leaving an area 
of trabecular bone on both sides not accounted for within the biomechanical analysis. 
Finally, in an effort to overcome the problem faced with the pointed tip, a flat tipped 
elongated fixture was created (Figure 21b). The full trabecular surface of the vertebrae 
was contacted by the flat tip as the cross-head descended through the cortical shell of the 
vertebrae (i.e. the outer cortical shell was bypassed). Despite tl1e ability of the flat tipped 
elongated fixture to fully contact the trabecular surface, no differences were seen in load 
until failure in the WT versus ctcgrp null during lactation. It is possible that there was no 
actual difference in biomechanical strength between genotypes, even in the presence of 
significant BMC loss in the ctcgrp null during lactation. However, it may also be 
considered that there' s probably too little trabecular bone present to be tested with 
existing biomechanical technology and thus, that may be why we couldn' t resolve a 
difference in strength between WT and ctcgrp null. 
There are, of course, a multitude of limitations when assessing animal bone 
biomechanically that must be discussed. Trabecular bone is physically challenging to 
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obtain from small animals, and thus bone strength tests are typically limited to larger 
animals (e.g. rats, pigs, sheep, primates). Sampling during lactation, with such significant 
reductions in trabecular BMC, makes it even harder to assess strength because there is 
less bone surface available to provide resistance. In two ctcgrp null vertebral samples 
only the outer cortical shell was visible, with very little trabecular bone present inside. 
These samples crumbled while placing them in the fixture and thus were not considered 
in the final analysis. This may infer that these samples may quite possibly have had a 
decrease in bone strength at this time. Finally, the general destructive nature of 
biomechanical testing ultimately precludes any further analysis of the samples being used, 
and thus repeat tests could not be performed on the samples. Therefore, contrary to DXA 
findings, biomechanical testing illustrated that skeletal strength was not significantly 
different at baseline or the end of lactation in WT and ctcgrp null mice. 
In summary, the first thesis that calcitonin is required physiologically during 
reproduction to protect the maternal skeleton against excessive resorption of mineral is 
supported by the fact that ctcgrp null mice experience significantly greater BMC losses 
by DXA and trabecular thinning and separation by J.!CT when compared to the WT 
counterparts, thus defining calcitonin physiologically important. Also, the results of the 
primary analysis and supplementation ("rescue") experiment support the primary 
hypothesis that absence of calcitonin leads to the observed bone phenotype during 
lactation and that absence of CGRP-a does not contribute. Admittedly, CGRP-a is 
thought to function predominantly as a neuropeptide and thus a once-daily subcutaneous 
injection might not be an adequate means of reversing CGRP-a deficiency in these mice, 
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and thus a role for CORP-a in contributing to the bone phenotype of ctcgrp null mice 
cannot be completely ruled out. 
D. Thesis 2: Lactational bone loss in the absence of calcitonin involves linked 
physiological pathways between breast and bone. 
Having confirmed that calcitonin is physiologically important to protect the 
maternal skeleton against excessive absorption of mineral during lactation, the 
mechanisms driving this significant lactational BMC losses seen in the ctcgrp null versus 
the of the WT were subsequently explored. Lactational bone loss typically occurs as a 
result of an uncoupling in the bone cells, such that ostoclastic bone resorption increases 
over that of bone formation (11-14). Therefore, loss of calcitonin was hypothesized to 
accentuate BMC loss simply by enabling more active osteoclasts to resorb bone, thus 
releasing the 'brake' that controls this process. Significant lactational BMC losses in the 
ctcgrp null could have occurred as a consequence of alterations within the bone 
microenvironment (i.e. increased bone resorption over bone formation). Consistent with 
this hypothesis, was the finding of significantly increased urinary Dpd levels during late 
lactation in the ctcgrp null versus that of the WT. Dpd is a crosslink product of collagen 
molecules found in bone and excreted in urine during bone degradation. Jn contrast, 
serum osteocalcin, which is secreted by osteoblasts and thought to play a role in bone 
mineralization, was no different between genotypes or at any time point. These results 
supported the hypothesis that lactation in the absence of calcitonin is dominated by bone 
resorption and not bone formation. 
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Bone turnover markers provide a broad picture of whole body bone formation and 
resorption, an assessment that does not lend much information regarding the bone cells. 
Histomorphometric analysis however, unlike bone markers, can provide a quantification 
of the osteoclasts, osteoblasts, osteocytes, as well as information describing the activity 
along the bone surface. The adult skeleton is continuously broken down and reformed by 
the coordinated activities of osteoblasts and osteoclasts on trabecular surfaces and in 
Haversian systems. Similar to the importance of considering the total bone volume when 
assessing the biomechanical properties of bone, assessment of calcium flux along the 
surface of bone is critical to reveal differences in bone cell activity during times of high 
turnover, such as during reproduction. In light of this, bones were collected and prepared 
for histomorphometric analysis in the ctcgrp null versus WT. It was hypothesized that 
absence of calcitonin would result in increased osteoclast number and function when 
compared to the WT controls, thus contributing to the rapid skeletal demineralization 
during lactation. 
Due to lack oflocal expertise and training in bone histomorphometry this analysis 
was completed by my supervisor (CS Kovacs) while visiting the University of Melbourne 
(237). The work by C.S. Kovacs illustrated that lactation samples had decreased 
osteoblast surface (OcS) and number (OcN) (as well as osteoid), and increased osteoclast 
number (OcN) and surface (OcS) in the nulls versus WT. This fits with the excess bone 
loss during lactation seen via DEXA in the ctcgrp nulls. In contrast, during late lactation 
and early weaning there was upregulation in osteoblast surface and number (and osteoid) 
in both the ctcgrp null and WT mice. The relative increase was a quadrupling in the null 
versus doubling in the WT, but the absolute level attained was the same in both 
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genotypes. Osteoclast parameters were reduced significantly from earlier in lactation, but 
the null still had greater osteoclast surface and number than the WT. Overall the pattern 
suggests that bone recovery has begun, and the normal osteoblast surface and number 
explains why the mice are able to recover from such a substantial loss ofbone, taking just 
a few more days versus the WT. 
It was also observed illustrated that ctcgrp null vertebral bone volume as a 
expression oftotal bone volume during lactation was lower than that seen in the WT 
siblings at this time (i.e. WT 14.3±1.1% (n=4) vs. ctcgrp null 11.3±1.3% (n= 3)). This 
was also seen in the tibia (i.e. WT 5.1 ±1.2% (n=5) vs. 2.9±1.2% (n=5)), These findings 
were also consistent with the bone phenotype in the ctcgrp at this time as seen via DEXA. 
Hypercalcemia PostPartum 
Blood ionized calcium, the physiological important fraction of calcium, typically 
remains unaltered by reproduction in humans and rodents with a few exceptions in 
rodents with larger litter sizes (5-8). Results indicated that transient hypercalcemia was 
experienced in the ctcgrp null at 24-48 hours post-partum, an effect that was not observed 
in the WT control siblings at this time. 
The two main hormones responsible for regulating calcium in the blood are PTH 
and calcitonin. When blood calcium falls, the CaR detects this change and the body 
produces more PTH and subsequently levels of calcium rise. On the other hand, if the 
calcium in the blood rises too high, the thyroid gland produces calcitonin, which slows 
the release of calcium from bone (2, 90-92). In the ctcgrp null, calcitonin production from 
the thyroid (as well as all other extrathyroidal sites) was completely absent and thus this 
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part of the regulatory feedback loop was not present to compensate for rapid increases in 
blood calcium. It is also possible that this early lactational hypercalcemic spike may have 
occurred as a consequence of increased mineral flooding the maternal circulation at a 
time when milk production or let-down was not fully established. The absence of 
calcitonin to counter this sudden flux of calcium to the system could have exacerbated 
this hypercalcemia. 
Hypercalcemia can also be caused by increased activity of the parathyroid glands 
(i.e. hyperparathyroidism). This however, was not the case in the ctcgrp nulls, as levels of 
serum PTH obtained at 24 - 48 hrs post-partum were actually suppressed to the limit of 
the detection of the assay (1.6 pg/ml) in both WT and ctcgrp null mice (i.e the time of the 
hypercalcemic spike in the ctcgrp null). Excessive dietary intake of calcium or vitamin D 
may also raise blood calcium levels above normal. Both WT and ctcgrp null mice were 
both on the same standard mouse chow with 1% calcium and 0.75% phosphorus by 
weight. 
After the second day post-partum maternal blood ionized calcium returned to 
normal and stayed there for the remainder of lactation. Thus, beyond the 24 - 48 hour 
period post-partum the absence of calcitonin did not have any long term effects on 
circulating blood calcium levels. 
Systemic Calcium Handling 
Calcium balance involves the activity of multiple physiological compartments 
including: storage of calcium in bones, blood and muscle, dietary intake, intestinal 
absorption, fecal excretion, renal excretion and reabsorption as well as bone resorption 
174 
(Figure 4). All of these pathways work synergistically to maintain the calcium levels in 
the blood, which is necessary for survival. Systemic balance of calcium can shift if one, 
or multiple, of these parameters increase or decrease (e.g. if dietary calcium is low, 
intestinal calcium absorption may increase to compensate). In the case of the ctcgrp null, 
in which BMC was significantly reduced during lactation compared to the WT control 
siblings, there were several possible routes that warranted exploration to determine how 
calcium balance was altered such that mineral losses were exacerbated. 
Hypercalcimia in the ctcgrp null was hypothesized as one of the possible 
explanations for the significant loss of mineral during lactation versus that seen in the 
normal WT siblings. 'Leakage' of calcium into the urine (i.e. increased excretion) could 
have caused a shift in calcium balance resulting in mineral breaking down from within the 
skeleton to sustain systemic calcium levels. Previous studies, however, in both humans 
and rodents have shown that the glomerular filtration rates typically decrease during 
lactation versus that seen in pregnancy and thus renal excretion of calcium is often times 
reduced (5-8). In this study we examined whether urine calcium levels were different in 
the ctcgrp null versus that seen in the WT. If levels were found to be higher in the urine 
of the ctcgrp null this would warrant further exploration of calcium handling by the 
kidneys to determine how calcitonin affects the active and passive processes involved in 
renal calcium handling. Findings indicated however, that in both WT and ctcgrp null 
mice, urinary calcium levels were decreased during lactation. More importantly, no 
differences were seen between the ctcgrp null and WT. Therefore significant losses of 
mineral in ctcgrp null were likely not attributed to a renal axis in which calcium excretion 
was exaggerated and systemic calcium balance was thrown off. With this pathway 
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eliminated, we next explored what was happening in the intestine in the ctcgrp null and 
WT. 
Intestinal calcium absorption is increased during pregnancy in both humans and 
rodents to meet the needs of the growing fetus (5-8). During lactation, however, intestinal 
calcium absorption typically decreases to a level that is no different than that during non-
pregnancy (5-8). In contrast, the predominant mechanism in which the additional needs 
for calcium are met during this time is through enhanced resorption of bone. It was 
hypothesized, however, that the absence of calcitonin could cause a substantial decrease 
in intestinal absorption of calcium, thus resulting in exaggerated bone resportion during 
lactation to sustain blood calcium levels. Duodenal 45Ca absorption, however, was no 
different at mid-lactation between WT and ctcgrp null mice. Thus, mice lacking 
calcitonin experienced a calcium absorption rate that was no different than nom1al during 
late lactation and thus this particular hypothesis was proven incorrect (Figure 36). 
During lactation the breast also actively participates in maintaining systemic 
calcium balance (5-8). The suckling neonate uses the mother's reservoir of skeletal 
mineral to nourish its growth and development. Another hypothesis was that the 
significant BMC loss in the ctcgrp null occurred as a result of calcium being drained into 
the milk supply during lactation. Indeed, despite the lack of a change in urinary calcium 
excretion or intestinal calcium absorption during lactation, ctcgrp null mice were found to 
have a higher mean milk calcium concentration during mid-lactation versus that of the 
WT siblings. Therefore increased skeletal resorption may have increased the loss of 
calcium into milk. 
176 
-------------------
Initially, considerable variation was seen in milk calcium in both genotypes with 
standard error values being quite large (Figure 37). In an attempt to control for some of 
the variability, pups were separated from the lactating mothers for an hour before 
milking, and milk was collected at similar times each day. Milk calcium concentrations 
can vary not only from time of day, but within a particular feed. Controlling for all of 
these inconsistencies, as well as dealing with small milk volumes for analysis created 
experimental road blocks that were challenging given the physical size of the animals and 
the numbers oflactating mice. At two weeks of lactation, however, milk calcium 
corrected for protein was significantly higher in ctcgrp null mice versus that of the WT 
mice (Figure 40). Excess calcium losses during lactation seen in the ctcgrp null mice 
(versus WT) appear to be drained into the milk supply. The cause of this drainage could 
be mammary tissue creating more calcium rich milk (possibly through increased local 
production ofPTHrP) and therefore causing increased bone resorption through the actions 
of systemic PTH and/or PTHrP. Or it is possible that the mammary tissue could be 
draining off the increased calcium that was initially created by increased bone resorption. 
Hormonal Milieu during Lactation 
During lactation osteoclast-mediated bone resorption is enhanced due to a unique 
hormonal milieu characterized by low circulating PTH and estradiol and elevated PTHrP 
and calcitonin. This particular microenvironment allows for the production of milk and 
thus the provision of nutrients required for neonatal growth and development. Thus, in 
further exploring the skeletal phenotype in the ctcgrp null versus WT, it was hypothesized 
that exaggerated BMC losses may result in high PTHrP levels that, in the setting of low 
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estrogen, plays a major role in the regulation of skeletal demineralization during lactation 
(6- 8, 174). Supporting this fact is the finding that mice lacking PTHrP in mammary 
tissue during lactation lose only a fraction of mineral as their WT counterparts (193). 
Considering these previous findings, it is possible that exaggerated BMC losses in the 
ctcgrp nulls may result from high PTHrP levels. Evidence refuting this theory, however, 
included lack of a difference in plasma PTHrP levels between WT and ctcgrp null mice 
(Figure 44). It is important to note, however, that plasma PTHrP levels fluctuate relative 
to suckling (174) and samples in this analysis were not timed to control for suckling 
patterns. Also, it is possible that the sensitivity and performance characteristic of the 
PTHrP RIA may have made it unable to detect a difference in circulating PTHrP. Despite 
lack of a detectable difference in circulating PTHrP levels, however, PTHrP mRNA was 
increased over 3 fold during late lactation in mammary tissue in ctcgrp null mice versus 
that seen in the WT controls at the same time point. Consistent with these finding as well 
was a qualitative increase in immunohistochemical staining ofPTHrP in the mammary 
epithelial tissue using an anti-PTHrP antibody and normal WT lactating mammary tissue 
as a negative control. Thus, evidence suggests that increased mammary derived PTHrP in 
the ctcgrp null contributed to increased bone resorption. 
It is relevant to note that PTH and PTHrP are equivalent in their ability to activate 
the PTH/PTHrP receptor on osteoblasts and communicate through the RANK-RANKL-
OPG pathway to stimulate osteoclast-mediated bone resorption; thus, the mechanism for 
enhanced bone resorption in the ctcgrp null mice may simply occur as a result of 
exaggerated stimulation ofPTH/PTHrP receptor-mediated bone resorption by PTH and 
PTHrP, coupled with absence of the effect of calcitonin to serve as a systemic break to 
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inhibit the activity of osteoclasts. Thus, because of increased mammary PTHrP in the 
ctcgrp null versus WT, it appears that the breast is an important physiological pathway 
regulating bone loss during lactation in the absence of calcitonin. 
High PTH levels (i.e. hyperparathyroidism, a group of conditions characterized by 
an overproduction ofPTH by the parathyroid glands) is a known cause of hypercalcemia 
and bone loss (34, 43). Findings, however, indicated that PTH levels were no different in 
the WT and ctcgrp null at 24-48 hours post-partum (i.e. at the time of hypercalcemia in 
the ctcgrp null). Thus, the early lactational hypercalcemia in the ctcgrp null was not due 
to hyperparathyroidism. PTH levels, however, did spike after 1 week of lactation in the 
ctcgrp null. This was not seen in the normal WT siblings, as PTH levels in these animals 
remained on the lower side of normal, a finding anticipated from previous studies in 
humans and rodents at this time (7, 8, 168). The cause of the elevated PTH may have 
been subsequent to the significant loss of calcium in the milk. Hypocalcemia resulting 
from an excess loss of calcium in the milk is a condition called 'milk fever'. Milk fever, 
characterized by a drop in blood calcium, paralysis, etc, is most commonly seen in dairy 
cows after calving. Milk fever could be a possible explanation for this secondary 
hyperparathyroidism occurring after the first 24 hrs post partum in the ctcgrp null. Milk 
calcium content was doubled during lactation in the ctcgrp nulls versus that in the WT 
mice, these changes could have been compensated for by elevations in PTH. This 
compensatory increase in PTH possibly prevented any hypocalcemia from occurring or, it 
is possible that the increase in PTH could have primarily contributed to the exaggerated 
skeletal mineral losses seen in the ctcgrp null. Other considerations include, larger litter 
size or a restricted calcium diet may also induce maternal secondary hyperparathyroidism 
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during lactation (6-8, 33). In these cases, loss of calcium into the milk may compromise 
the mother's ability to maintain her own blood calcium. 
E. Breast and Bone Circuitry 
Evidence from this research has pointed to both the breast and bone as key players 
in the cycling of bone during reproduction. In the absence of calcitonin mammary tissue 
stimulates skeletal resorption during lactation by producing a temporary spike in PTH, 
excess PTHrP during lactation and resorption becomes exaggerated in the bone 
microenvironment (Figure 49). The data collected for this dissertation clearly indicates 
that calcitonin plays a role by modulating the degree of skeletal resorption during 
lactation. Absence of calcitonin in the systemic circulation leads to increased bone 
resorption (likely due to an increase in OcS/BS (237)). However, since the CTR is also 
expressed in mammary tissue it is possible that calcitonin acts at both sites to modulate 
lactation - possibly to inhibit osteoclasts during mid-lactation, and within mammary 
tissue to modulate PTHrP or milk production. 
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Calcitonin 
Figure 49: Breast, Brain and Bone Circuitry during Lactation. Enhanced skeletal 
resorption of calcium in the ctcgrp null versus WT during lactation is due mainly to 
increased mammary production of PTHrP and increased bone resorption (red arrows). 
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F. Limitations of Using Animal Models 
A scientific model (whether animal or cell) is a useful starting point in research. 
The process, however, of extrapolating findings and ultimately applying them to the 
etiology of human disease is (recognizably) a convoluted process. The work completed in 
this dissertation, although useful in its suggestion of a physiological role for calcitonin, is 
certainly not exempt from scientific critique. At the end of the day, it must be recognized 
that there are many notable differences between human and mouse physiology, and 
limitations of using genetically engineered animal knockout models. 
The surge of sex hormones at puberty terminates linear growth in humans by 
fusing the growth plates of the long bones (3 , 13, 14). Rodents, in contrast, do not 
experience this fusion of the long bones, and thus have continual bone growth throughout 
life. This lack of growth cessation may infer drastic differences in the bone remodeling 
process of mice versus that ofhumans, especially during lactation. As well, unlike 
humans, mice go through continual estrus cycles, and thus could theoretically lactate 
almost continuously throughout much of their adult life. Number of offspring in mice 
averages from 8-12 pups per litter, versus mainly singleton births in humans. Mice and 
humans have obvious postural differences which make biomechanicalloading patterns 
quite different and comparing biomechanical results across species may be difficult. 
Furthermore, rodents may exhibit different remodeling pattems in cortical versus 
trabecular bone. 
Use of gene ablation techniques in mice permits the exploration of mechanisms 
underlying the regulation of calcium and bone metabolism that would otherwise be 
impossible (at this point in time) to examine in humans. These techniques however, like 
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most in science, have notable limitations. Notable challenges include: 1) transferability 
of outcome from mouse to human 2) secondary, tertiary, etc effects of gene ablation and 
3) effect of mouse background variability on phenotype. 
Global knock-out of a gene, or any genetic variation thereof (i.e. conditional 
knockout, knock-in, etc) can have various unexpected outcomes. In some cases (e.g. 
PTHrP null, CTR null) ablation of the gene of interest may result in embryonic or 
neonatal lethality. Thus, if the HET survives, it would be considered the experimental 
animal, used to compare to the normal WT littennate. As well, one must always 
remember that modifying the genetic structure of an organism may cause other genes to 
have compensatory effects. Thus, the outcome may not be straightforward, and may 
involve multiple pathways. 
The genetic background is another necessary consideration when completing work 
in animals. Knowing the phenotype will allow the researcher to use caution in making 
conclusions about the outcome of a genetic manipulation based on the background 
characteristics of the colony (e.g. BLKSW mice have higher blood calcium and larger 
litter sizes when compared to some inbred strains of mice and therefore larger little size 
may not be the result of the ablation). 
G. Clinical Implications 
A few case series have examined male and female thyroidectomized individuals 
taking thyroid hormone replacement and reported conflicting results as to whether such 
patients develop a long-term deficit in bone mass or an increase in fracture risk relative to 
matched individuals with intact thyroids (82-84). No study, however, has examined the 
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bone mass of thyroidectomized individuals after a cycle of pregnancy and lactation, and 
of course such individuals would retain the ability to make calcitonin in pituitary and 
mammary tissue and therefore would not be truly calcitonin-deficient. Vertebral 
compression fractures occasionally occur during lactation in otherwise healthy young 
women, a condition termed osteoporosis oflactation (203-206). In such cases excess 
bone resorption during lactation, and possibly a low baseline BMC, is presumed to have 
led to increased fragility that resolved after weaning. Our results raise the possibility that 
some of these human cases might represent the human equivalent of absence of 
calcitonin. 
H. Future Considerations 
Pituitary Axis 
Due to the presence of the CTR within the pituitary lactotrophs, and published 
evidence showing that pharmacological administration or targeted overexpression of 
calcitonin in this area of the brain causes hypoprolactemia (200, 201) preliminary data 
was collected to provide the basis for future exploration of this intricate physiological 
loop. Based on these findings, one could hypothesize that absence of calcitonin would 
result in increased prolactin production and secretion. This in tum would cause more 
profound ovarian suppression, lower estradiol, and thus significant bone resorption. Also, 
increased prolactin could also result in increased PTHrP, thus perpetuating bone 
resorption from this angle. 
Preliminary results indicated that there was no difference in mean circulating 
prolactin levels at any time point in ctcgrp null mice versus WT (Figure 41). It is 
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important to note, however, like many hormones, prolactin is released into the system in a 
pulsatile fashion throughout lactation (194). Ideally multiple serum samples would need 
to be collected from one mouse to assess peak levels of prolactin. The proposed role of 
calcitonin to regulate pituitary lactotrophs and systemic prolactin levels may indeed be a 
physiologically important pathway. Pooled pituitary samples could also be assessed to 
determine if prolactin, LH, FSH or markers of apoptosis in lactotrophs are altered in 
ctcgrp nulls. Altered production of these brain peptides could result in markedly 
increased or decreased milk production, translating into associated skeletal changes 
linking calcitonin with the brain during lactation. Lack of a role of these pep tides, will 
reinforce the mammary-tissue as the main calcitonin physiological loop during lactation. 
In addition to the possibility of alterations in prolactin, exaggerated BMC losses 
may also be caused by decreased estradiol production during lactation, or increased 
sensitivity to estradiol. Preliminary experiments indicated that estradiol levels for all 
genotypes and time points were barely at the limit of delectability for the commercial EIA 
(data not shown). An assay with more acute sensitivity may have detected differences in 
the genotypes or it could be possible that estradiol levels were extremely low during 
lactation in WT mice or were no different than the ctcgrp nulls. To overcome the 
commercial assay detection limitations, large volumes of serum were collected and sent 
to Dr. A.F. Parlow (National Hormone & Peptide Program, Torrance, California, USA) 
for analysis using an in-house highly sensitive 17~- estradiol assay. Unfortunately, after 
the samples were received by the Parlow lab they were stored at room temperature and 
thus rendered un-analyzable. Due to the work involved in pooling multiple serum samples 
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to achieve 300)..1.1 samples (i.e. up to 5-6 mice per sample, for at least 20 samples), it was 
not possible to collect enough additional serum in the given time frame to be assessed. 
Role of the Calcitonin Receptor 
It is a possibility that the CTR may also control BMC losses during lactation. 
Unfortunately, studies suggest that CTR null mice die at mid-gestation and therefore 
cannot be studied (92, 93, 1 07). Mice HET for the CTR, however, are healthy, fertile and 
have been shown in one study to have a higher bone mass with age (1 07). Proof of role 
of the receptor for calcitonin during lactation could facilitate additional in vitro studies 
regarding the role of calcitonin. 
Exploration of the Post-weaning Period 
The weaning period is a physiological paradox in that the cessation of lactation in 
the adult skeleton can stimulate the skeleton to completely and rapidly reverse the 
significant mineral losses that occurred during that time. This challenges the classic 
catabolic skeletal response s~ten throughout adulthood in that significant BMC losses 
typically cannot be regained. In our studies, we have found that during the post-weaning 
period ctcgrp null mice completely regain the mineral lost after 21 days of lactation, as 
per that seen in the nonnal, WT siblings (Figure 24). It is important to note however, that 
ctcgrp nulls, take several days longer to remineralize their skeletons post weaning, a 
finding that was not unexpected due to the greater BMC loss experienced versus that seen 
in the WT. Therefore, in contrast to the physiological requirement for calcitonin during 
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the lactation period, calcitonin does not appear to be required for the skeletal recovery 
process post-weaning, as mice recover completely for lactational BMC losses. 
Despite the finding that calcitonin does not appear to be of physiological 
importance in the long-term (i.e. post lactation) the aforementioned results nonetheless 
may remain clinically relevant. Normally the adult skeleton is unable to significantly 
regain mineral that has been lost through such things as: prolonged periods of 
weightlessness, the use of corticosteroids, metabolic disease, etc. Understanding the 
means which the mouse skeleton completely and rapidly rebuilds itself post lactation, 
could provide useful insight into anabolic therapies for bone disease. Ctcgrp null mice 
may be an ideal model to examine skeletal recovery since the factors stimulating recovery 
are likely to be upregulated further in these mice compared to normal as these mice are 
able to recover from over a 50% deficit in spine BMC. 
Furthermore, perhaps the most useful, albeit ambitious, future study could focus 
on the mechanisms underlying the skeletal recovery of mineral during the post-weaning 
period in the ctcgrp null versus WT. A genome-wide microarray analysis could be 
completed on bone samples specifically during the recovery period. More obvious 
calcitropic candidate genes (e.g. RANKL, OPG, osteocalcin) would be included (i.e. 
those associated with skeletal anabolism), as well as other genes of interest. Differentially 
expressed candidates could be further explored. 
I. Conclusions 
Osteoporosis Canada has estimated that 1.4 million Canadians suffer from this 
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disease. The associated financial costs are estimated to be $1.9 billion each year in 
Canada alone. Considering the aging demographic, this number will likely rise in the 
years to come. In light of these statistics, future research contributing to the etiology and 
treatment of this disease is critical. The ctcgrp null mouse model fits in this picture by 
offering a physiological context in which to study the anabolic behavior of bone. The post 
weaning skeleton of the ctcgrp null is capable of rebuilding over half of its vertebral 
mineral content within a relatively short period oftime. Our evidence has pointed to two 
important physiological pathways in bone flux during reproduction: the breast and bone. 
Mammary tissue enhances skeletal resorption of mineral during lactation through the 
production of excess PTHrP and bone resorption is increased in the absence of the 
calcitonin gene. Further work is needed to determine how the pituitary axis is involved 
during reproduction in the absence of calcitonin. 
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APPENDIXC 
In-House Mouse PTHrP Radioimmunoassay 
Reagents 
Standard: Recombinant PTHrP (1-84), reconstitute 2 f..Lg/1 Ofll aliquot in 1 ml assay 
buffer which gives a concentration of 200,000 pmol/L, Make up several dilutions from 
0.8 to 400 pmol/L concentrations (i.e. 0, 0.8, 2, 4, 8, 15, 20, 30, 40, 80, 200, 400pmol/L). 
Antibody: INCSRAR antihuman PTHrP (1-40) Goat number 906. Dilute 11100 stock 
solution to 1/10, 000 and use 100 fllltube. Final dilution 1/40,000. 
Tracer: 1251 Tyr0PTHrP (1-34), 10, 000 cpm in 100 fll 
Assay Buffer: 0.05 M barbitone pH 8.6 with 0.5% BSA. 0.02% Tween, 0.05% Sodium 
Azide, 0.5 ml (20TIU) Aprotinin (Trasylol)/1 00 ml assay buffer 
Antigoat Sac Cel: SAC-CEL Anti-sheep/goat code AA-SAC2. 
Aprotinin: Protease inhibitor from bovine lung (Sigma A-1153), reconstitute 100 mg with 
1 0 ml 0.05M barbital buffer, pH 8.6. 
Plasma samples: Collect in 0.5 M EDTA 100 fll (or EDTA coated tube) and Aprotinin 
100 fll (4TIU)/10 ml ofblood. 
Pooled Normal Plasma: EDA plasma with aprotinin from haemochromatosis patients are 
pooled and used as control for bonding changes observed in the presence of plasma. 10 fll 
is added to each standard tube. 
Controls: C1, C2, C3. Low, medium and high levels of recombinant human PTHrP (1-84) 
are added to nonnal human plasma. 
Assay Procedure: 
DAY 1 
Incubate the following: 
Standard or sample (1 OOfll) 
Antibody (1 OOfll) 
Assay buffer/Pooled normal plasma (1 OOfll) 
Non-specific Binding Tube Containing: 
Assay buffer (200fll) 
Normal plasma ( 1 OOfll) 
At room temperature for 4 hours 
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Add tracer 10,000 cpm (1 OOJ.!l) and incubate overnight at room temperature. Final 
incubation volume is 400J.!l per tube. 
DAY2 
Add antiOgoat Sac-Cel (1 OOJ.!l) and incubate for 30 minutes at room temperature to weight 
protein down. Add 1 ml distilled water to each tube. Centrifuge and aspirate supernatant. 
Count pellet using multigammer counter. 
NOTE: For mini assay use half the amounts of standard, sample, assay buffer, and tracer. 
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APPENDIXD 
Structural parameters of trabecular bone measured by the 
Skyscan micro-CT. 
Relative bone volume 
Symbol: BV/TV 
This is bone volume I tissue volume, the proportion of a studied volume of trabecular 
bone occupied by bone as opposed to marrow. This parameter is only relevant if the 
studied volume is fully contained within a trabecular bone region, and does not extend 
into or beyond the bounding cortical wall of the bone. Unit: %or fraction of 1. 
Bone surface to volume ratio 
Symbol: BS/BV 
This parameter can be measured from 3D micro-CT images of bone regions after a 
surface has been fitted to the image. BS/BV is a useful basic parameter in characterising 
the complexity of structures and is the basis of model-dependent estimates of trabecular 
thickness. Unit: mm-1• 
Trabecular thickness 
Symbol: Tb.Th 
Calculation - or estimation - ofTb.Th from 2D measurements requires an assumption 
about the nature of the bone structure. Two simple bone structure models, the parallel 
plate and the cylinder rod model, provide the boundary values within which a 
hypothetical "true" Tb.Th will be located. Thickness defined by these two models (Parfitt 
eta/. 1987) is given: 
Parallel plate model: 
2 
Tb.Th = ( ) Unit: mm or J.lm 
BS I BV 
Cylinder rod model: 
4 
Tb.Th = ( ) BSIBV Unit: mm or J.lm 
Where BSIBVis the surface to volume ratio, mm-1• 
With 3D image analysis by micro-calcitonin a true 3D thickness can be measured which 
is model-independent. This is determined as an average of the local thickness at each 
voxel representing bone (Ulrich et a/. 1999). Local thickness for a point in bone is 
defined by Hildebrand and Ruegsegger ( 1997a) as the diameter of a sphere which fulfils 
two conditions: 
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(a) the sphere encloses the point (but the point is not necessarily the centre of the 
sphere); 
(b) the sphere is entirely bounded within the bone surfaces. 
Therefore for this direct Th.Th parameter to be measured it is necessary for a bone 
surface to be fitted to the micro-calcitonin image ofbone. 
Histomorphometrists typically measure a single mean value ofTh.Th from a trabecular 
bone site. However a trabecular bone volume can also be characterised by a distribution 
of thicknesses. The Skyscan micro-CT outputs a histogram of trabecular thicknesses with 
variable interval to allow flexible and powerful thickness analysis of bone - or of any 
other structure. 
Trabecular separation 
Symbol: Th.Sp 
Trabecular separation is essentially the thickness of the marrow spaces between 
trabecular structures. It can also be calculated either from 2D images with model 
assumptions or directly in 3D. Applying the two models as for Tb.Th, trabecular 
separation is calculated: 
Parallel plate model: 
Tb.Sp = (-1-) - Tb.Th 
Tb.N 
Cylinder rod model: 
Tb.Sp = TbTh X [[ (; H:)] -I) 
Unit: mm or J..Lm 
Unit: mm or J..Lm 
where TV is total volume of the volume analysed and BV is bone volume (Parfitt et al. 
1987). Note that each of the above definitions takes the Th.Th value derived from the 
corresponding plate or rod model. 
In practice it is undesirable to employ inaccurate 2D model assumptions, especially 
because the "plate-like" or "rod-like" character of trabecular bone can change from one 
end of a studied volume to the other (see "structure model index", below). Therefore 
Skyscan analysis software can measure Tb.Sp directly and model-independently in 3D 
from micro-CT images by the same method used to measure trabecular thickness (see 
above), with the analysis applied to the marrow spaces instead of the bone. 
Trabecular number 
Symbol: Tb.N 
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Trabecular number implies the number of traversals across a trabecular structure made 
per unit length on a linear path through a trabecular bone region. Plate and rod model 2D-
based definitions ofTb.N again take the corresponding Tb.Th values: 
Parallel plate model: 
Tb.N = (BV /TV) 
Tb.Th 
Cylinder rod model: 
((;)x(;;)J 
Tb.N = --=-------
Tb.Th 
Unit: mm-1 
Unit: mm-1 
Again the complexities of model dependence are eliminated by true 3D calculation of 
Tb.N from micro-CT images. Trabecular structure is calculated from micro-calcitonin 3D 
images of trabecular bone as the inverse of the mean distance between the middle axes of 
trabecular structures (Ulrich et al. 1999). These axes are identified by a skeletonisation 
process. 
Trabecular pattern factor 
Symbol: TBPf 
This is an index of connectivity of trabecular bone, which was developed and defined by 
Hahn eta!. (1992). It was applied by these authors to 2D images, and calculates an index 
of relative convexity or concavity of the total bone surface, on the principle that concavity 
indicates connectivity, and convexity indicates isolated disconnected structures. TBPf is 
calculated in 2D (slice-by-slice) and in 3D by Skyscan software. TBPf is calculated by 
comparing bone area and perimeter before and after an image dilation. It is defined: 
Unit: mm-1 
Where P and A are bone area and perimeter, and the subscript numbers 1 and 2 indicate 
before and after image dilation. 
Where trabecular connectedness results in enclosed marrow spaces, then dilation of 
trabecular surfaces will contract the perimeter. By contrast, open ends or trabecular nodes 
will have their perimeter expanded by surface dilation. As a result, lower TBPf signifies 
better connected trabecular lattices while higher TBPf means a more disconnected 
trabecular structure. 
Loss of trabecular connectivity can lead to loss of strength in bone disproportionate to 
bone volume loss, and is a particular concern regarding osteoporosis. 
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Euler-Poincare number 
The Euler-Poincare- or the abbreviated "Euler number" - is also an indicator of 
connectedness of a 3D complex structure. The Euler number is characteristic of a three-
dimensional structure which is topologically invariant (it is unchanged by inflation or 
compression of the structure). It measures what might be called "redundant connectivity'' 
- the degree to which parts of the object are multiply connected (Odgaard et al. 1993). 
The components of the Euler number are the three Betti numbers: Po is the number of 
objects, P 1 the connectivity, and P2 the numner of enclosed cavities. The Euler-Poincare 
formula for a 3d object X is given: 
Connectivity in the Euler sense of"redundant connectivity" is a measure of how many 
connections in a structure can be severed before the structure falls into two separate 
pteces. 
Euler analysis provides a measure of connectivity density, indicating the number of 
redundant connections between trabecular structures per unit volume. To calculate this, 
divide the connectivity P1 (a unitless number) by the analysed volume. Trabecular 
connectivity may contribute significantly to structure strength although this relation is a 
question requiring further research (Odgaard 1997) 
Unit: none. 
Degree of anisotropy 
Symbol: DA 
Isotropy is a measure of 3d symmetry or the presence or absence of preferential alignment 
of structures along a particular directional axis. Apart from percent volume, DA and the 
general stereo logy parameters of trabecular bone are probably the most important 
determinants of mechanical strength (Odgaard 1997). Mean intercept length (MIL) and 
Eigen analysis are used to calculate DA, and these involve some quite advanced 
engineering mathematics. However the essentials of the MIL eigen analysis can be 
summarised in normal English. 
Consider a two phase complex object, like a region of trabecular bone, where there are 
two phases (bone and marrow) and the shape ofboth phases is complex. We can study a 
volume selected within the object to be representative of the whole object, to determine 
isotropy of the object. Ifthe object is isotropic, then a line passing through the object at 
any angle will pass through a similar length of solid phase as a proportion of its total 
length. A bag of marbles would be isotropic. However a packet of spaghetti would be 
non-isotropic, or anisotropic, since lines going along the direction of the spaghetti would 
pass through spaghetti only while lines crossing at right-angles would alternate between 
spaghetti and air. 
Mean intercept length (MIL) analysis measures isotropy (it is usual to talk of 
measurement of the negative quantity anisotropy). Mean intercept length is found by 
sending a line through a region of trabecular bone, and recording what part of the line's 
length passes through bone and what part through non-bone. The length passing through 
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bone is the MIL for bone for that line. In a 3d MIL analysis, you need to send multiple 
lines through the volume over the full range of 3d angles. Also, for each angle, many 
parallel lines are sent covering the whole test volume, and the MIL for that angle is 
calculated as an average for all these lines. This requires that a spherical region is first 
defined within which the MIL analysis will be done and isotropy measured, since the test 
lines must all cross the sphere centre and have an equal distribution of lengths, covering 
all 3d angles but distributed at random. 
Say we start a MIL analysis of a spherical region of trabecular bone by sending multiple 
lines through the sphere as described above. The next step involves visualisation of the 
3d distribution of MIL lengths. All the MIL lines are drawn passing through the sphere 
centre, but the length of each line is reduced to the bone phase MIL for that line. This 
process is called a polar plot of MIL. In 3d this creates a dense pin-cushion like effect 
with lines in all directions at different lengths. 
Figure 1 shows in a simple diagram the appearance of an MIL distribution in 3d. Any 
asymmetry in the MILs with respect to 3d angle- which will represent the anisotropy of 
the bone in the spherical region - will make the line distribution depart from an overall 
spherical shape and become elongated in the direction where the solid structures have the 
longest MIL (such as the axis of the spaghetti packet). 
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Figure 1. An ellipsoid (3D ellipse) is fitted to the 3D distribution of MILs (mean intercept 
lengths) measured over a full range of 3D stereo-angles. This ellipsoid is fitted statistically and 
has 3 vectors which are orthogonal (at right-angles to each other). A tensor (matrix) of9 (3x3) 
eigenvectors describes the directions of the three vectors - one for each column. The three 
eigenvalues are the ellipsoid lengths (representing the mean MIL) in each vector direction. 
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Clearly the MIL "pin-cushion" is a complex object, and a method is needed to extract 
some summary numerical parameters defining the orientation and isotropy I anisotropy of 
the MIL distribution. This is where the anisotropy tensor analysis steps in. (Tensor means 
matrix.) This method is probably best attributed to Harrigan and Mann (1984) and 
essentially describes the MIL distribution as an ellipsoid. An ellipsoid is a 3d ellipse. As 
shown in figure 1, an ellipsoid has three axes. These describe the longest orientation, and 
the length and width (major and minor axes) of the ellipse section at right-angles to the 
longest orientation. The ellipsoid can be asymmetric in one axis only, like a rugby ball, or 
in two axes, like a bar of soap. 
An ellipsoid is fitted to the MIL "pin-cushion" 3d polar plot. This is a statistical fit, 
finding the ellipsoid which most closely describes the 3d shape of the MIL distribution. 
MIL analysis therefore should also output values indicating the strength of fit of the 
ellipsoid and associated error, such as the correlation coefficient. 
A tensor or matrix is a way of describing an ellipse by a 3x3 matrix of numbers. 
Technically this is a second order tensor. The tensor (or matrix) describing the anisotropy 
ellipsoid is in the class of orthogonal tensors, since it describes the ellipsoid axes which 
are orthogonal (at right angles) to each other. The end result of the anisotropy tensor 
analysis is called the eigen analysis, eigen meaning characteristic. This comes in two 
parts. You have the 3x3 matrix of eigenvectors which describe the 3d coordinates of the 
three axes of the ellipsoid as described above - one column of 3 numbers for each vector. 
And the three eigenvalues are each an index of the relative length or amount ofbone 
present in each of the three axes described by the eigenvectors. 
Finally, you can derive from the tensor eigenanalysis a single parameter measuring 
anisotropy: this is the degree of anisotropy (DA), and is simply the maximum eigenvalue 
divided by the minimum eigenvalue. A value of 1 for DA means a fully isotropic object-
a large bag of small marbles for example. Increasing anisotropy gives increasing values 
above 1. (This is somewhat unhelpful in mathematic indices - it would be better if 0 
meant isotropic and 1 meant totally anisotropic. However we are stuck for the time being 
with aDA having values from I to infinity.) 
It should be noted that stereology analysis can also identify principal 01ientations that are 
not orthogonal to eachother. Each of these directions has its own associated degree of 
anisotropy, which should not be confused with the "global" DA derived from the MIL 
ellipsoid eigenanalysis. 
Unit: none. 
Structure model index 
Symbol: SMI 
Structure model index indicates the relative prevalence of rods and plates in trabecular 
bone - of importance in osteoporosis. An infinite parallel plate and cylindrical rod have 
SMI values of 0 and 3 respectively. A sphere has a SMI of 4. This scale of SMI values 
applies where the structures occupy a relatively small volume fraction of space - less than 
half. However, where a structure such as bone occupies more than half of the volume of 
interest, then the SMI parameter result becomes inverted and negative SMI values are 
obtained. 
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For this reason, SMI applied to trabecular bone in practice varies sensitively with relative 
bone volume (BV/TV). This might give strong differences between experimental groups 
in in-vivo bone studies, but in this situation SMI cannot be said to be giving information 
purely about surface topography. For this reason another parameter can also be employed 
to give an index of the prevalence of plates and rods in trabecular bone - the "percent 
plate" parameter described next. 
SMI is calculated by a differential analysis of the triangulated surface of trabecular bone 
and involves a measurement of surface convexity (Hildebrand and Ruegsegger 1997b ). 
Unit: none. 
Percent plate 
Symbol: P.Pl 
Percent plate is a parameter devised by Borah et at. (2002) which compares the true 3D 
thickness measured by micro-calcitonin (as described above) with thickness 
measurements based on 2D plate and rod models. Note that the BS/BV value on which 
the model-dependent Tb.Th values are based is itself obtained in 3D by micro-calcitonin 
surface-fitting. The parameter essentially assesses whether the measured direct 3D 
thickness is closer to the plate or the rod model-based thickness estimate. Percent plate is 
calculated as: 
[ [ 
(
Th . -Th JJ P .P/ = l - d~rect plate-model X l OO 
Throd - mod el- Thplate - mod el 
Unit:% 
where Th is trabecular thickness. 
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Appendix E 
Immunohistochemistry Protocol 
Peroxidase antioperoxidase protocol 
1. Fix tissue in 10% buffered formalin as briefly as possible. Embed in paraffin wax. 
Cut 5 f.!m sections. 
2. Dry slides overnight in a 37° Coven. 
3. Dewax slides in xylene; 2 changes x 5 minutes. 
4. Wash in absolute ethanol for 30-60 seconds. 
5. Put slides in methanol with 1% hydrogen peroxide for 30 minutes to block 
endogenous peroxidase activity of the sections. Make up 1 litre phosphate 
buffered saline. 
6. Wash in phosphate buffered saline for 3 x 1 minute. Wipe slide dry around 
section. 
7. Carefully pipette over the section 1/10 normal goat antiserum in phosphate 
buffered saline to block nonspecific background binding. Incubate in a humid box 
at room temperature for 30 minutes. 
8. Tip off phosphate buffered saline and drain. 
9. Pipette on the primary antiserum at the required dilution e.g., rabbit anti PTHrP at 
1/200 in phosphate buffered saline and incubate for 1 hour at room temperature or 
overnight at 4 oc at a lower dilution. Include a negative control of non-immune 
rabbit serum at the same dilution. 
10. Rinse sections with a stream of phosphate buffered saline then was in 3 changes of 
phosphate buffered saline (3 x 10 minutes). 
11. Pipette on the secondary antibody e.g. goat anti rabbit immunoglobulin diluted 
1/40 in phosphate buffered saline. Incubate for 30 minutes. 
12. Rinse sections with a stream of phosphate buffered saline then wash again 3 x 5 
minutes in phosphate buffered saline. 
13. Incubate sections for 7 minutes in Diaminobenzidine tris, l 00 mg 3,3 
diminobenzidine, 180 ml water, 20 m1 Tris buffer pH 7 .6. Mix well and just 
before incubation, add 0.01 m1 hydrogen peroxide (30%). 
14. Rinse in distilled water 3 x 5 minutes. 
15. Stain with Mayer' s haematoxylin 30-60 seconds. 
16. Wash in distilled water 3 - 5 minutes. 
17. Put in tap water for 10 minutes. 
18. Dehydrate through graded absolute ethanol ethanol 75%, 90%, 100% x 2. 
19. Move through two rinses of xylene. 
20. Mount samples. 
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Appendix F 
Endocrinology publication 
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Printed 111 U.S.A. 
Endocnnology 147(9):4010-402 1 
CopynghL 0 2000 by The Endocrine Society 
doi: 10.1210/en.200S· l616 
Calcitonin Plays a Critical Role in Regulating Skeletal 
Mineral Metabolism during Lactation 
Janine P. Woodrow, Christopher J. Sharpe, Neva J . Fudge, Ana 0. Hoff, Robert F. Gagel, and 
Clu-istoph er S. Kovacs 
Faculty of Medicine-Endocrinology (J.P. W. , C.J.S., N.J. F., C.S.K), Memorial University of Newfoundland, St. J ohn's, 
Newfoundland, Canada AlB 3V6; and University of Texas M.D. Anderson Cancer Research Center (A.O.H. , R.F.G.), 
Houston, Texas 77030 
The maternal skeleton rapidly demineralizes during lacta tion 
to provide calcium to milk, responding to the stimuli of es-
trogen deficiency and mammary-secreted PTH-related pt·o-
tein. We used calcitonin/calcitonin gene-related peptide-a 
(Ctcg1p) null mice to determine whether calcitonin also mod-
ulates lactational mineral metabolism. During 21 d of lacta-
tion, spine bone mineral content dropped 53.6% in Ctcgrp 
nulls vs. 23.6% in wild-type (WT) siblin gs (P < 0.0002). After 
weaning, bone mineral content return ed fully to baseline in 
18.1 d iu Ctcg1p null vs. 13.1 d in WT (P < 0.01) mice. Daily 
treatment with salmon calcitonin from the onset of lactation 
normalized tbe losses in Ctcgrp null mice, whereas calcitonin 
THE SKELETON FULFILLS several obvious and impor-tant roles; it protects the vita l organs, it is the scaffold 
from which organs and tissues are hung, it enables locomo-
tion on land in a biped or quadruped posture, and it houses 
the bone marrow. Common clinical concerns about the skel-
eton include traumatic fractures, fragility fractures from os-
teoporosis, and a multitude of d isorders that crowd the mar-
row space. Far less well appreciated is the function of the 
skele ton to serve as a s torehouse of minerals and alkali, even 
to the point of compromising its integrity and strength. 
Among the times of great demand for calcium and other 
minerals are lactation, egg laying, and ant ler formation (1, 2). 
In each of these time periods, the skeleton undergoes a sig-
nificant, rapid, and reversible d emineralization to provide 
mineral, respectively, to the neonate, egg shell, and antlers. 
Clinical s tudies have demonstrated (by dua l x-ray absorp-
tiometry) that a woman will lose an average of 5-10% of 
trabecula r mineral content during 6 months of near-exclusive 
lactation and then fully regain it within several months of 
w eaning (reviewed in Refs. 1, 3, and 4). Depending upon a 
woman's peak bone mass, these losses during lacta tion are 
sufficient enough to temporarily reduce her bone density 
into the osteopenic or osteoporotic range. In contrast, mice 
and rats will lose approximately 30% of skeletal mineral 
content (by dual x-ray absorptiometry or by ash weight) 
First Published Online May 4, 2006 
Abbreviations: BMC, Bone mineral content; BMD, bone n1ineral den· 
sity; CaTl , calcium transport protein subtype 1; CGRPa, calcitonin gene· 
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gene-related peptide-a or vehicle was without effect. Com -
pared with WT, Ctcgrp null mice had increased circulating 
levels of PTH and up-regulation of mammary gland PTH-re-
lated protein mRNA. In addition, lactation caused the Ctcgrp 
null skeleton to undergo more trabecular thinning and in-
creased trabecular sepat·ation compared with WT. Our stud-
ies confirm that an important physiological role of calcitonin 
is to protect the maternal skeleton against excessive t·esorp· 
tion and attendant fragility during lactation and r eveal that 
the postweaning skeleton has the remarkable a bility to rap-
idly recover e ven from losses of ovet• 50% of skeletal mineral 
content. (Endocrinology 147: 4010- 4021, 2006) 
during 3 wk of lactation and then fully restore it wi thin 2-3 
wk after weaning (1). The rapid and complete recovery from 
the large losses of skeletal mineral induced by lactation is a 
clinica lly important finding, because the adult skeleton nor-
mnlly recovers s lowly and incompletely from insu lts in-
duced by glucocorticoids, prolonged bed rest, menopause, 
GnRJ-1 analog treatment, and weightlessness (1 , 5-10). 
The mechanism by which the skeleton demineralizes du r-
ing lactation is not fully understood (1, 11-13). Mammary 
tissue dramat ica lly up-regula tes the expression and release 
of PTH-related protein (PTHrP), which enters the mother's 
bloodstream to stimulate bone resorption (12, 14, 15) and, in 
so doing, m imics the actions of sustained high levels of PTH. 
At the same time, hyperprolactinemia and other factors sup-
press the release of GnRH within the hypothalamus, thereby 
suppressing in sequence the pituitary gonadotropins, ova-
ries, ovulation, and the sex steroids (especially estradiol) (16). 
In add ition, low estrad iol levels of lactation permit enhanced 
osteoclast-mediated bone resorption and, thereby, potentiate 
the effect of PTHrP on the skeleton (13). 
Calci ton in was originally thought to be an important reg-
ula tor of calcium and bone metabolism in adults (17), but 
evidence gathered over the yea rs has la rgely forced the con-
clusion that it is a vestigial hormone in mammals (18). The 
effects o f calcitonin to reduce osteoclast-media ted bone re-
sorption (to treat osteoporosis or Paget's d isease) or to en-
hance urinary ca lcium excretion (to treat hypercalcemia of 
malignancy) require pharmacological doses of the hormone 
and not physiological levels (19, 20). However, several in-
vestigators had orig inally proposed that calcitonin m ight 
p rotect the skeleton against excessive resorption during 
pregnancy and lactation (21-24). The experimental approach 
4010 
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to test this hypothesis had been to remove the thyroid glands 
from sheep, goats, or rats, to replace thyroid hormone, and 
to determine the effect of a fu ll cycle of pregnancy and 
lactation on the maternal bone mineral content (BMC) or ash 
weight of these thyroidectomized vs. sham-operated animals 
(21-24). Although some investigators detennined that these 
presumably ca lcitonin-deficient an imals had reduced BM 
at the time of weaning, other investiga tors found no such 
effect (21-24). It wasn't appreciated at the tin1e tha t thyroid-
ectomized an imals were not devoid of calcitonin because of 
extra thyroid al sources of calcitonin in mammary tissue (25, 
26), p lacenta (27, 28), a nd pi tuitary (29). Thyroidectomized 
women experience increases in circu la ting calcitonin d uring 
lactation and express no rmal levels o f calci tonin in mi lk (26). 
We have retested the hypothesis tha t physiologica l levels 
of calcitonin are required to protect the maternal skeleton 
against excessive resorption during pregnancy and lacta tion. 
To do this, we used an established murine model in which 
exons 3-5 of the calcitonin I calcitonin gene-related peptid e-a 
gene (Ctcgrp) have been ablated (30). Calcitonin gene-related 
peptide-a (CGRPa) is an a lternative splice product of the 
calcitonin gene, whereas a second gene produces CGRP/l 
Therefore, Ctcgrp nu ll mice completely lack calcitonin in all 
tissues bu t still produce C RP through the CGRP/3 gene. 
Using this model, we determined that ablation of the gene 
doubled the losses of maternal m ineral content d uring lac-
ta tion and that the effect was speci fie to loss of calcitoni n and 
not CGRPa. 
Materials and Me t hods 
Animal husbandry 
Ctcgrp null mice were obtained by targeted ablation of exons 3-5 of 
the murine gene and genotyped by PCR as previously described (30). 
The o riginal strain was bc.ck-crossed into Black Swiss (Taconic, Ger-
mantown, NY) for at leetst six generatio ns, and the colony wa.~ main-
tained by bR>eding heterozygous-dele! d mice together. Vi rgin fi rst-
degree relative pairs o f wild-type (WD and Clcgrp null females were 
selected for s tudy after 10 wk o f age (attainment of peak bone mass). 
Mice were mated overnight. and the presence of a vaginal mucus plug 
on the m orning after mating marked ges tational d 0.5. Normal gestation 
in these mice is 19 d. We p l•nned to cu ll litte rs within 48 h of delivery 
if needed to rnainttl in s imilar numbers o f pups (8 :!: 1) per rnouse, ttnd 
weaning was forced at 21 d by removing the pups from the 1nother. All 
n1ice were given a standcud chow (1% calcium, 0.75% pho phorus) diet 
and water nd Jib. All stud it'S wt:re performed with the previous approv<\l 
of the Institutio nal Animal Care o mrnittee of Memorial Universi ty of 
ewfoundland. 
Reproductive cycles ond data collection time points 
These studies were completed accord mg to itil approx1matc 70-d 
reprod uctive cycle. Baseline scans were collected for 5-10 d before melt-
ing and subsequent pregnancy (prepregnancy interval). Pregnancy 
lasted 19 d , lactation lasted 21 d . and postweaning recovery was 21 d . 
The four ma in data collection points included prepregnancy. end of 
pregnancy (day before expected delivery), end of lacta tion (forced wean-
ing at d 21 of lacta tion), and end or postweaning recovery of the skeleton 
(d 21 after wea ning). Add itiona l time points included start of lacta tion 
(24- 48 h). early lactation (5-7 d ), and mid-lacta tion (10- 14 d). 
BMC and bone mineral density (BMD) 
BMC a nd BMD were measured using the PJXImus 2 none Densi-
tometer (GE Lunar, Madison, WI) and analy1ed with P IXIm us software 
version 2.1. A s tondud phantom (fot 11 .9% ond BMC 0.063 g) was used 
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to calibrc1 te the PIXlmus daily . Anesthesia w~s induced \Vith isoflura ne 
(Baxter Corp., Toronto, Ontario, Cani\da) and mruntained w 1th a single 
1p mjectton of either thiopental sodium (Abbot L.1boratnr ies, Toronto, 
Ontano, Canada) or a 5:1 combmrt tion of ketamine hydrochloride 
(Wyeth Canada, Guelph. Ontario, a11ada) ond xylazine (Bayer Inc., 
Toronto, Ontario, Canada). The anesthetized mice were 1mmobilized 
prnn ~ on a plastic tray with the spine straightened, and to maintain 
reproduc1biltty with less than 1•1., precision t:!rror, the head was excluded 
111 all scons. In additional quality contro l studies, mice on d 18.5 of 
pregnancy were scanned immediately beforet\nd arter a cesarean section 
in whiCh the pups were removed; this determined that the fetal skeletons 
contributed 1% or less to the apparent maternal 13M or BMD and were, 
there fore, negligible. Total body (minus head) and regional (spine and 
h ind limb) UMC and BMO measurements were obtained for each moLLo;e, 
and the absolute values were norm;dized lo the nonpregnant baseline 
me"s urcments. ln the in itial studies to determ ine the pallernof BMC and 
BMD change (comprising data in Fig . 1), each mouse was scanned every 
2 d throughout the entire reproductive cycle. In la ter studies in which 
tissue would be IMrvested at s pecific time points, the mice were scanned 
at the main time points to ensure that the expected 13MC and BMD 
chang+..~ Wl:!rc occurring. The re were a few ancsthetic·rt!la ted death , but 
othcnvi~. the outcomes or the rl!productivc cycll! (live pups and mag-
nitude ur UMC lus.'i and recovery) were no d1frerent between dams that 
had lx.'Cn scC\nncd every 2 d liS. those ti'Mt htld bt.>cn scanned a t the main 
time point&. Pups that had received iu utrm exposure to x-ra.ys \vere 
euthanized at we;,.ning, whereas the dams were euthanized at the end 
or the pnstweaning recovery phase. 
Chemical and hormone assays 
Seria l blood samples were tt\kcn from tai l veins, whereas a cardiac 
puncture was done to obtain larger samples at the time thflt each mouse 
wa~ c uthanized. Urine was collected by allov.,ing the mice to void into 
~ clean, empty ca ge. loni1.ed calcium \·Vas measured on w hole blood 
us ing a Chi ron Diagnostics 634 Ca2 ' /pH Analyzer (Chi ron Diag nostics, 
Rast Walpole, MA}. Urine calcium was measured using a colorimetric 
as<ay (Sigma-Aldrich, Oakville, Ontario, anada). P'TH w"s measured 
u<ing a rat 1'TH 1-3-1 ELISA k•t· (lmm utopics, San Clemente, CA). Os-
teoci\lcin was assessed using a lwo-site 1mmunoradiomctric tlssay (lm-
mutopics) Prolactin was assessed u<ing • RIA by Dr. i\. F. Parlow 
(N,,tional Ho rmone and Peptide Program. Hnrbor-UCLA Medical Cen-
ter, Tnrrtlnce, CA). Estradiol w;,.s mea..;ur<:'d with an cnzvme immuno-
ass.1y kit (Cayman ChemiCal Co., Ann Arbor, Ml). Plas n;a PTI-IrP w as 
measured using a sensitive RIA \Vith iln ;,ntibody directed to an a mino-
term ina I epitopc o n samples that had been collected m a cocktail of 
aprotinin and EDTA (31). Deoxypyridinoline was me"sured using the 
METRA DPD enzyme immunoassay kit (Quidel Corp., San Diego, CA). 
Urinary measurements o r dcoxypyridinolinc ,,nd calcium were cx-
prcsM.-d rela tive l"o creatinine to correct for variations in urine concen-
tratio n. C reatinine was measured llsing nn a lk~ l ine picrate colorimetric 
asStly (Diagnostic Chemicals Ltd ., Charlottetown, Prince Edward ls iMld, 
Cannda). 
Millt collection and analysis 
On d 7 of lactation, ancsthcti.wd mice were injected with 1.2 U 
oxytoc111 (Hospira Healthcarc o., Montre,ll, Quclx-c, anada). After1- 2 
min, milk was obtained using a scl f·designed pump consisting o r a 1-ml 
pipette t1p (Mandel Scientific Co. Inc., .uclph, Ontario, Canada) inserted 
into thick rubber tubing that in turn was conncct "d to vacuum suctton. 
The wide end of the pipette tip wos p laced over o nipple. and a gentle 
pumping action was used to obtain milk. which was then s tored a t 20 
until assayed. The m ilk was dilu ted 1:100 with distilled water a nd 
ilnalyn.>d for calcium content us1ng o Modd 2380 Atomic Absorption 
Spe-ctrophotometer (PerkinEimer, Norwalk, C:T). Because much of the 
calci urn content of milk i$ bound to p rotei11s (32), and to control for 
di ffe ring milk concentrations, the p rotein con tent o r milk was measured 
using the BCA Protein Assay Kit (Pierce, Rockford, IL.) . Fi11a l results arc 
expressed as microg ran1s calcium per m icrogrom protein. 
Duodenal calcium. absorption 
We adapted the method of Fleet ond colleagues (33) to measure 
duodenttl calcium itbsorption iu l'il'O durmg mid-lactation and in non-
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pregnant mice. Food was removed from the cages 3 h before the ex-
perinlent to empty the duodenum and jejunum. Under anesthes1a, an 
abdominal incisio n was made and a closed duodenal loop was creatt.>d 
by ty ing two ligatures, one at the pyloric juncture and the second one 
ebout 1.5 em distal to the first one. Forty microliters of "Ca buffer (150 
nM NaCI, 2 mm CaCJ2, 30 mM Tris-HCJ, and l6 fl.Ci 40Ca/ml at pH 7.4) 
were injected into the closed loop (45Ca was obtained from Promega/ 
Fisher Scientific Ltd ., Burlington, Onterio, Cenede). After 10 min, the 
loop was inspected to ensure that no areas of ischemia were evident. The 
loop \Vas excised, solubilized in Scintigest (Promega/Fisher), and then 
cow1ted on a liquid scintillation counter. To measure the total ·~5Ca 
activity administered, and to control for the effect of biological tissue to 
q uench the apperent level of redioactivity, additionel scintil letion v ie is 
were prepared in which the same amount of 45Ca and an identical length 
of nonradioactive duodenum w ere added. Efficiency of 45Ca absorption 
wAs expressed as (1 - 45Ca remaining in each loop/amount of 45Ca 
injected into the loop) X 100. 
Biomechanical analysis 
Left hind limbs were s tored at - 20 C after first removing the soft 
tissues and then thawed to room temperature in normal saline before 
analysis. Cortical bone strength was assayed using an I nstron Series 3340 
e lectromechanicel test instrument (Instron, Norwood, MAJ. In brief, the 
femur was immobilized at each end in a fixture, and a load cell with 
maximum capacity of 10 N of force was positioned 2-3 em above the 
mid-shaft of the tibie . The force requi red to break the femur(fai lure) was 
recorded, as \'Vas the land-d isplacement curve from which other bio-
mechc\ilica l parameters could be derived . 
Rescue experiments 
Beginning on the day of delivery and for 21 d of lacta tion, selected 
WT and Ctcgrp null mice received once daily im injections of0.9% saline 
(vehicle), selmon calcitonin (Rhone-Pou lenc Rorer, Collegeville, PA), or 
rat CGRPrx (Americen Peptide Co., Sunnyvale, CA). Mice were briefly 
anesthetized with isoflurane to receive the injection. Bone densitometry 
WitS used every second d ay throughout the experiment to precisely 
determine the excursion of BMC. 
Microcomputed tomography (11-CT) analysis 
Right hind limbs and lumbar spines were harvested, adjdcent flesh 
W cl S removed, dnd then the samples were fixed in paraformaldehyde for 
18 h. The bones were then rinsed and stored in lOX PBS et room 
temperature until analysis. The quantitative and qualitdtivc 11CT ani\ I ~ 
ysis for each femur and for the fi rst and second lumbar vertebrae was 
completed at the Centre for Bone and Periodontal Reseerch e t McGill 
University using the SkyScan 1072 (SkyScan, Aartselau, Belgium), es 
p reviously described (34). 
Mammary tissue collection and stomge 
Mammary glands were harvested after a rapid cervical dislocation 
during late pregnancy, mid~lactation, and late lactation. Lymph nodes 
were removed and mammary tissue \Vas washed with water containing 
O. l 'Yo diethylpyrocarbonate. Tissues we re e ither snep-frozen in liq u id 
nitrogen and then placed at - 70 C or p laced immediately in 10().-{, for-
melin [37% formaldehyde, lOX PBS (pH 7.3), and distilled weter]. 
RNA e."<traction and eDNA synthesis 
RNA was extrdcted fron1 '"'hole mammary glands using an RNeasy 
Midi Kit (Q1AGEN, Mississauga, Onterio, Ceneda). Approximately 
100 g of mouse rnamrnery gland yielded 0.6-1.3 ,.,.g RNA / fll solution. 
eDNA synthesis wes carried out with the SuperScript lll Firs t-Strand 
Synthesis System (Invitrogen Canada Inc., Burlington1 Ontario, Cantlda). 
Real-time quantitative RT-PCR 
eDNA synthesis was performed using the Supe rscript Ill First-Strand 
Synthesis Sygtem (Invitrogen) es previously d escribed (35). Quantitetive 
real-time RT-PCl~ data and anc:tlysis wereobtrtined usiJ"lg the ABI PRJSM 
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7000 Sequence Detection System (Applied Biosystems, Foster City, CA), 
also as previously described (35) . For the calcitonin receptor, the calcium 
receptor, and the vitamin D receptor, TaqMa n Gene Expression Assays 
were used thet included predesigned primers end probes for optunal 
amplification (Applied Biosyste ms) along with TeqMan Universe! PCR 
Master Mix (Applied lliosystems). All gene expression esseys have e 
FAM reporter dye at the 5' end of the TeqMen MGlJ probe end e 
nonfluo rescent quencher et the 3' end of the probe. Other gene-specific 
p rimers used for th is s tudy were as follows: for PTHrP, forward 
5' -TCCACACAGCCGAAATCAGAGCTA-3' end reverse 5 '-TTCTCC-
TGTTCTCTGCGTTTCCCA-3'; f<>r 1-a-hydroxylese, forward 5'- CAG-
AGCGCTGTAGTTTCTCATCA-3' and reverse 5' ATGAAGGTTTC'TG-
TGTCAGGAGGG-3'; fo r celcium trensport protein subtype I (CeT1), 
forward 5'-ATCGATGGCCCTGCGAACT-3' end reverse 5'-CAGAG-
TAGAGGCCATCTTGITGCTG-3' (36); and for epithelial calcium chan-
nel (ECeC or CaT2), forward 5'-AITGACGGACCTGCCAATTACA-
GAG-3' end reverse 5' -GTGTTCAACCCGTAAGAACCAACGGTC-3' 
(36). Thc'Se primers were used along with SYBR Green PCR Mas ter Mix 
(App lied lliosystems). The real-time PCR thermel cycler protocol in-
cluded one cycle etSO C for 2 min, one cycle et 95 C for 10 min, and 40 
cycles of 95 C for IS sec and 1 min at 60.0 C. For p rimer& using SYJJR 
G reen PCR Master Mix, the real-tirne PCR program was the same but 
without the first cycle at SOC for 2 min. All samples were analyzed in 
triplicate. Relative expression ratios were representati ve of the threshold 
cycle (the PCR cycle at which <1n increase in reporter fluorescence is 
ebove a beseline signal) normelizecl to g lycere ldchyde-3-phosphate de-
hydrogenase (GAPDI-1) and compered with the WT. 
Statistical analysis 
DMo were "ne lyzed using SYST i\ T 5.2.1 for Macintosh (SYSTi\ T Inc., 
Evanston, IL). ANOVA waf. used for the initial analysis; a post hoc test 
(Tukey's) W?IS used to determine wh ich pairs of n H!fH'IS differed signif-
icttntly fr01n each other. Real-time PCR results , ... ,ere anaJyzed by the 
2-~.1cT method where the target and referencel\re ampli fied in separate 
wells (37). Two-teiled probabilities ere reported, a nd a ll clete ere p re-
sented as mean :!: SE. 
Results 
BMC during pregnancy, Lactation, and recovery 
At the baseline age of 10-12 wk, and consistent with an 
earlier report (30), Ctcgrp null mice had a BMC of 0.397 ~ 
0.02 g vs. 0.383 ~ 0.02 gin WT (P = 0.61). At the level of the 
whole body, WTand Ctcgrp null mice gained a similar degree 
of BMC during 18 d of pregnancy, but Ctcgrp null mice lost 
approximately twice the amount of BMC as WT during 21 d 
of lactation (Fig. 1A). The difference was present from early 
in lactation; WT mice lost 4.5 ~ 3.6 and 15.7 ~ 3.7% of 
baseline BMC by 7 and 14 d of lactation, respectively, 
whereas Ctcgrp null mice lost 10.1 ~ 3.1 cmd 29.6 ~ 3.1%. of 
baseline BMC at the same time points. Both genotypes re-
stored their BMC to their respective baseline values after 
weaning (Fig. lA), although full recovery took several more 
days for Clcgrp null mice (Fig. 1 B). Closer examination of the 
BMC excursion indicated that the lactational losses were 
much more profound in the trabecular-rich vertebral bodies, 
such that Ctcgrp null mice lost more than half of their baseline 
BMC in the spine (Fig. 1C). At the hind limb, which contains 
relatively more cortica l bone than the vertebral bodies, the 
losses were proportionately less, bu t Ctcgrp null mice still lost 
twice the WT value (Fig. 10). The losses were not a result of 
any difference in litter sizes, which did not require any cull-
ing and were 8.9 ~ 0.9 in WT a nd 7.6 ~ 1.2 in Ctcgrp null (P = 
not significant) . 
The enhanced skeletal demineralization during lactation 
ind icates increased bone resorption in the Ct.cgrp nu ll mice. 
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FIG. 1. Ctcg1p null m1ce lose more BMC during lactation but recover fully post weaning. A, Total-body BMC at end of pregnancy, lactation, 
and post weaning expressed as a percentage of prepregnancy baseline BMC; B, mean days taken to recover to baseline BMC post weaning; C, 
spine BMC: D, hind limb BMC. All values are mean :': SE. The numbers in porentfteses indicate the nwnbers of mice studied. 
Consis tent with this, the urinary excretion of d eoxypyridino-
line/crea tinine (a marker of bone resorption) was increased 
significantly in C/cgrp null vs. WT mice during lactation (Fig. 
2A). On the other hand, no difference was observed in the 
serum level of osteocalcin (a marker of bone formation) be-
tween Ctcgrp null and WT mice a t any time point (Fig. 2B). 
Mineral and hormones 
We meas ured mineral and hormonal indices to examine 
possible mechanisms and consequences of the enhanced 
bone demineralization observed in Ctcgrp null mice. ln our 
labora tory, WT mice in several inbred, outbred, a nd mixed 
s tra ins maintain a normal ionized calcium dur ing pregnancy 
and lacta tio n and have suppressed levels of PTH during the 
sam e interva ls compared w ith prepregnancy (not shown). 
Both WT and Ctcgrp null mice generally maintained a normal 
ionized calcium throughout pregnancy, lacta tion, and post 
weaning (Fig. 3A); however, Ctcgrp null mice were Iran-
siently hypercalcemic during the firs t 24-48 h postpartum at 
1.40 ± 0.02 mmol / liter vs. 1.26 ::!: 0.02 mmol/ lite r in WT mice 
(P < 0.001). Urinary excretion of calcium normally d ecreases 
during lactation, likely because of the effect of PTHrP to 
enhance urinary calcium reabsorption. Ctcgrp nuU and WT 
mice both showed the same trend to d ecreased urinary cal-
cium excretion d uring lactation but with no significant dif-
fe rences between the genotypes at any time point (Fig. 3B). 
Serum PTH is normally suppressed to the lower end of the 
normal range during pregnancy and lacta tion, and this was 
observed in the WT mice (Fig. 3C). Although PTH was also 
redu ced during pregnancy in Ctcgrp n ull mice, PTH became 
significantly elevated in Ctcgrp null mice during lactation 
and may have contributed to the enhanced demineralization 
observed in these mice (Fig. 3C). The elevation in PTH oc-
curred during the interval of normoca lcemia and no t during 
the initial 24- 48 h postpartum in which the ionized calcium 
was tra nsiently elevated. ln a separa te analysis of serum 
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obtained at 24- 48 h (to correspond with the transient hy-
percalcemia), PTH levels were suppressed to the limit of 
detection (1.6 pg/ ml) in both WT and Ctcgrp null mice (P = 
not significant). Es tradiol is normally suppressed during lac-
tation as a consequence of hyperprolactinemia, and low es-
tradiol contributes to the skeletal resorption during this time 
period. We found that estradiol levels at mid-lactation were 
suppressed to the level of sensitivity of the estradiol assay (8 
pg/ml) in all samples from both WT and Ctcgrp null mice 
(P = not significant). Prolactin levels (Fig. 3D) were also not 
significantly diffe rent between Ctcgrp null and WT mice at 
any time point. 
We assayed duodenal 45Ca absorption at mid-lactation in 
WT and Ctcgrp null mice to rule out impaired intestinal 
absorption as an indirect cause of the enhanced skeletal re-
sorption in Ctcgrp null mice. Efficiency of absorption was 
grea ter than SO'Yo at 10 min in both WT and Ctcgrp null mice 
Woodrow et a/_ • Calci tonin Rnd I....actation 
and not s ignificantly different from the nonpregnant WT 
value (Fig. 4A). 
Given that the Ctcgrp null mice are resorbing more bone 
than WT but are not losing the excess calcium in urine and 
do not have impaired intestinal calcium absorption, we ex-
pected to find increased calcium content in milk. There are 
several challenges to measuring milk content in mice: milk 
conten t is highly variable with in and between feeds (38, 39), 
much of the calcium is bound to proteins (32), and collecting 
milk is technically difficult. Despite these issues, we found an 
apparent (bu t not statistically significant) increase in milk 
calcium content corrected from the protein content (Fig. 4B). 
PTHrP in lactating mammary tissue and circulation 
Given the established importance of mammary-derived 
PTHrP to s timulate skeletal d emineralization during lacta-
tion, we measured both mRNA and protein levels of this 
honnone. Within mammary tissue, PTI-JrP mRNA was sig-
nifican tly elevated as assessed by real-time quantitative RT-
PCR (Fig. SA), and the protein level was v isibly increased by 
immunohistochemistry (Fig. SB). Within the circula tion, the 
plasma PTHrP level showed no significant difference during 
lactation compared with WT, with most values clustered 
near the assay detection limit of 2 pmol / liter (Fig. 5C). 
Other calciotropic hormones and receptors within lactating 
mammw:y tissue 
We also examined the expression of other calciotropic 
genes that are knov.rn to be expressed in mammary tissue, 
includ ing the mRNAs for the calcium receptor, calcitonin 
receptor, ]-a-hydroxylase, and the vitamin D receptor. ln 
addition, mRNAs for the epi thelial calcium channels (CaTl 
and CaT2} were also examined. There was no diffe rence in 
the expression of any of these mRNAs between WT and 
Clcgrp null mice, whereas CaTl and CaT2 were not detected 
(data not shown). 
Skeletal strength cuul microarchitecture 
We also examined the consequences o f enhanced demi-
nera liza tion during lactation on skeletal microarchitecture of 
the femur and lumbar vertebrae and on the strength of the 
tibia. J.tCT measurements demonstrated that Ctcgrp null mice 
had greater trabecula r thickness and more closely spaced 
trabeculae at baseline compared with WT in both femora and 
lumbar vertebrae (Table 1). Ctcgrp null mice experienced 
more marked trabecular thinning and reached an equivalent 
level to WT at the end of lactation (Table 1). Trabecular 
spacing increased significantly in Ctcgrp null femora and 
approached the level of the WT at baseline, whereas trabec-
ular spacing did not change significantly within vertebrae 
(Table 1). The J.tCT results also indicate a greate r trabecular 
bone volume at baseline in Ctcgrp null mice vs. WT. Whereas 
WT trabecular bone volume increased signi ficantly during 
lactation (a normal finding), the changes were blunted in 
Ctcgrp null bones at both the femora and vertebrae (Table 1). 
Bone strength was assessed by the three-point bend test of 
the femur, a measurement that reflects cortical bone strength 
more than trabecular strength. Ul timate load requ ired to 
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l"IG. 3. Chemistry and hormone measurements. A , Ionized calcium remained constant throughout tile reproductive cycle and showed no 
cii fTerence between Ctcgrp nu ll and W'f at the ma in t ime points apart from 24-48 h postpa rtum; B, urine calcium/creatinine showed a trend 
to decreased ca lcium excretion during lactation as expected, but no significant difference between genotypes; C, serum PTH was elevated during 
lactation in Ctcgrp null us. WT but suppressed at 24-48 h postpartum (see text); D, serum prolactin was increased during pregnancy and early 
lactation but was no different between the genotypes. '!'he numbers in parentheses indicate the numbers of mice studied. 
cause breakage showed an apparent decrease from b<1seline 
to the end o(Jactation in both WT and Ctcgrp null mice but 
was not significantly different within or between groups 
(Table 2). Not included in the calculations were two Ctcgrp 
null femurs that were evidently fragile because they broke 
upon being placed into the device and thus could not be 
subjected to the three-point bend test. Additional intrinsic 
nnd extrinsic bone parameters a re shown in Table 2 that 
suggest that cortical bone strength is not significantly dif-
ferent between WT and Ctcgrp null mice at any time point. 
Rescue of skeletal phenotype during lactation 
Lastly, we determined whether the enhanced skeletal 
losses during lactation were a consequence of absence of 
calcitonin, CGRPa, or both . Preliminary dose-finding exper-
iments indicated that a mean dose of 10 IU salmon calcitonin 
daily would prevent the excessive losses of lactation in Ctcgrp 
null mice; larger doses reduced the normal losses during 
lactation, whereas 1 IU daily had minima l effect (not shown). 
Starting at the day of delivery and continuing for 2'1 d, WT 
and Ctcgrp null mice were treated with daily injections of 
calcitonin or vehicle, and several Ctcgrp nul l mice were 
treated with an equimolar dose (255 J.Lg) ofCGRPa. The mean 
losses of BMC observed in saline or CGRPa-treated mice 
were similar, showing enhanced losses approximately dou-
ble that of WT (Fig. 6). In contrast, treatment with calcitonin 
resulted in lactational losses that were no different from 
those observed in saline-treated WT mice (Fig. 6). Calcitonin 
treatment was without visible effect in WT mice (Fig. 6). 
Disc ussion 
We have compared Ctcgrp null mice to their WT siblings 
to test the hypothesis that calcitonin protects the mate rnal 
skeleton from excessive resorption during pregnancy and 
lactation. We found that calcitonin was not required during 
pregnancy, which is an interval of net bone forma tion as 
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FIG. 4. Duodenal calcium absorption and milk calcium content. A, 
The efficiency of '°Ca a bsorption atlO min was no different between 
W'l' and Ctcgrp null during mid-lactation, and both showed a non-
signjf'icani increnso over the nonpregnant W'r value; B, the cHkium 
content of expressed milk, corrected for protein content, showed a 
higher mean value that was not statis tically different from the W'f 
value. Nnmber.< in parentheses indicate the numbers of mice studied . 
indicated by the rise in maternal BMC between mating and 
delivery. On the other hand, we found that ca lcitonin is 
required during lactation because Ctcgrp null mice lost about 
twice the amount of BMC during lactation as their WT rel-
ati ves, with more profound losses at the trabecular-rich spine 
to the extent that over half of baseline BMC was lost. The 
enhanced losses were accompanied by increased circulating 
PTH and mammary expression of PTHrP, transient hyper-
calcemia in the first 24 h postpartum, increased bone resorp-
tion, normal intestinal calcium absorption, a nd apparently 
increased m ilk calcium content. Despite the dri'tmatic losses 
in BMC, cortical bone strength was not significantly differen t 
between Ctcgrp null and WT mice at the end of lactation. The 
excessive resorption in Ctcgrp null mice was prevented by 
treatment with daily injections of calcitonin but not by treat-
ment with CGRPa, confirming tha t the skeletal phenotype is 
specific to loss of calcitonin and not to loss of CGRPa. Fini'l ll y, 
Ctcgrp null mice fully regained to their baseline BMC after 
Woodrow et al. • Calcitonin nnd LactJ\tion 
weaning, demonstrating the skeleton's tremendous ability to 
repair itself from il greater than 50% deficit. 
Physiological role for calcitonin during lactation 
Our confirmation of a physiological role for calcitonin 
d uring lactation brings closure to a hypothe~i~ that had been 
raised more than 30 yr ago but left unresolved {21-24). The 
inconsistent results among these early investigations likely 
reflected the confounding effects o f thy roid abla tion and 
thyroid hormone replilcement, but especially the previously 
unrecognized fact that extrathyroidal sources of calcitonin 
existed (25, 27, 29). Only through the use of il gene ablation 
model has it become possible to examine the effect of com-
plete absence of calcitonin on skeletal metabolism during 
pregnancy and lactation. 
Ctcgrp null mice have enhanced skeletal resorption as 
demnnstril ted by the large drop in BMC from either prepreg-
nancy or peak of pregnancy to end of lacta tion, the trabecular 
thinning and increased trabecular separation on JLCT, and 
the elevated excretion of urinary deoxypyridinoline/creati-
nine. The transient hypercalcemia in the first24 h postpartum 
may be i'l consequence of enhanced bone resorption flooding 
the maternal circulation with ca lcium at a time when milk 
production is not fully established; the ionized ca lcium was 
normal throughout the rest of lactation. 
Calcitonin evidently plays a central role in modulating 
skeletal responsiveness during lilcti'ttio n, a role tha t mily not 
be limited to its direct actions on osteoclasis. The presence of 
calci tonin a nd its receptor in mammary tissue (25) and pi-
tuitary (29, 40) indicates that there are several possible routes 
through which absence of calcitonin may leild to enhanced 
bone resorption in Ctcgrp null mice. We will consider the 
osteoclast, pituita ry, and mammMy tissue in turn. 
Calcitonin, osteoclasis, and increased trabecular 
bone res01ption 
During lacta tion, enhanced osteoclast-mediated bone re-
sorption is driven by a hormonal milieu in which circulating 
PTH is low, PTHrP is elevated, estradiol is low, and calci-
tonin is elevated (1, 3, 4). ln Ctcgrp null mice, circula ting PTH 
w,1s elevated, mammary gland expression of PTHrP was 
up-regulated above normal, estradiol was low, a nd calcito-
nin was absent . The circulating level of PTHrP was not sig-
nificantly increased in Ctcgrp null mice, but the assay sen-
sitivity (2 pmol / liter) was likely insufficient to detect a true 
difference given that most values were clustered near the 
detection limit. PTH and PTHrP are equ ivalent in their ability 
to activate the PTH/PTHrP receptor on osteoblasts and com-
municate through the RANK-RANKL-OPG pathway to 
stimulate osteoclast-mediated bone resorption (41, 42); in 
contrast, calcitonin acts directly on osteoclasis to inhibit bone 
resorption (18). Thus, the mechan ism for enha nced bone 
resorption in the Ctcgrp null mice may be simply a result of 
exaggerated stimula tion of PTH/PTHrP receptor-mediated 
bone resorption by both f'Tl-1 and I'THrP, coupled with ab-
sence of the effect of calcitonin to directly inhibit the activ ity 
of osteoclasis. In turn, pituitary and mammary t issue may 
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both contribute to the up-regulation in PTH and PTHrP as 
described below. 
Calcitonin, pituitwy, and prolactin 
With respect to the pituitary, both pharmacological ad-
ministration of calcitonin (43) and targeted overexpression of 
calcitonin within pituita ry lactotrophs have been found to 
inhibit production of prolactin (44). Therefore, loss of calci-
tonin might be expected to lead to enhanced synthesis and 
release of prolactin, which in turn would cause more pro-
found ovarian suppression, lower estradiol, and enhanced 
bone resorption. Low estradiol (45) and high prolactin (15, 
46-49) are factors that stimulate PTHrP production by mam-
ma ry tissue i11 r>ivo. However, we found no significant dif-
ference in mean prolactin levels at any time point in Ctr:grp 
null r>s. WT mice, and estradiol levels were undetectable in 
both genotypes during mid-lactation. Prolactin is released in 
pulsa ti le fashion during lactation (16), but it was not possible 
TABLE 1. p.CT analysis of t.rabeculm· bone parameters wi thin femora And lumbal' vertebrAe 
BV (mm3 l 'L'V (mm:1) BVfi'V (');) BS (mm2 ) SMI Tb.'L'h. (Mrnl Tb.Sp. lJ.Lml 
Femora 
Ctcgrp null baseline (n = 3) 0.43:!:0.07" 3.34 .!_ 0.22 12.8 • 1.8" 28.5 ~ 4.3 1.83 • 0.09" 72.7 + 5.311•1'·{' 277 + 26"·1' 
Ctcgrp nu ll trough (n = 6) 0.42 .!_ 0.05 3.70 .!_ 0.16 11.6 ' 1.3'' 29.7 :t. 3.0" 1.79 + 0.061' 47.7 • 3.611 363:!: 26"·r 
wr baseline (n = 3) 0.19 :!.. 0.07" 3.11 :!.. 0.22" 6.2 ~ 1.8".1' 15.0 • 4.3" 2.21 + 0.08"·1'·' 53.3 
' 
5.11' 413:!: 261' 
W'l' trough (n ~ 5) 0.34 + 0.06 3.90 + 0.17" 8.8 :!: 1.4 24.5 :!:. 3.3 l.92 :!: 0.07' 52.0 :!: 3 .9'' 495 :!: 32r 
Vertebrae 
Ctcgrp null baseline (n = 3) 0.65 :': 0.05 2.71 :': 0.15" 23.7 :t. 1.1" 31.4 :!.. 2.1"·" 1.11 "!: 0.06 54.5 z 2.0"·h 213 :!: 12 
Ctcgrp null trough (n = 6) 0.77 :': 0.04" 2.93 :!: 0 .12'' 25.2 •. 0.91' 38.2 :!:. 1. 7"·" 1.10 :!: 0.05" 46.2 :!.. 1.6" 201 :!.. 9 
W'l' baseline (n = 3) 0.56 :': 0.05"·1' 2.92 :': 0.13'' 19.0 ± 1.]''·1'·< 29.5 :!.. 2.1r.d 1.31 :': 0.06" 49.0 :!: 2.0 225 :!: 11 
WT trough (n = 5) 0.82 :': 0.05" 3.54 ~ 0.12fl,l),t" 23.3 :!: l.Y 42.1 :!: 1.9''·d 1.15 :!. 0.06 44.6 :!.. 1.8" 217 :!: 11 
,...c'l' a nalysis of femora and lumbar vertebrae was performed at baseline (nonpreb'rlant) and a t the end of lactation (trough). Within femora, 
Ctcgrp null mice s howed higher trabecular bone volumes, greater trabecular thickness, and more densely packed trabeculae a t baseline. Ctcgrp 
nu ll mice underwent more pronounced thinning of trabeculae than WT by the end of lactation but did not increase trabecula r bone volumes. 
Lumbar spine s howed a s imila•· pattern of changes. Lumbm· spine values include results from both the first and second lumlmr vertebrae. llS, 
Trabecular bone surface; BV, trabecul a r bone volume; BVf fV, t rabecular bone volume relative to total volume; SJ\1"1 , s tructure-model index; 
Tb.Sp., tra becular spacing; 'l'b.Th., trabecular thickness; TV, total volu me including trabecular bone <but excluding cortica l bene). 
a - d Shared letters withJn. columns indicate statis tical si!,.rni ticancc of P < 0 .05 (or lower) by 'J'ukey ann lysis . 
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TABLE 2. BiomechRnical pa1·arncters derived from the tJnee-point bend test of femurs 
Ultimate load Stiffness Toughness Ultimate stress Work lo fRi lure Moment of 
(g) tN/mm) lJ/mm:1) (mPA> (N X mm) inertia (mm"l 
Ctcgrp null baseline (n - 3) 1678 :!: 265 91 :!: 14 3.56 :!: 0.65 189 = 27 :.!.21; :!: 0.39 0.086 :!: 0.001 
Ctcgrp null trough (n = 6) 1430 :!: 229 102 :!: 14 3.46 :!: 0.65 179 :!: 27 2.17 :!: 0.:.19 0.100 = 0.00 1 
WT baseline (n = 3) 1914 :!: 266 132 :!: 14 4.00 :!: 0.65 208 :!: 27 2.64 = o.:l9 0.088 :!: 0.001 
WT trough (n = 5) 1737 = 226 96 :!: 18 3.78 :!: 0.80 143 = 34 2.78 :!: 0.48 0.120 :!: 0.001 
This test of cortical strength showed a nonsignificant trend for decreased bone strength between baseline (nonpregnant) and end of lactation 
(trough). with no significant difference between groups at any time point. 'l'wo Ctcgtp null femurs were clearly fragi le because they broke upon 
being placed into the device but could not be included in the data analysis. Numbers in parentheses i11the first colnm11 indicate Uw numbers 
of mice studied. 
to collect multiple serum samples from each mouse to assess 
peak levels of this hormone. Our results indicate that the 
proposed role of calcitonin to regulate pituitary lactotroph 
and systemic prolactin levels may not be a physiolog ica lly 
important pathway. 
Calcitonin in mammary tissue 
The presence of calcitonin and its receptor within mam-
mary tissue (25) may indicate a local regulatory role for 
calcitonin in which the loss of it leads to enhanced ITHrP 
production. The calcium receptor has been shown to locally 
regulate the production of PTHrP within mammary tissue as 
well as the calcium and fluid content of milk (50). We did not 
observe a change in calcium receptor mRNA expression by 
real-time quantitative RT-PC!~. and thus the pathway by 
which absence of calcitonin leads to stimulation of PTHrP 
may be independent of the calcium receptor. 
TI1e factors that conh·ol milk production are not well un-
derstood, although it is known that the calcium receptor, 
PTHrP, prolactin, and uckling all contribute to the regula-
tion of the calcium and fluid content of milk (12, 50, 51). The 
numerous calcium regulatory genes that are expressed by 
lactating mammary tissue include the calcium receptor, ca l-
citonin receptor, 1-a-hydroxylase, and vitamin D receptor 
20 
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Ji'JG. 6. Calcitonin but not CCRP rescues tJ>e Ctcgrp null phenotype. 
Snlmon calcitonin administered im once doily throughout 21 d of lac-
tation resulted in n loss ofBMC in thcCtcglp null mice that wassimilnr 
to WT. Ctcgrp null mice Uutt received saline (controls}. as well as Ctcgrp 
null mice that received an ~'quimolar dose ofCGRPo-, lostsignificantly 
more BMC than U1c Ctcg1p null mice receiving calcitonin lrc;olmcnt. '.rhe 
numbers in parentlwses indicate the number of mice studiL'<l. 
(25, 50, 52). We did not observe any alte ration in the expres-
sion of these genes within mammary tissue; the only con-
sistent finding was an elevation in PTHrP in mammary tissue 
that lacks calcitonin. No previous publications have exam-
ined CaTl or CaTI mRNA expression in lactating mammary 
tissue, a lthough CaTl protein had previously been detected 
by immunohistochemistry in nonlactating human breast tis-
sue (53). We did not detect CaTl or aTI mRNA in lactating 
mammary tissue of WT or Ctcgrp null lactating mice, which 
suggests that the epithelial calcium channels are not involved 
in milk production. 
S econdat:Y hyperparathyroidism in Ctcgrp null mice 
Normally PTH is suppressed during lactation in humans 
and rodents (1), but we observed a significant elevation in 
PTH in Ctcgrp null mice during mid-lacta tion and to a lesser 
degree dw·ing late lactation. The cause of I he elevated PTH 
may be an indirect consequence of loss of calcitonin. It has 
previously been demonstrated tha t larger litter sizes or a 
restricted calcium intake will induce maternal hypocalcemia 
and econda ry hyperparathyroidism during lactation (54-
56). In such cases, loss of calcium into milk may overwhelm 
the mother's ability to maintain her own blood calcium, 
resulting in hypocalcemia !hat in turn acts through the ca l-
cium receptor to induce PTH release. Ctcgrp null mice have 
low urinary calcium excretion, normal duodenal calcium 
absorption, and enhanced skeletal resorption; these factors 
should obviously lead to increased availability of calcium for 
milk production. The fac t that PTH is elevated in Ctcgrp null 
mice may indica te that the loss of calcium into milk exceeds 
the requirement to maintain a normal blood calcium in the 
mother. Milk production by mammary tissue is controlled by 
both local and systemic factors (16, 57) and can induce hy-
pocalcemia and tetany (milk fever) in lactating animals (58, 
59); therefore, it is conceivable that loss of calcitonin within 
mammary tissue leads to an up-regulation in milk produc-
tion that, in turn, challenges !he ability of the mother to 
maintam her own serwn calcium. 
Confowuling influences on bone strength 
Ctcgrp null mice lost twice as much minera l conten t as WT 
siblings, and yet skeletal strength (as assessed by the three-
point bend test) was not significantly d ifferent from WT at 
the end of lactation. TI1is likely reflects several factors. First, 
the three-point bend test examines the strength of cortical 
bone, which undergoes very mode t resorption during lac-
tation (1, 60). Second, it is trabecular bone that is rapid ly 
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mobilized during lacta tion because of its large surface aren 
and vascularity, factors that enable it to be resorbed by os-
teoclasis on multiple surface (60, 61). Third, absence of cill-
citonin from conception leads to increa ed trabecular bone 
mass, as indicated in the original report (30) and in our study 
in which the Ctcgrp null skeleton had thicker and more 
densely packed trabeculae compared with WT. Thus, even a 
50% drop in skeletal mass wa well tolerated by the Ctcgrp 
null mice because the large los es re ulted in a trabecular 
thickness that was equivalent to the level of WT mice at the 
end of lactation. Fina lly, p regnancy and lactation are nor-
mally associated with other changes in skeleta l architecture 
(increased bone volume and expansion of periosteal surfaces 
w hile en do tea l bone is being lost) that will offset the weak-
ening effect that skeletal demi nera lization d uring lactation 
would be expected to induce (62). Ctcgrp null mice have 
g reater trabecular and total bone volumes than WT at base-
line; although these volumes increased substantially in WT 
mice, the changes were comparably modest in Ctcgrp null 
mice. The larger bone volumes of the Ctcgrp null mice likely 
compensated for the loss of trabecular bone during lactation. 
Re/e(lance to lactation in humans 
A few case series examined male and female thyroidec-
tomized individuals who received thyroid hormone replace-
ment and reported con flicting results as to wheth r such 
patients developed a long-term deficit in bone mass or an 
increase in fracture risk relative to matched individual with 
intact thyroids (63-67). No study has examined the bone 
milss of thyroidectomized women ilfter a cycle of pregnancy 
and lactation, and of cour e such women would retain the 
ability to make calcitonin in pituitary and mammary tis ue 
and would not be fully calcitonin deficient (26). Vertebral 
compression fractures occasionally occur during lactation in 
otherwise healthy young women, a condition termed osteo-
porosis of lactation (68). In such cases, excess bone resorption 
during lactation is presumed to have led to increased fragility 
that resolves after weaning. Our results raise the possibili ty 
that at least some of these case might represent the human 
equivalent of absence o f calcitonin or its receptor. 
Slteletal recovery after weaning 
In contrast to the demineralization that occurs during lac-
tation, the factors that arc required to stimulate recovery of 
the skeleton after weaning remain unknown. Our results 
indicate that calcitonin is not required for skeletal recovery 
to be achieved in full, although its absence may contribute to 
a delay in recovery. Calcitonin is required in the short term 
during lactation to prevent xcessive resorption of the skel-
eton and likely attendant fragility, but it is not required in the 
long tetm because the skeleton recovers fully despite its 
absence and despite the increased minera l deficit induced by 
lactation. Resolving the mechanism by which the skeleton 
recovers remains a clinically important and relevant task 
because the skeleton is able to recover so completely and 
ra pidly from the large losses of skeletal mineral content that 
are induced by lactation. Clcgrp null mice may be an ideal 
model to examine keletal recovery because the factors s lim-
Endocrinology, S•ptcmi>cr 2006. 147(91:4010-4021 4019 
ulating recovery are likely to be up-regulated more in these 
m ice compared with normal. 
Breast, brain, and bone circuit 
In summary, evidence from recent s tudies has pointed to 
the centra l role of mammary tissue to stimulate skeletal re-
orption during lactation by producing PTHrP under the 
control of the calcium receptor and also to the central role of 
the pituitary to secrete prolactin and, thereby, suppress es-
trildiol and stimulate PTHrP (the breast, brain, and bone 
circuit, Fig. 7). The data in our manuscript indicate that 
calcitonin plays a key role by modulating the extent of skel-
etal resorption during lactation . Absence of calcitonin in the 
systemic circulation will lead to increased osteoclast activity 
through loss of its direct effects via the ca lcitonin receptor to 
inhibit osteoclast number and function. However, because 
the calcitonin receptor is also expressed in mammary tissue 
and pituitary (two tissues that also produce calcitonin), it is 
po sible that calcitonin acts at all three sites to modulate 
lactation: directly to inhibit osteoclasis, within pituitary to 
• ••• 
•• 
••• 
• • 
• 
• 
• 
• 
• 
• 
• 
FIG. 7. Breast, brain. and bone cn·ctut. lligh prolactin (PRL) levels 
dunng lactation stimulate PTilrP production by mammary tissue, 
and suppress t.he GnRH pulse center in U1e hypothalamus, in turn 
suppressing t.hc pituitary gonadulropms (LII and FSJ I) and then t.he 
ovaries !ovulation, estradiol CE2 l, and progesterone (PROG) produc· 
lion]. Low estradiol and mammary-derived PT!IrP act synergistically 
to enhance osteoclast-mediated bone resorption. The presence of cnl-
citonin (GT) and its receptor in mammary tissue, pituitary, and bone 
(red lines) allows for at least thrPC pathways by which ca lcitonin could 
modulate OMC losses during lactation. Our observation Uutt serum 
llfolnctin levels were no diiTerent between Ctcwp null and WT indi-
cates that the postulated role of calcitonin to inhibit pituitary lac-
iolrophs (dashed red line) may not be physiologically important. 
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inhibit prolactin release, and within mammary tissue to mod-
ulate PTHrP or milk production. Additional work is needed 
to determine the relative importance of these three physio-
logical loops. 
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Lack of Calcitonin Accentuates Bone Loss During Lactation by Enhanced 
Osteoclast Formation and Reduced Osteoblast Formation 
F. Calciotropic and Phosphotropic Hormones and Mineral Metabolism 
Authors/Speakers: C. S. Kovacs\ B. J. Kirby*\ J. P. Woodrow*\ R. F. Gagel2, N. A. Sims3. 
1Memorial University, St. John's, NL, Canada, 2MD Anderson Cancer 
Center, Houston, TX, USA, 3St. Vincent's Institute, Melbourne, Australia . 
Lactation in mice induces substantial reductions in bone mineral content (BMC, assessed by 
DXA) that are reversed rapidly after weaning. Ctcgrp-null mice, with a global deletion of the gene 
encoding calcitonin and calcitonin gene-related peptide, suffer a 55% reduction in BMC during 
lactation (versus 25% in wild type [WT] mice) followed by complete restoration post-weaning. 
Ctcgrp-null mice also demonstrate upregulated mammary gland PTHrP and serum PTH during 
lactation, which may increase osteoclast-mediated bone resorption during lactation even further 
above normal. To assess this, we performed histomorphometry in WT and Ctcgrp-null mice 
during lactation and weaning. Pairs of sister WT and Ctcgrp-null mice were sacrificed at day 7 of 
lactation and at weaning (day 21 after parturition) and histomorphometry was carried out on 
toluidine blue stained undecalcified sections of vertebrae and tibiae. 
During lactation, both WT and Ctcgrp-null mice demonstrate reduced trabecular thickness and 
increased trabecular separation, compared to non-pregnant mice of the same genotype, as well 
as high osteoclast and osteoid surfaces (OcS/BS and OS/BS). In lactating Ctcgrp-null vertebrae 
and tibiae, OcS/BS was more than double that of WT (vertebrae: 13.9 ± 2.2 vs 4.9 ± 0.6%, 
p<0.003; tibiae: 24.5 ± 4.3 vs 9.6% ± 0.5, p<0.01 ). In contrast, osteoblast parameters were halved 
in Ctcgrp-null vertebrae and tibiae compared to WT (vertebral osteoblast surface [ObS/BS]: 10.7 
± 2.0 vs 20.4 ± 2.9%, p < 0.03; OS/BS: 11 .7 ± 2.3 vs 21 .0 ± 3.0, p < 0.04). Large osteocytic 
lacunae consistent with osteocytic osteolysis were evident in both genotypes. 
At weaning, the very high OcS/BS persisted in Ctcgrp-null mice. However, between day 7 and 21 
ObS/BS quadrupled in Ctcgrp-null to 40.0 ± 4.8%, and doubled in WT to 46 ± 2.9%; similar 
changes were observed in osteoblast number and OS/BS. 
Thus, we have confirmed upregulated osteoclast-mediated bone resorption and osteocytic 
osteolysis during normal lactation. Absence of calcitonin led to a greater increase in OcS/BS, 
consistent with elevated circulating PTH, but also led to a milder increase in ObS/BS vs WT. The 
sum of these differences may explain the more substantial bone loss in lactating Ctcgrp-null mice. 
Moreover, Ctcgrp-null mice retain the ability to upregulate osteoblast generation to a maximal 
level at the onset of weaning. This suggests that calcitonin normally dampens the effect of 
lactation on osteoclasts but not on osteocytic osteolysis, yet enhances the effect of lactation on 
osteoblasts, and is not required for skeletal recovery after lactation . 
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